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Abstract 
 
Introduction: 
Diaphragm weakness is a strong predictor of poor outcome in patients. Acute hypoxia 
is a feature of respiratory conditions such as acute respiratory distress syndrome and 
ventilator-associated lung injury. However, the effects of acute hypoxia on the 
diaphragm are largely unknown despite the potential clinical relevance. 
 
Methods: 
C57BL6/J mice were exposed to 8hr of acute hypoxia (FiO2 = 0.10) or normoxia. A 
separate group of mice were administered N-acetyl cysteine (NAC; 200mg/kg, I.P.) 
immediately prior to acute hypoxia exposure. Ventilation was assessed using whole-
body plethysmography. Oxygen consumption and carbon dioxide production were 
measured as indices of metabolism. Diaphragm muscle contractile performance was 
determined ex-vivo. Gene expression was examined at 1, 4, and 8 hrs using 
quantitative real-time reverse transcription PCR (qRT-PCR). Protein and 
phosphoprotein content was assessed using a sandwich immunoassay. Proteasome 
activity was measured using a spectrophotometric assay. 
 
Results: 
Acute hypoxia decreased diaphragm peak force, force-frequency relationship, and 
fatigue. Minute ventilation during acute hypoxia was initially increased during the 
first 10 minutes, but quickly returned to normoxic levels for the duration of gas 
exposure. CO2 production (VCO2) throughout gas exposure and post-mortem body 
temperature (metabolism) following gas exposure, were reduced by acute hypoxia, 
and gene expression driving mitochondrial uncoupling was increased. Acute hypoxia 
increased atrophic gene expression and signalling protein content. However, 
proteasome activity was unaffected by acute hypoxia. Acute hypoxia increased 
hypertrophic and hypoxia protein signalling. NAC pre-treatment prevented the acute 
hypoxia-induced diaphragm weakness. 
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Conclusions: 
Diaphragm weakness is reported in mechanically ventilated patients, which is 
primarily attributed to inactivity (unloading) of the muscle, although this is 
controversial. The potential role of hypoxia in the development and/or exacerbation of 
ICU-related weakness is unclear and perhaps underestimated. Our data reveals that 
acute hypoxia is sufficient to cause diaphragm muscle weakness, which may relate to 
atrophy, as evident from increased pro-atrophy signalling. Muscle weakness likely 
relates to direct hypoxic stress, as there was no persistent change in ventilation 
(muscle activity) during hypoxic exposure. Moreover, muscle weakness was 
prevented by antioxidant supplementation, independent of the hypoxia-induced 
hypometabolic state. These findings highlight a potentially critical role for hypoxia in 
diaphragm muscle dysfunction observed in patients with acute respiratory diseases. 
Moreover, the work highlights the potential benefits of NAC in preventing acute 
hypoxia-induced diaphragm dysfunction. 
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1.1 Hypoxia 
 
Hypoxia represents an imbalance between oxygen supply and demand, where the 
oxygen supply to a tissue is outweighed by the metabolic demand for oxygen in that 
tissue. This can occur in health, upon exposure to high altitude or during endurance 
exercise. Hypoxia can also occur in disease, in particular respiratory conditions, and it 
is a feature of chronic respiratory disease that is known to affect skeletal muscle 
structure and function (Gamboa and Andrade, 2012, 2010; Lewis et al., 2015c; 
McMorrow et al., 2011). 
 
The normal partial pressure of oxygen in arterial blood (PaO2) is in the range of 90-
100 mmHg, while a drop in PaO2 below 60mmHg is considered clinically to be 
hypoxaemic and can lead to tissue hypoxia due to its effect on the oxyhaemoglobin 
curve (see below), and this can be seen in patients with respiratory diseases. 
Remarkably PaO2 as low as 28mmHg has been reported near the summit of Mount 
Everest (West et al., 1983), and at the summit of Mount Everest, the highest point on 
the earth’s surface (8848 m), the partial pressure of inspired oxygen (PiO2) is believed 
to be very close to the limit that is tolerable to acclimatised humans while maintaining 
functionality (Grocott et al., 2009). From the oxyhaemoglobin curve, we can deduce 
that once PaO2 is above 60mmHg the curve is relatively flat and there is little change 
in the oxygen saturation of haemoglobin (SaO2). However, once PaO2 drops below 
60mmHg, the curve becomes very steep such that a small change in PaO2 can 
translate into a large change in SaO2. 
 
Hypoxia can be further subdivided into several distinct types based on the etiology. 
There are primarily 4 categories. (1) Hypoxic hypoxia occurs when there is 
inadequate O2 in the inspired environmental air, decreased O2 partial pressure (PO2) 
in the alveolus or insufficient O2 transfer from the alveoli to the pulmonary 
capillaries. Situations of hypoxic hypoxia can arise during ascent to high altitude, 
hypoventilation, gas diffusion abnormalities at the alveoli, pulmonary shunting or a 
mismatched ventilation/perfusion ratio. (2) Anaemic hypoxia is a situation where the 
O2 carrying capacity of the blood is too low. This can occur due to either a lack of 
sufficient functional haemoglobin (Hgb), as can occur during hypovolaemia, or poor 
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Hgb-O2 binding capacity, as can occur during carbon monoxide poisoning. (3) 
Stagnant/Ischaemic hypoxia can present when blood O2 is normal but the perfusion of 
blood in a tissue is reduced or uneven and is insufficient to meet local metabolic 
demand. This can arise in several cardiovascular conditions which affect blood flow 
and/or the microcirculation. (4) Histotoxic/Cytopathic hypoxia occurs when blood 
supply of O2 may be normal but cells cannot effectively metabolise this O2. This type 
of hypoxia can be occur under conditions of poisoning, such as cyanide poisoning 
(McLellan and Walsh, 2004; Ward, 2006; Wheeler, 2011), as well as being a feature 
in sepsis (Berdichevsky et al., 2010; Fink, 2002; Fink, 2001; Fink, 2001b; Schwartz et 
al., 1998; van boxel et al., 2012). As well as these four main categories, genetic 
hypoxia can also occur due to mutations in genes involved in the regulation of oxygen 
homeostasis, such as those involved in the degradation of hypoxia-responsive proteins 
under normoxic conditions, mitochondrial genetic disease and congenital 
polycythaemia, and can give rise to dysfunctional oxygen utilisation and homeostasis 
in cells (Cortopassi et al., 2006; Gordeuk et al., 2004). Demand for hypoxia may also 
supervene when there is over-utilisation of oxygen within the cells. This condition can 
present in hyperthyroidism, seizures and cases of severe burn (Ash, 1956; Varney et 
al., 1998). 
 
Sustained hypoxia causes apparently unique adaptations in the muscles of respiration. 
There remains however a general paucity of information concerning the molecular 
mechanisms underpinning respiratory muscle remodelling in hypoxia, including the 
manifestation and progression of these adaptations over time. Aberrant remodelling, 
and dysfunction of the respiratory muscles, is known to occur in the respiratory 
muscles of patients with chronic obstructive pulmonary disease (COPD), and it is 
thought that this may, at least in part, be due to hypoxic adaptation (Barreiro et al., 
2005; McMorrow et al., 2011; Nguyen et al., 2005; Ottenheijm et al., 2008), though 
this is often under-appreciated in the context of disease-related changes in loading and 
systemic inflammation. Indeed, many studies have reported similar functional and 
molecular changes in respiratory and limb muscle in animal models of chronic 
hypoxia to those seen in COPD patients (Gamboa and Andrade, 2012; Lewis et al., 
2016, 2015d, 2014; Lewis and O’Halloran, 2016; McMorrow et al., 2011). 
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1.1.1 Altitude Hypoxia 
Pathophysiological conditions aside, hypoxia also occurs during exposure to high 
altitude. The first ascent to the summit of Mount Everest was achieved by Hillary and 
Tenzing in 1953 using supplemental oxygen. It was a further quarter century after 
their ascent before the summit was reached without supplemental oxygen by Messner 
and Habeler, and less than 4 % of people who climb Mount Everest do so without 
supplemental oxygen (Grocott et al., 2009), due to the effects of high altitude 
hypoxia. High altitude/hypobaric hypoxia is known to affect skeletal muscle, 
including the diaphragm, and the effects of exercise on the diaphragm differ when 
performed at high altitude or at sea level (Bigard et al., 1992; Levett et al., 2012). 
 
The first written report of high altitude effects on humans was documented in 37-32 
B.C., when Chinese official Too Kin wrote of Big Headache Mountain, where he 
experienced mountain sickness while travelling over the western edge of the 
Himalayan Karakoram Range, while travelling from Kashi to Kabul (Gilbert, 1983).  
Later, in a record breaking attempt in 1875, three French balloonists ascended from 
Paris in the Zenith balloon to around 8,500 meters. They failed to breathe from bags 
containing 65% oxygen, which they had brought with them under the advice of 
French physiologist Paul Bert, due to a feeling of intense hypoxia-induced euphoria 
before losing consciousness. Two of the men died. The third man, M. Gaston 
Tissandier, although in a delirium, was able to start a descent and lived to tell the tale. 
In the same year, Bert published La Pression Barometrique, in which he included the 
story of the Zenith tragedy and proposed that the reduced partial pressure of oxygen 
in the air, and thus in the blood, was a vitally important effect of altitude on humans. 
This sparked the beginning of our understanding of altitude (patho)physiological and 
respiratory science (Severinghaus, 2016).  
 
 
1.2 Skeletal Muscle 
 
Skeletal muscle mass alone accounts for 40 – 50 % of total human body weight, 
making it the largest tissue mass in the body (Sanchez et al., 2014). This combined 
skeletal muscle mass consumes roughly 20% of available oxygen in the body under 
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normal resting conditions, and this percentage increases under exercise conditions. 
Skeletal muscle is a syncytium, and has a variety of roles in the human body such as 
movement of the skeleton, posture, speech, respiration, and aiding in blood 
circulation. The motor unit is the functional unit of the skeletal muscle system, and is 
comprised of a motor neuron and the bundle of muscle fibres which it innervates, 
which all have similar, if not identical, structural and functional properties (Schiaffino 
and Reggiani, 2011). Many distinct motor units are assembled together to form a 
muscle, and selective recruitment of units allows appropriate muscle response to a 
given functional demand (Schiaffino and Reggiani, 2011). The motor nerve branches 
in the muscle, with each branch innervating a single muscle fibre. One nerve 
innervates only a few muscle fibres where fine control is involved, such as the 
muscles of the eye, whereas in large, strong muscles, such as those involved in 
posture, hundreds of fibres are innervated per nerve. 
 
 
1.2.1 Respiratory Muscle 
The act of breathing depends on the coordinated activity of many respiratory muscles. 
The striated muscles involved in breathing are made up of skeletal muscle tissue and 
can be broadly categorised into two classes; (1) ventilatory pump muscles (the 
diaphragm being the primary inspiratory pump muscle) and (2) those muscles that 
modulate upper airway patency and calibre (the sternohyoid muscles are important 
upper airway dilator muscles). The diaphragm has a mixed muscle fibre type 
composition (22% type 1, 24% type 2a, 19% type 2b and 28% type 2x), comprising 
all fibre types grouped together into motor units of common muscle type (McMorrow 
et al., 2011; Rowley et al., 2005). The sternohyoid muscles are fast glycolytic muscles 
(77% type 2b) and as such they are very fatigable, which has implications for the 
control of airway patency (O’Halloran, 2016; O ’Halloran et al., 2016). Respiratory 
muscles face unique physiological demands due to the continuous rhythmic activity of 
breathing, making them among the most active skeletal muscles in the human body. 
Many of these muscles also participate in a variety of other (non-respiratory) 
functions including swallowing, sneezing, coughing and phonation (Rowley et al., 
2005).  
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1.2.1.1 Sternohyoid Muscles 
The upper airway is surrounded by a complex anatomical arrangement of skeletal 
muscle and soft tissue, allowing the necessary dynamic changes in airway size for 
varying respiratory patterns as well as a variety of non-respiratory functions such as 
swallowing, phonation, etc., mentioned above. There are 20 or more upper airway 
muscles surrounding the airway that play active roles in constriction and dilation of 
the airway lumen (Ayappa and Rapoport, 2003). The sternohyoid is a primary upper 
airway dilator muscle involved in maintaining the calibre and patency of the upper 
airway. It is made up primarily of fast glycolytic type 2b muscle fibres. The 
sternohyoid muscle is an excellent representative upper airway dilator muscle and one 
which has been the focus of much of the research into upper airway muscle 
physiology (Bavis et al., 2007; Bradford et al., 2005; Carberry et al., 2014a; El-
Khoury et al., 2012, 2003; Gamboa and Andrade, 2012; Lewis et al., 2015c; McGuire 
et al., 2002; O’Halloran et al., 2003, 2002, Skelly et al., 2012a, 2012b, 2011, 2010; 
van Lunteren et al., 2010; Williams et al., 2015). 
 
1.2.1.2 The Diaphragm 
The diaphragm is the primary pump muscle of inspiration and, as such, it is active 
throughout life – due to breathing as well as other activities such as airway clearance 
manoeuvres and speech. Thus, normal function of the diaphragm muscle, much like 
that of the heart muscle, is essential to life. The diaphragm is an extremely adaptable 
and malleable muscle, comprised of a mixed muscle fibre type composition, 
containing the four major myosin isoform subtypes (McMorrow et al., 2011). This 
mixed muscle fibre type composition is fundamental to the balance between force 
generating capacity and endurance necessary for normal diaphragm function. 
During quiet breathing, the diaphragm is the primary muscle of respiration. During 
inspiration the diaphragm contracts and moves downward, lowering pleural pressure, 
which lowers alveolar pressure, and air is drawn into the expanding lungs. 
Meanwhile, expiration during quiet breathing is predominantly a passive mechanical 
process. The diaphragm relaxes and returns to resting position, restoring the thoracic 
cavity to pre-inspiratory volume, and the elastic lungs return passively to resting 
volume (functional residual capacity). During exercise or forced/active respiration, 
many other muscles are involved. During active inspiration, the external intercostal 
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muscles raise the lower ribs up and out, and the scalene muscles and sternomastoids 
are recruited, raising and pushing out the upper ribs and sternum. During active 
expiration, the most important respiratory muscles are those of the abdominal wall, 
including the rectus abdominus, internal and external obliques, and transverse 
abdominus, raising intra-abdominal pressure and pushing up the diaphragm, raising 
pleural pressure and driving air out of the lungs. The internal intercostal muscles also 
play a role in active expiration, pulling the ribs down and in, decreasing thoracic 
volume. 
 
The effects of hypoxia on the diaphragm are poorly understood, despite the clinical 
relevance of such an understanding. Indeed, hypoxia is a feature of many respiratory-
related disorders, both acute and chronic. Our laboratory group, and others, have 
examined some of the effects of chronic hypoxia exposure on the respiratory muscles 
(Carberry et al., 2014a; Chaudhary et al., 2012; El-Khoury et al., 2012, 2003, Gamboa 
and Andrade, 2012, 2010, Lewis et al., 2015a, 2015c; McMorrow et al., 2011; Shortt 
et al., 2014; Skelly et al., 2012a, 2012b), with relevance to certain chronic respiratory 
conditions in which hypoxia features, such as chronic heart failure (CHF),chronic 
obstructive pulmonary disease (COPD) and bronchopulmonary dysplasia (Gosker et 
al., 2000; Testelmans et al., 2010). Indeed hypoxia may also play a prominent role in 
early life disorders such as sudden infant death syndrome (SIDS), where critical 
diaphragm failure (CDF) is a postulated cause of SIDS, and early life exposures to 
hypoxia can have long lasting developmental effects on respiratory muscle (Carberry 
et al., 2014a; Neary and Breckenridge, 2013; Siren, 2016; Siren and Siren, 2011). 
Acute hypoxia features in many acute respiratory conditions such as acute lung injury 
(ALI), ventilator-induced/associated lung injury (VILI/VALI) and hypoxaemic 
respiratory failure or acute respiratory distress syndrome (ARDS). However, very 
little to nothing is currently known about the effects of acute hypoxia on the 
respiratory muscles, and this knowledge gap is one which needs to be addressed, 
given its clinical relevance. 
 
1.2.2 Hind-limb Muscles 
Two muscles of the hind-limb, namely the extensor digitorum longus (EDL) and the 
soleus muscles, are useful muscles to use as comparators to the respiratory muscles, 
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the diaphragm and sternohyoid muscles, when aiming to assess whether certain 
induced effects are respiratory muscle specific or global in skeletal muscle. Both of 
these muscles have very different functions and fibre type make-ups. The EDL is a 
fast, powerful, glycolytic muscle (76% type 2b) which lies along the anterolateral side 
of the hind-leg, deep to the tibialis anterior, and functions in dorsiflexion of the foot. 
The soleus, however, is composed of slow, highly endurant, oxidative fibres (96% 
type 1), and is positioned deep in the gastrocnemius muscle, posterior to the leg, and 
is employed in the maintenance of posture. These two muscles provide two distinct 
comparative view-points to respiratory muscle adaptations to hypoxia, which may be 
linked to muscle activity, fibre type composition, or simply muscle specific responses. 
 
 
1.3 Acute Hypoxia 
 
As stated previously, a knowledge gap exists concerning whether acute hypoxia is 
implicated in the pathophysiology of conditions in which it features, and this must be 
addressed. Acute hypoxia can occur as a result of airway obstruction/occlusion, 
blockage of the alveoli by pulmonary oedema or infectious exudate, or acute 
haemorrhage (Chapman et al., 1989; Cook and Macdougall-Davis, 2012; Gutierrez et 
al., 2004; Safar, 1969; Schaible et al., 2010). Acute hypoxia also features in many 
(acute) respiratory-related disorders, which shall be discussed in greater detail in the 
next section (1.4 Clinical Relevance). At present, while much work has been 
conducted in the area of skeletal muscle adaptations to chronic sustained hypoxia, 
very little is known about the early/acute adaptations of skeletal muscle, including the 
respiratory and upper airway muscles, to sustained hypoxia (Lundby et al., 2009). 
This is particularly true in the time frame of a number of hours in humans and animal 
models. However, it has been reported that mechanisms of gene expression regulation 
are distinct in acute and chronic exposure to hypoxia and that the cellular response to 
acute hypoxia is dynamic over time (Koritzinsky et al., 2006). Understanding the 
temporal effects of hypoxia over both the short- and long-term is essential to 
understanding the pathophysiological progression of respiratory-related disorders in 
which hypoxia features. It is also essential to understand how quickly maladaptations 
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to hypoxia can arise in order to intervene with therapeutic strategies in a timely 
manner. However, knowledge in this area is currently lacking and underexplored. 
 
Modulation of metabolism attributed to chronic hypoxia has also been reported in 
skeletal muscle (Hoppeler et al., 2003; Levett et al., 2012; Palma and Ripamonti, 
2007), and alterations in mitochondrial content and distribution specific to the 
diaphragm have been seen in chronic hypoxia (Gamboa and Andrade, 2010). While 
little work in this area has focused on the acute metabolic or mitochondrial response 
to hypoxia, mitochondrial UCP-3 messenger RNA (mRNA) and protein expression 
were found to be increased in rat skeletal muscle after only 30 minutes of hypoxia 
(Zhou et al., 2000), demonstrating the potential for acute hypoxia to alter skeletal 
muscle mitochondrial programming in a relatively short period of time, which may 
have functional outcomes in terms of muscle performance. This evidence further 
bolsters the argument that there is a need to explore hypoxic effects on the diaphragm 
within an acute timeframe. 
 
Chronic hypoxia generally leads to a negative regulation of protein balance and an 
overall loss in skeletal muscle mass, or atrophy (Deldicque and Francaux, 2013), 
likely contributing to chronic hypoxia induced muscle weakness, while acute hypoxia 
has been reported to have a positive effect on human skeletal muscle protein balance 
(D’Hulst et al., 2013), although this area is, as of yet, largely under studied and under 
explored. This is further evidence of how the effects of hypoxia on skeletal muscle 
can differ based on the temporal profile of exposure, and how it cannot necessarily be 
inferred that hypoxia has a defined set of effects on skeletal muscle no matter the 
length of exposure. Rather, it is emerging to be a dynamic process, which warrants 
further exploration, particularly in acute timeframes where information is most scarce 
and the potential role of hypoxia is understated. 
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1.4 Clinical Relevance 
 
1.4.1 Acute Respiratory-Related Disorders 
The effects of acute hypoxia on diaphragm form and function are largely unknown 
despite the fact that hypoxia is a prominent feature of many respiratory conditions, 
and while some inroads have been made regarding hypoxia’s role in diaphragm 
dysfunction under chronic conditions, its role in acute respiratory-related disorders is 
as of yet unexamined. Two acute respiratory conditions often encountered in the 
intensive care unit (ICU), and in which acute hypoxia features, are VILI and ARDS. 
These two pathophysiological conditions can give rise to a recognised phenomenon 
known as ICU acquired weakness (ICUAW). ICUAW includes weakness of the 
skeletal muscle, and that extends to the respiratory muscles, which is of particular 
significance due to diaphragm muscle weakness being a strong predictor of poor 
outcome in patients (Batt et al., 2013; Callahan et al., 2015; Callahan and Supinski, 
2013; Sieck, 2015; Supinski and Callahan, 2013). ALI and ARDS are syndromes of 
acute respiratory failure that result from acute pulmonary oedema and inflammation. 
The development and/or progression of ALI/ARDS is associated with several clinical 
disorders including direct pulmonary injury from pneumonia and aspiration as well as 
indirect pulmonary injury via trauma, sepsis and disorders such as acute pancreatitis 
and drug overdose (Matthay et al., 2003). Whether hypoxia, which features in these 
acute respiratory-related disorders, contributes to or causes diaphragm weakness in 
patients is as of yet unknown. 
 
1.4.2 Acute Lung Injury 
ALI is a significant source of morbidity and mortality in critically ill patients, 
characterised clinically by an acute onset of bilateral pulmonary infiltrates, 
hypoxaemia and oedema, with an absence of left arterial hypertension, in 
predominantly young, previously healthy people (Johnson and Matthay, 2010; Parekh 
et al., 2011). Sepsis, a clinical syndrome caused by systemic inflammation responses 
to infection and to molecular mechanisms of cell injury, is a common cause of ALI 
and ARDS (Campos et al., 2012; Matthay et al., 2003; Wheeler and Bernard, 1999). 
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1.4.3 Acute Respiratory Distress Syndrome 
In the United States, patients with ARDS occupy 1 in 10 critical care beds (Powers, 
2007). ARDS is a condition of the alveoli characterised by widespread inflammation 
in the lungs. It is a manifestation of acute lung injury, often due to sepsis, trauma and 
severe pulmonary infection, characterised clinically by dyspnoea, profound hypoxia, 
decreased lung compliance, and diffuse bilateral infiltrates on chest radiography 
(Udobi et al., 2003). Hypoxaemia occurs largely due to pulmonary shunt and 
ventilation/perfusion mismatch (M. J. Tobin, A. Jubran, 1998). ARDS affects around 
200,000 patients annually in the USA (Fuller et al., 2014; Salman et al., 2013). The 
prevalence rate of ALI/ARDS is around 7.1% of patients admitted to an ICU and 
16.1% of all mechanically ventilated patients in the ICU (Fuller et al., 2014; Goyal et 
al., 2012; Saguil and Fargo, 2012) and the mortality associated with the condition 
varies based on disease severity, age, and the presence or absence of confounding 
conditions, but is high at around 40%. Survivors of ARDS exhibit long-term 
morbidity across a wide range of important clinical outcomes, impacting significantly 
on public health and quality of life (Bernard, 2005; Fuller et al., 2014; Rubenfeld and 
Herridge, 2007; Salman et al., 2013). Mechanical ventilation of patients, in 
conjunction with supplemental oxygen therapy, is a strategy commonly employed in 
the management of ARDS (Udobi et al., 2003). However, whether hypoxia, featured 
in this condition, causes diaphragm dysfunction leading to worsened patient prognosis 
is understudied, which is surprising given the prevalence and severity of the condition 
and the fact that mechanical ventilation is often a necessary intervention. 
 
1.4.4 Mechanical Ventilation 
The use of mechanical ventilators, in the form of negative-pressure ventilation, first 
appeared early in the 1800s, later followed by positive-pressure devices around 1900, 
and finally the typical ICU ventilator of today began to be developed in the 1940s 
(Kacmarek, 2011). Modern positive-pressure mechanical ventilator strategies involve 
complicated feedback systems, matching ventilation to patient respiratory effort, 
attempting to provide sufficient ventilation and diaphragm unloading while causing 
minimal damage to the lungs, controlling for pressure and volume, and maintaining 
phrenic neural drive to the diaphragm, thus maintaining a level of stimulation of the 
diaphragm, helping to limit diaphragm atrophy. The number of patients that required 
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mechanical ventilation in hospital ICUs in the USA in 2005 was estimated at around 
800,000 with an estimated national cost of $27 billion, 12% of all hospital costs 
(Wunsch et al., 2010). The number of patients mechanically ventilated has risen 
drastically in the past 25 years. Indeed mechanical ventilation is an essential 
component of general anaesthesia for surgery, and it can be a life-saving intervention, 
particularly in critically ill patients.  However, mechanical ventilation can also have 
negative influences on the respiratory system, being associated with various short- 
and long-term complications including lung injury, infection, inflammation, 
diaphragm atrophy and weakness, and possibly leading to conditions such as 
VILI/VALI, ARDS and ventilator-induced diaphragmatic dysfunction (VIDD) 
(Callahan et al., 2015; Jaber et al., 2011a; Petrof et al., 2010; Serpa Neto et al., 2014; 
Supinski and Callahan, 2013). Mechanical ventilation has also been shown to induce 
collagen accumulation within two hours in the rat lung (Chen et al., 2015), 
interestingly, a complication which can be alleviated by pre-treatment with the thiol 
antioxidant NAC, suggesting that NAC may be useful in aiding the prevention of 
ventilator-induced lung fibrosis. Problematically, it can often become difficult to 
wean patients off mechanical ventilators after prolonged periods of time or when 
complications and confounding factors arise. 
 
Respiratory muscle weakness is reported in ICU patients on mechanical ventilation 
(Azuelos et al., 2015; Batt et al., 2013; Godoy et al., 2015; Hooijman et al., 2015; 
Jaber et al., 2011b; Jubran, 2006; Kallet, 2011; Petrof et al., 2010; Powers et al., 2013; 
Supinski and Callahan, 2013; Watson et al., 2001) and in animal models of VIDD 
(Mrozek et al., 2012; Powers et al., 2013, 2011, 2009, Smuder et al., 2015, 2012). 
Indeed, when a hypoxaemic respiratory patient in the ICU is placed on a mechanical 
ventilator, due to respiratory failure, diaphragm atrophy and dysfunction (VIDD) 
occurs in a matter of hours (Bruells et al., 2013), and there is recent evidence to 
suggest that the ubiquitin-proteasome pathway, as well as mitochondrial 
abnormalities, may be involved (Hooijman et al., 2015; Picard et al., 2015).Whilst 
inactivity of the diaphragm, due to the mechanical ventilator performing the work of 
breathing, is widely accepted as a major cause of this weakness (Jaber et al., 2011a; 
Levine et al., 2008; Supinski and Callahan, 2013), often compounded by infection 
(Petrof et al., 2010; Supinski and Callahan, 2013), the potential role, if any, that 
hypoxia may play in the development and/or exacerbation of this weakness is unclear. 
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Indeed, there now exists some controversy as to whether inactivity per se induces 
diaphragm muscle atrophy, and it has been suggested that other factors such as 
neurone-derived trophic factors may be at play (Sieck and Mantilla, 2013), which 
warrants further exploration. Thus, while there is much evidence of VIDD (Azuelos et 
al., 2015; Jaber et al., 2011a; Petrof et al., 2010; Petrof and Hussain, 2016; Powers et 
al., 2013), the exact mechanisms by which this weakness manifests are unknown. 
Acute hypoxia – as a feature of the initial illness which led to a patient requiring 
mechanical ventilation and/or persistent hypoxaemia – may play a part in the 
development of this weakness, and this area requires further elucidation. 
 
1.4.5 Ventilator-Induced Diaphragmatic Dysfunction (VIDD) 
Diaphragmatic function is a primary determinant of the ability to successfully wean a 
patient from mechanical ventilation, but animal models have demonstrated that the 
use of mechanical ventilation itself results in a major reduction in the force-generating 
capacity of the diaphragm as well as structural injury and atrophy of diaphragm 
muscle fibres. This leads to the condition termed ventilator-induced diaphragmatic 
dysfunction, or VIDD (Jaber et al., 2011a). Diaphragm weakness may also increase 
the risk of fatal airway obstruction incidents, due to the decreased peak force 
generating capacity limiting the ability of a patient to inspire the volume of air needed 
to perform the necessary expiratory airway clearance manoeuvre to clear the airway 
and restore pulmonary ventilation. As well as the other factors which contribute to 
VIDD, discussed earlier in this chapter, NF-κB signalling contributes to mechanical 
ventilation-induced diaphragm weakness in the rat. Furthermore, in this model 
oxidative stress is an upstream activator of NF-κB, and the authors suggest that 
prevention of mechanical ventilation-induced oxidative stress in the diaphragm could 
be a useful therapeutic strategy used clinically to prevent VIDD (Smuder et al., 2012). 
Indeed, it has been demonstrated that targeting of mitochondrial ROS with 
mitochondrial targeted antioxidants protects against VIDD (Powers et al., 2011), 
suggesting that mitochondrial ROS may play a causative role in VIDD. 
 
Prolonged mechanical ventilation alters the structure and function of the diaphragm 
(Powers et al., 2009), primarily manifesting in diaphragmatic atrophy (increased 
protein breakdown and decreased protein synthesis) and dysfunction. Patients who 
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undergo prolonged mechanical ventilation have a high mortality rate within the first 
12 months post-weaning, with COPD, cardiac and renal failure and respiratory muscle 
weakness all being factors recognised to contribute to this mortality (Johnson and 
Johnson, 2012). Interestingly, there may also be a high prevalence of under-
recognised sleep-disordered breathing (SDB) conditions such as obstructive sleep 
apnoea (OSA) in patients who wean from prolonged mechanical ventilation (Diaz-
Abad et al., 2011; Johnson and Johnson, 2012), which might relate to weakness in 
upper airway dilator muscles such as the sternohyoid muscles. 
 
1.4.6 Ventilator-Induced/Associated Lung Injury 
VILI and VALI both represent an acute injury to the lung, occurring during 
mechanical ventilation. VILI is caused by the act of mechanical ventilation itself, with 
an inadequate ventilator mode used to mechanically ventilate initially healthy lungs, 
while VALI is an injury to already disease-affected lungs during mechanical 
ventilation. In both cases, the lung injury primarily results from the differences in 
transpulmonary pressure, which consequently create an imbalance in lung stress and 
strain (Kuchnicka and Maciejewski, 2013). The incidence of VALI is around 24% of 
mechanically ventilated patients who do not have ALI from the outset, with a likely 
higher incidence in patients also suffering from ARDS/ALI (Gajic et al., 2004). This 
lung injury may lead to systemic hypoxia which, if it is a cause of diaphragm 
dysfunction, could exacerbate and perpetuate the need for mechanical ventilation 
causing further lung injury and the initiation of a vicious circle of ventilation, injury 
and hypoxia. 
 
1.4.7 Confounding Factors 
Through over-distension of the lung, mechanical ventilation induces substantial 
inflammation that is thought to increase mortality among critically ill patients, and 
may have relevance for the development of multisystem organ failure (Chiumello et 
al., 1999; Ranieri et al., 1999; Woods et al., 2015). 
 
Obesity has been suggested to independently increase the risk of developing ARDS 
(Karnatovskaia et al., 2014). Obese patients display alterations in baseline pulmonary 
mechanics, including airflow obstruction, decreased lung volumes, and impaired gas 
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exchange, which can have implications for many diseases including ARDS (Hibbert 
et al., 2012). However obesity does not, somewhat surprisingly, impact on the length 
of time a patient is likely to require mechanical ventilation, although it does increase 
the length of the ICU stay (Boles et al., 2007). 
 
Infection can be a major confounding factor in VIDD. Lower respiratory tract 
infections often present as severe sepsis or septic shock with respiratory dysfunction 
in mechanically ventilated patients (Rello et al., 2014). Pneumonia is the second most 
common nosocomial infection occurring in critically ill patients, presenting in 
approximately 27% of all critically ill patients (Koenig and Truwit, 2006). Severe 
sepsis and multiorgan failure invariably leads to muscle dysfunction. Reduced 
diaphragm muscle force generation, associated with deranged mitochondrial 
bioenergetics and hypometabolism, was observed in a rodent model of sepsis 
(Zolfaghari et al., 2015a). Although there was also an increase in UCP-3 expression in 
this model, these functional and metabolic changes were also present in a UCP-3 
knockout version of the same model, suggesting that these alterations are independent 
of the increase in UCP-3 expression seen in this model, and that reduced 
mitochondrial coupling efficiency by increased uncoupling (i.e. increased proton 
leak), potentially limiting mitochondrial ROS production, did not play a role. 
 
Given the prevalence of conditions featuring acute hypoxia discussed above, insight 
into the acute adaptations of the respiratory muscles to hypoxia may be clinically 
relevant. Respiratory muscle plasticity is reported in animal models of chronic 
hypoxia (Carberry et al., 2014; Gamboa and Andrade, 2012, 2010; Lewis et al., 
2015a,b; McMorrow et al., 2011); however, very little is known about the effects of 
an acute hypoxic stress on diaphragm muscle performance. 
 
1.4.8 A Potential Role for Hypoxia 
The role of acute hypoxia in the development, progression and exacerbation of acute 
respiratory related disorders, particularly diaphragmatic dysfunction as a feature of 
such disorders, is currently under-recognised, despite the clinical relevance of critical 
diaphragm failure, leading to respiratory failure and poor patient outcomes. In nature, 
a state of hypoxic tolerance is achieved through the integration of 1) a reduction in 
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metabolic state, 2) protection against hypoxic cell death/injury and 3) the maintenance 
of functional integrity (Ramirez et al., 2007). Knowledge of the mechanisms at play 
in all three of these areas is essential in order to develop novel therapeutic strategies 
for clinically hypoxic patients. Hypoxia has been shown to significantly decrease 
diaphragm end-expiratory length in awake canines (Ji et al., 2014), which may exert 
influence over the force generating capacity of the contracting diaphragm in vivo. 
This may be relevant to respiratory failure patients in an ICU setting and may be 
another hypoxia-induced factor affecting diaphragm function, as well as those effects 
exerted at a cellular level. The need to explore whether acute hypoxia contributes to 
diaphragm muscle weakness is currently most pertinent given the debate as to 
whether inactivity per se causes diaphragm muscle atrophy in mechanically ventilated 
patients. 
 
 
1.5 Skeletal Muscle Plasticity 
 
Skeletal muscle fibres are not regarded as fixed units but as highly versatile, 
adaptable, and malleable tissues. Skeletal muscle has huge capacity for remodelling 
and shows plasticity to adapt to a variety of stimuli including contractile activity (use 
and disuse, frequency of activity, etc.), loading conditions, substance supply and 
environmental conditions, such as hypoxia – the focus of this thesis (Flück and 
Hoppeler, 2003). Functional adaptations appear to involve alterations in contractile 
properties of the muscle, metabolic capacity of the mitochondria and regulatory 
mechanisms/intracellular signalling (Flück and Hoppeler, 2003; Hoppeler et al., 2003; 
Hoppeler and Fluck, 2003). Adaptations include alterations in muscle fibre size (e.g. 
hypertrophy, atrophy) and distribution (Bigard et al., 2000; Faucher et al., 2005; 
McMorrow et al., 2010), oxidative capacity (Faucher et al., 2005), contractile 
performance (El-Khoury et al., 2003; Faucher et al., 2005), angiogenesis (Deveci et 
al., 2002) and fibre type (e.g. slow-to-fast fibre type switching) (Pette and Staron, 
1997; Schiaffino and Reggiani, 2011). Indeed the diaphragm muscle atrophies in a 
mere matter of hours when a patient is put on a mechanical ventilator (Levine et al., 
2008), demonstrating remarkable structural maladaptive plasticity. 
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Respiratory muscles continually undergo remodelling as they adapt to the changing 
demands of respiration e.g. exercise, altitude changes, pathophysiology, etc. 
Respiratory muscle remodelling is a feature of COPD and may be the result in part of 
hypoxic adaptation (McMorrow et al., 2011). Dysfunction of respiratory muscle, 
particularly the diaphragm, is known to occur in patients with severe COPD (Heunks 
and Dekhuijzen, 2000; Polkey et al., 1996) and muscle oxidative capacity and 
bioenergetics are disturbed in COPD patients (Hoppeler et al., 2003; Mador & 
Bozkanat, 2001). However, the exact mechanisms by which skeletal muscle can alter 
its phenotypic profile are still unclear and under-explored. Furthermore, it is thought 
that the diaphragm, and other respiratory muscles, may adapt differently than most 
skeletal muscles due to the fact that, unlike limb skeletal muscle, its activity may be 
increased in some cases in response to hypoxia, and this needs to be addressed 
further. Translational animal models of hypoxia allow the examination of the effects 
of hypoxia on respiratory skeletal muscle without the influence of other confounding 
factors, which may present in disease states. They also offer an opportunity to explore 
the underlying molecular mechanisms contributing to adaptation and maladaptation in 
respiratory muscle. Illumination of such mechanisms could have enormous clinical 
relevance to conditions in which hypoxia features, and would contribute significantly 
to this field of research and the development of future therapeutic strategies. 
 
1.5.1 Structural and Function Plasticity in Hypoxia 
Some previous studies have looked at various structural and functional changes using 
animal models of hypoxia, both chronic hypoxia (sustained) and chronic intermittent 
hypoxia (CIH). McMorrow et al. (2011), using a translational animal model, found 
that chronic hypoxia decreased diaphragm muscle force and fatigue concomitant with 
increased sodium-potassium ATPase pump content, which plays a dynamic role in 
muscle fibre excitability during contractile activity. Moreover, the study suggested 
that this effect is NO dependent, and also that chronic hypoxia-induced muscle 
plasticity is time-dependent, further underlining the need to examine the effects of 
acute hypoxia to determine whether it has a role in diaphragm dysfunction in acute 
respiratory-related disorders. In another study by Skelly et al. (2010), it was found 
that CIH caused a significant decrease in sternohyoid muscle force, while chronic 
hypoxia has been shown to cause both diaphragm and sternohyoid muscle dysfunction 
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(Lewis et al., 2016, 2014). Fibre size, distribution and oxidative capacity were shown 
to be altered in hypoxia studies (Faucher et al., 2005; McMorrow et al., 2011), and it 
was also found that hypoxia induces prolonged angiogenesis in skeletal muscle in the 
rat (Deveci et al., 2002). The adaptation of skeletal muscle to hypoxia includes the 
loss of oxidative capacity (mitochondrial content) and a decreased fibre size and cross 
sectional area. The fatigue resistance of a skeletal muscle is proportional to its 
mitochondrial content, and so fatigue resistant muscles have a higher mitochondrial 
content than those with more fatigable fibres. Gamboa & Andrade (2010) stated that 
chronic hypoxia reduces aerobic capacity, and mitochondrial content, in limb skeletal 
muscles, and one of the causes seems to be decreased physical activity. Thus, they 
believed that diaphragm, and other respiratory muscles, may have a different pattern 
of adaptation as hypoxia may increase the work of breathing and so their activity may 
increase in response to hypoxia.  However, they found that chronic hypoxia was 
associated with a reduction in mitochondrial volume density (content) in mouse 
diaphragm. Reduced mitochondrial biogenesis and increased mitophagy seemed to be 
responsible. Then in 2012, the same group uncovered evidence to suggest that the 
diaphragm muscle retains its endurance during chronic hypoxia due to a combination 
of morphometric changes and optimisation of mitochondrial energy production. 
Changes include reduction in fibre size, increased surface contact between the 
capillary and fibre, increased mitochondrial complexes IV & V, and reduced 
mitochondrial uncoupling protein – 3 (UCP-3) content, allowing the muscle to remain 
highly fatigue resistant (Gamboa and Andrade, 2012). There are also some conflicting 
results in this area, such as the effects of hypoxia on diaphragm muscle force and 
endurance in the rat (El-Khoury et al., 2003; McMorrow et al., 2011). McMorrow et 
al. (2011) found chronic hypoxia decreased force and increased endurance of the 
diaphragm muscle, while El-Khoury and colleagues found twitch force was increased, 
tetanic force was unchanged, and there was little effect on endurance in the 
diaphragm muscle following chronic hypoxia. However, this may relate to differences 
in protocol, such as muscle bath temperature (30°C and 25°C in each set up, 
respectively) during the in vitro muscle function tests (Ranatunga and Wylie, 1983), 
& barometric pressure of the chambers during CH treatment (380mmHg and 
450mmHg respectively), and as such the intensity of the hypoxic stimulus. Indeed, it 
is clear from work performed by our group that chronic hypoxia (380mmHg or FiO2 = 
0.1) results in substantial diaphragm muscle weakness in rat (McMorrow et al., 2011) 
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and mouse (Lewis et al., 2016; Lewis and O’Halloran, 2016), presumably a functional 
trade-off to molecular changes that subserve other apparent advantages such as 
improved endurance (Gamboa and Andrade, 2012; Lewis et al., 2016; McMorrow et 
al., 2011) and hypoxic tolerance (Lewis et al., 2015a) . 
 
Recently, the previously unknown function of a protein involved in the cellular 
response to hypoxia was discovered. When activated by hypoxia, the protein 
(p75NTR) initiates a cascade of events resulting in increased blood vessel production 
to replenish oxygen supply in disease (Le Moan et al., 2011). Rowley et al. (2005) 
stated that muscle plasticity, which occurs following perturbations in the load and/or 
activity, includes changes in myosin heavy chain (MHC) isoform expression, MHC 
content per half-sarcomere, fibre cross-sectional area, mitochondrial density, and 
actomyosin ATPase activity, and that these structural changes are tied to functional 
plasticity, reflected by changes in some or all of the following: ECC, force, velocity 
of shortening, and susceptibility to fatigue. The relevance of this is that hypoxia can 
induce a perturbation of activity in respiratory muscle in humans, and one different to 
that of other skeletal muscles i.e. altered muscle activity due to increased ventilation. 
However, it has been demonstrated in humans that hypoxia itself, rather than activity 
changes, exacerbates diaphragm and indeed abdominal muscle fatigability (Verges et 
al., 2010). 
 
The mitochondria are the primary location of oxygen consumption and reactive 
oxygen species (ROS) production, and are becoming recognised as playing a pivotal 
role in oxygen sensing (Cummins and Taylor, 2005). It is established that in long-
term exposure to severe hypoxia there is a decrease in mitochondrial content of 
skeletal muscle fibres, oxidative muscle metabolism is shifted towards a greater 
reliance on carbohydrates as fuel, and intramyocellular lipid substrate stores are 
reduced (Hoppeler et al., 2003). Transcription of genes encoding the mitochondrial 
proteins involved in beta oxidation can be regulated separately from the genes of the 
Krebs cycle and the respiratory chain (Hoppeler and Fluck, 2003). Zhou & Lin (2000) 
demonstrated hypoxia and exercise induced mRNA expression for the mitochondrial 
transporter protein UCP-3 after only 30minutes in rat EDL muscle, and a 
corresponding UCP-3 protein increase. Changes in mRNA expression for proteins 
involved in energy production, as well as muscle structure, function and performance 
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in response to hypoxia is an important area in understanding hypoxia-induced 
alterations in respiratory muscle. Muscle fibre mitochondrial function and energy 
production is clearly a very malleable component contributing to muscle performance 
and an area that warrants investigation when examining how a stimulus such as 
hypoxia affects skeletal muscle. 
 
 
1.6 Skeletal Muscle Signalling 
 
Skeletal muscle is an extremely adaptable and malleable tissue responding 
functionally, structurally and molecularly to a variety of stimuli and, as such, requires 
a complex network of signalling pathways to guide these changes. Hypoxia has a 
profound impact on the cellular transcriptome and triggers a multifaceted cellular 
response that plays important roles in both normal physiology and pathophysiological 
disease states. The signalling pathways associated with transcriptional activation in 
CIH differ from those in chronic hypoxia (Nanduri et al., 2008). Tavi & Westerblad 
(2011), state that a major part of the activity-dependent plasticity of skeletal muscle 
relies upon transcriptional alterations controlled by intracellular Ca2+ signals. Muscle 
specific programmes of gene expression that match genetic phenotype with 
environmental demands are recruited by transcription factors, most of which are 
affected by Ca2+-dependent signalling cascades (Bassel-Duby and Olson, 2006; Tavi 
and Westerblad, 2011). However, the activity of these transcription factors is also 
affected by other factors in the cellular environment and so the result depends on a 
combination of both Ca2+-dependent and Ca2+-independent signalling (Gundersen, 
2011). An understanding of these signalling mechanisms in acute hypoxia is key to 
understanding how structural and functional changes manifest, and to highlighting 
targets for therapeutic interventions. 
 
Transcription factors, or transcriptional activators, affected by hypoxia include: 
hypoxia-inducible factors (HIF-1 & HIF-2), nuclear factor kappa B (NF-κB), cyclic 
AMP-response element-binding protein (CREB), activating protein-1 (AP-1), p-53, 
early growth response-1 (Egr-1), nuclear factor for interleukin 6 (NF-IL6), nuclear 
respiratory factor-1 (NRF-1), among a whole host of others (Cummins and Taylor, 
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2005; Gutsaeva et al., 2008; Nanduri et al., 2008). NRF-1 mediates expression of 
multiple nuclear genes encoding for mitochondrial proteins, including subunits of the 
respiratory chain complexes, among others (Gutsaeva et al., 2008). 
 
1.6.1 Signalling Pathway 
Skeletal muscle requires an array of complex signalling pathways in order to function 
normally and maintain homeostasis in the face of changing demands placed on the 
muscle. Many of these pathways have both common and distinct targets, and there 
exists a large amount of interplay between many of them to regulate factors such as 
growth, fibre type, metabolic activity, contractile performance, etc. in response to 
various stimuli. 
 
1.6.1.1 Hypertrophy/Atrophy Balance 
Atrophy of skeletal muscle can be a major consequence of numerous diseases, 
mediated via an imbalance between protein synthesis and degradation, or hypertrophy 
and atrophy, which are regulated by a complex system of signalling pathways (Bodine 
et al., 2001; Favier et al., 2010; Glass, 2005, 2003). The ubiquitin-proteasome system 
is a protein degradation system whereby proteins are tagged by poly-ubiquitination 
for proteasomal degradation. This ubiquitin-proteasome system, along with the 
autophagy-lysosomal system, is regulated by the FoxO transcriptional network. These 
two systems are responsible for the majority of protein breakdown in eukaryotes 
(Altun et al., 2012; Milan et al., 2015a). Diaphragm muscle fibre atrophy signalling, 
increased proteasome activity and decreased fibre cross-sectional area are features of 
chronic hypoxia exposure that may contribute to diaphragm muscle weakness in 
animal models (Lewis et al., 2015b; McMorrow et al., 2011). Diaphragm weakness 
and atrophy is a recognised consequence of mechanical ventilation in patients, as 
discussed earlier in this chapter, and the hypertrophy/atrophy balance is an intuitive 
place to look when examining the cause of muscle weakness, or changes in muscle 
contractile performance. 
 
 22 | P a g e  
 
1.6.1.1.1 Akt Pathway 
Akt is a serine-threonine protein kinase that can act as a modulator of both 
hypertrophy and atrophy in skeletal muscle, depending on its phosphorylation state. 
Akt regulates skeletal muscle fibre size and promotes hypertrophy via activation of 
downstream signalling pathways which are implicated in inducing protein synthesis: 
those downstream of mammalian target of rapamycin (mTOR) and glycogen 
synthesis kinase 3 (GSK-3) (Bodine et al., 2001; Léger et al., 2006; Rommel et al., 
2001). Indeed, activation of the Akt/mTOR pathway can oppose muscle atrophy 
induced by muscle disuse in vivo (Bodine et al., 2001), and it has been suggested that 
pharmacological activators of Akt, mTOR or p70S6K (a downstream positively 
regulated target of Akt/mTOR) may prove beneficial as therapeutic strategies to 
attenuate muscle atrophy in patients (Rommel et al., 2001). p70S6K exerts its pro-
hypertrophic action, partly via activation of S6RP (downstream target), by promoting 
protein synthesis. GSK-3β becomes inactivated via phosphorylation by Akt, thus 
suppressing its anti-anabolic effect and aiding pro-hypertrophic mechanisms such as 
protein synthesis activation. 
 
Activation of the PI3K-Akt-FoxO pathway induces cell growth while inhibition of 
this pathway reduces cell survival and, in skeletal muscle, causes fibre atrophy. 
Trim32 is a ubiquitin ligase which reduces PI3K-Akt-FoxO signalling in both normal 
and atrophying muscle (Cohen et al., 2014). Akt also promotes muscle hypertrophy 
by blocking the transcriptional upregulation of certain key mediators of skeletal 
muscle atrophy, namely the E3 ubiquitin ligases muscle RING-finger 1 (MuRF1) and 
Atrogin-1 (a.k.a. MAFbx), via the phosphorylation, and hence inhibition of nuclear 
translocation, of the Forkhead box class O (FoxO) family of transcription factors. 
Upon phosphorylation by Akt, the FoxOs are precluded from entering the nucleus and 
thus the upregulation of MuRF1 and Atrogin-1 is blocked. MuRF1 and Atrogin-1 
mediate their atrophic action via ubiquitination of specific protein targets, tagging 
them for proteasomal degradation. Targets of MuRF1 include components of the 
sarcomeric thick filament, including the MHC discussed further in section 1.7.2, 
which can be broken down under atrophic conditions (Cohen et al., 2009; Glass, 
2010). Meanwhile Trim32 catalyses the disassembly and degradation of the desmin 
cytoskeleton, Z-band and thin filament proteins in muscle atrophy (Cohen et al., 2014, 
2012; Sanchez et al., 2014). This targeting of the contractile units, in particular, as 
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well as others, of skeletal muscle highlights the central role these atrogenes play in 
skeletal muscle atrophy, and how they may lead to alterations in contractile 
performance. 
 
1.6.1.1.2 Mammalian Target of Rapamycin (mTOR) Pathway 
mTOR, as mentioned above, holds an important position in the regulatory control of 
skeletal muscle fibre hypertrophy. Downregulation of the Akt/mTOR pathway in 
skeletal muscle has been shown to occur in response to chronic hypoxia, linked to 
skeletal muscle fibre atrophy and a negative regulatory effect on skeletal muscle mass 
(Favier et al., 2010). mTOR is considered to be a central player in the control of 
skeletal muscle hypertrophy/atrophy balance. 
 
1.6.1.1.3 Mitogen Activated Protein Kinases (MAPK) Pathway 
Mitogen-Activated Protein (MAP) kinases are a family of signalling serine/threonine 
protein kinases which elicit intracellular effects in response to extracellular signals 
and physical or chemical cellular stresses. They are involved in regulating cell 
proliferation and differentiation, development, motility, inflammation, cell survival 
and apoptosis. ERK1/2, p38 and JNK are all MAP kinases, activated by MAPK 
kinases MEK1/2, MKK3/6 and MKK4/7, respectively (Zhang and Dong, 2005). ERK 
and  p38 MAPK-Activated Protein Kinases are a family of protein kinases with 
diverse biological functions (Roux and Blenis, 2004). Whether the MAPK pathway is 
pro-hypertrophic or pro-atrophic depends on the combination of signalling 
mechanisms converging together. However, ERK1/2 is predominantly pro-
hypertrophic, while p38 and JNK are predominantly pro-atrophic. 
 
1.6.1.1.4 FoxOs/FOXO-3a Pathway 
FoxO transcription factors, discussed above, are highly conserved, playing important 
roles in cellular homeostasis, regulating processes such as metabolism, cellular 
proliferation, stress tolerance and potentially lifespan (Sanchez et al., 2014; van der 
Horst and Burgering, 2007). The four FoxO members in humans, FoxO1, FoxO3 
FoxO4 and FoxO6, are all expressed in skeletal muscle and are involved in the control 
of skeletal muscle plasticity. FoxO1 and FoxO3 have central roles in energy 
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homeostasis and mitochondrial metabolism, as well as being key regulators of protein 
breakdown/atrophy, modulating the activity of certain factors in the ubiquitin-
proteasome and the autophagy-lysosome proteolytic pathways (Accili and Arden, 
2004; Chung et al., 2013; Mammucari et al., 2007; Milan et al., 2015b; Sanchez et al., 
2014). FoxO3 has been shown to be necessary and sufficient for the induction of 
autophagy in skeletal muscle in vivo (Mammucari et al., 2007). FoxO1 and FoxO3 are 
downstream targets of Akt and the major regulatory transcription factors of the 
atrogene Atrogin-1 (Milan et al., 2015b; Sandri et al., 2004). FoxO has been shown to 
be necessary for the activation of key proteolytic mechanisms; ubiquitin-proteasome 
system, autophagy/lysosomal system and caspase-3, some of these being essential for 
mechanical ventilation-induced diaphragm atrophy, and contractile dysfunction in the 
rat diaphragm (Smuder et al., 2015), making FoxO signalling an essential area of 
interest when examining diaphragm muscle atrophy signalling mechanisms under 
hypoxia. 
 
1.6.1.1.5 Atrogenes 
Development of atrophy from many sources such as fasting, cancer, sepsis, diabetes 
and kidney failure require or share the transcription and activation of a common 
programme of atrophy-genes, termed ‘atrogenes’, by FoxO transcription factors, 
whose activation is sufficient to produce accelerated proteolysis and atrophy (Cohen 
et al., 2014; Lecker et al., 2004; Sanchez et al., 2014; Sandri et al., 2004). These 
atrogenes encode proteins which catalyse important steps in autophagy-lysosomal and 
ubiquitin-proteasome systems, ROS detoxification and mitochondrial function and 
energy balance. The primary orchestrators of atrogene signalling inducing atrophy in 
skeletal muscle are muscle-specific ubiquitin ligases; Atrogin-1 and MuRF1 (Milan et 
al., 2015a). The actions of these ubiquitin ligases are negatively regulated by pro-
hypertrophic Akt signalling, via the inhibition of FoxO by Akt, as discussed above. 
FoxO-1 and FoxO-3 are two of the main transcriptional activators of Atrogin-1. 
 
1.6.1.1.6 Autophagy 
Autophagy, or the autophagy-lysosomal system, is a lysosomally mediated proteolytic 
process which can be activated by oxidative stress, or ROS. As mentioned above, the 
autophagy-lysosomal system is regulated by FoxO. Autophagy can be induced in the 
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diaphragm by mechanical ventilation but is not thought of as being a primary cause of 
diaphragm weakness in VIDD. In fact, autophagy may instead be a possibly 
beneficial adaptive response in the face of VIDD, working to optimise muscle cellular 
makeup (Azuelos et al., 2015). Indeed, autophagy allows for cell survival during 
starvation, via the bulk degradation of proteins and organelles by lysosomal enzymes 
(Mammucari et al., 2007). LC3B, BNIP3 and GABARAPL3 are key genes positively 
regulating autophagy and specifically mitophagy (autophagy mediated mitochondrial 
degradation) signalling (Hamacher-Brady and Brady, 2016; Saito and Sadoshima, 
2016), often functioning toward a pro cell survival programme rather than autophagy 
mediated atrophy. The investigation of autophagy in diaphragm muscle adaptations to 
hypoxia is therefore pertinent when considering we are dealing with a muscle 
attempting to maintain or optimise contractile performance in the challenge of a 
reduced oxygen environment. 
 
1.6.1.2 Hypoxia-Inducible Factor (HIF) Signalling 
Hypoxia-inducible factor (HIF) plays a central role in orchestrating the cellular 
hypoxia response. HIF is a heterodimeric protein belonging to the basic helix-loop-
helix PAS family of transcription factors (Lundby et al., 2009) and plays a central role 
in orchestrating the cellular hypoxia response. HIF-1, the most ubiquitously expressed 
and the best characterised of the family, is recognised as a master regulator of hypoxia 
signalling (Cummins and Taylor, 2005; Hoppeler et al., 2003; Semenza, 2004) and is 
known to play a very general role in hypoxia signalling (Lundby et al., 2009). Its 
activity is regulated by oxygen-dependent degradation of the dominant HIF-1α 
subunit (post-translational modification), which occurs at normal oxygen levels 
(normoxia). However, under hypoxic conditions this degradation rate decreases and 
HIF-1α stabilises, accumulates, and associates with HIF-1β to form the functional 
transcription complex, initiating the transcription of an array of hypoxia-inducible 
genes possessing a hypoxia response element (HRE) (Chi et al., 2006). 
 
Hypoxia in cells and tissues leads to the transcriptional induction of a series of genes 
that participate in angiogenesis, oxidative metabolism, iron metabolism, glucose 
metabolism and cell proliferation and survival, and the primary factor mediating this 
response is HIF-1 (Ke and Costa, 2006; Lundby et al., 2009). There are two other 
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members of the family, HIF-2 and HIF-3, and transcriptional activation by HIF-2 
regulates some target genes in common with HIF-1 as well as other genes uniquely 
regulated by HIF-2 (Peng et al., 2011), supporting the idea that HIF-1 and HIF-2 have 
many unique targets (Hu et al., 2003). Indeed, HIF-1α mRNA and protein levels have 
been found to be constitutively higher in more glycolytic muscles when compared 
with more oxidative muscles (Pisani and Dechesne, 2005), supporting the hypothesis 
that the oxygen homeostasis regulation system is fibre type dependent. HIF-1 
activation by CIH seems to be linked to increased pro-oxidant(s), while down-
regulation of HIF-2 by CIH is coupled to transcriptional down-regulation of 
antioxidant enzyme(s) (Prabhakar et al., 2009) such as manganese superoxide 
dismutase (MnSOD). Previous research has shown that mitogen-activated protein 
kinases (MAPKs) and phosphor-ionositol-3 (PI-3) kinases play a critical role in 
continuous hypoxia-induced activation of HIF-1 mediated transcription (Nanduri et 
al., 2008; Sang et al., 2003). Given the central and integral regulatory role of HIF-1α 
in orchestrating the hypoxia response within muscle fibres it is appropriate to explore 
how acute hypoxia may alter HIF-1α expression and regulation in respiratory muscle. 
 
MicroRNAs (miRNAs) are small (approx. 19-23 nucleotides long) noncoding RNAs 
which function in transcriptional and post-transcriptional regulation of gene 
expression through RNA degradation (Hoppeler et al., 2011). In recent years, studies 
have established a link between a specific group of miRNAs and hypoxia, known as 
hypoxia-regulated miRNAs (HRMs or hypoximirs), several of which exhibit 
induction in response to HIF activation (Kulshreshtha et al., 2008). miR-210 is one of 
the most hypoxia sensitive miRNAs and has been found to be up-regulated in 
response to hypoxia and can negatively regulate mitochondrial respiration activity and 
increase ROS production in cancer cell lines (Chen et al., 2010; Shen et al., 2013). 
miRNAs have been shown to be critically involved in the regulation of skeletal 
muscle myogenesis, modulating proliferation and differentiation (Hoppeler et al., 
2011). 
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1.7 Skeletal Muscle Contractile Mechanism 
 
1.7.1 Excitation-Contraction Coupling 
Excitation-contraction coupling (ECC) is a term coined by Alexander Sandow in 1952 
to describe the physiological process of converting an electrical stimulus (the motor 
neuron action potential) to a mechanical response (muscle contraction) (Sandow, 
1952). In skeletal muscle, when a depolarising action potential (AP) is transmitted 
along the sarcolemma of the muscle fibre and down the transverse tubules, it is 
thought to cause a conformational change in the dihydropyridine receptor (DHPR) in 
the t-tubule membrane which, by means of a protein-protein interaction, opens the 
ryanodine receptor (RyR), a Ca2+ release channel, in the terminal cisternae of the 
sarcoplasmic reticulum (SR) causing Ca2+ to be released into the myoplasm. The SR 
stores Ca2+ at high concentrations, creating a favourable concentration gradient 
facilitating efflux of Ca2+ from the SR into the myoplasm when RyR opens. 
Calsequestrin is a high capacity, low affinity Ca2+ binding protein localised in the 
lumen of the terminal cisternae of the SR, and is by far the most abundant of such 
proteins (Beard et al., 2004; Fliegel et al., 1987; Wei & Gallant, 2009). It appears to 
be anchored near the RyR by intra-membrane/transmembrane proteins including 
triadin and junctin, which also bind RyR, thereby increasing Ca2+ buffering capacity 
at the site of Ca2+ release (Wei et al., 2009). Histidine-rich calcium binding protein 
(HRC) is another, less abundant, low affinity Ca2+ binding protein in the SR and 
appears to bind triadin in a Ca2+ dependent manner, and so could have a role further 
than Ca2+ buffering (Sacchetto et al., 1999). Sarcalumenin is another Ca2+ binding 
protein in the SR and is thought to contribute to Ca2+ buffering and maintenance of 
Ca2+ pump proteins (Yoshida et al., 2005). 
 
The rise in intracellular Ca2+ concentration, due to SR Ca2+ release, promotes actin-
myosin interactions and causes a contractile twitch to occur. Ca2+ released from the 
SR binds to Troponin C causing the troponin complex to pull tropomyosin away from 
the myosin cross-bridge binding sites on the actin filaments. The myosin heads, 
bound to ADP+Pi, bind actin (cross bridge) at their binding sites. ADP+Pi 
immediately release, causing cocking of the myosin head and the myosin and actin 
filaments to slide past each other, known as the power stroke. ATP then binds the 
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myosin head, causing it to release actin, and ATP is then hydrolysed to ADP+Pi by 
myosin ATPase in the myosin head. Thus, in the presence of enough ATP and SR 
released Ca2+, this cycle continues. Relaxation of skeletal muscle occurs as 
intracellular Ca2+ is resequestered by the SR. Uptake of Ca2+ into the SR is facilitated 
by the sarco/endoplasmic reticulum Ca2+-ATPase pumps (SERCAs), which are 
distributed throughout the longitudinal tubule and terminal cisternae of the SR in 
skeletal muscle. It is clear that SR Ca2+ handling is central to muscle contractile 
activity, and thus it is logical to examine the expression of some of these key players 
in SR Ca2+ handling, mentioned above, when investigating how a stimulus such as 
hypoxia may alter contractile performance in respiratory muscle. 
 
1.7.2 Skeletal Muscle Fibre Types 
The MHC is the motor protein of the muscle sarcomeric thick filament. MHC 
isoforms – MHCslow, MHC2A, MHC2B and MHC2X provide a useful marker for muscle 
fibre types and can be identified by immunoreactivity to specific antibodies or by 
protein electrophoresis (Rowley et al., 2005; Schiaffino & Reggiani, 2011; Schiaffino 
et al., 1989). There are four major skeletal muscle fibre types: type I, type IIa, type IIx 
and type IIb, and these fibre types have varying properties such as fast-/slow-twitch 
kinetics, fatigue resistance, mitochondrial enzyme activity (oxidative, glycolytic), 
which influence their contractile and fatigue properties. Type I muscle fibres (red 
muscle) are slow contractile fibres with high fatigue resistance and low power 
production. They have a very high mitochondrial density and high capillary density 
and oxidative capacity, while glycolytic capacity is low. Type IIa fibres (red muscle) 
produce moderately fast contractions with medium power output and have a fairly 
high resistance to fatigue. They have a high mitochondrial density and intermediate 
capillary density with high oxidative and glycolytic capacity. Type IIx fibres are fast 
contracting fibres with an intermediate fatigue resistance and high power production. 
They have a medium mitochondrial density, low capillary density, and a high 
glycolytic capacity and intermediate oxidative capacity. Finally, type IIb muscle 
fibres (white muscle) produce very fast contraction velocities and have a very high 
power production, with a low resistance to fatigue. They have a low mitochondrial 
and capillary density and low oxidative capacity while glycolytic capacity is high in 
this fibre type. As discussed in section 1.6.1.1.1, MHC can be targeted for 
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ubiquitination and degradation by MuRF-1 under atrophic conditions in skeletal 
muscle, directly affecting the contractile unit of the muscle fibre. 
 
 
1.8 Reactive Oxygen Species (ROS) in Skeletal Muscle 
 
The mitochondria, due to oxidative metabolism, are the primary source of ROS 
production in skeletal muscle. There is now clear evidence that ROS are not only 
toxic species but, within certain concentrations, are useful signalling molecules 
regulating physiological processes (Barbieri and Sestili, 2012). ROS can activate 
HIFs (Prabhakar and Semenza, 2012), and plasticity of respiratory muscles following 
chronic hypoxia may be due to the generation of ROS (Bavis et al., 2007). ROS such 
as hydrogen peroxide (H2O2), superoxide anions (
.O2
-) and hydroxyl radicals (.OH) 
are chemically reactive, oxygen containing molecules, that are continually produced 
within skeletal muscle cells as a by-product of oxidative metabolism, and it has been 
shown previously that components of the contractile machinery are differentially 
responsive to alterations in the oxidation-reduction balance of muscle fibres (Andrade 
et al., 1998) and that maximum force production by fast- and slow-twitch skeletal 
muscles of rats and mice is modified by redox modulation (Plant et al., 2013). In 
figure 1 below, the baseline () muscle redox balance at rest is to the left (slightly 
reduced state) of the peak redox-balance for force production, and so maximum force 
production is not optimal. Reduction by Dithiothreitol (DTT) shifts the redox balance 
further to the left (), away from the optimal and decreases force production. A slight 
shift in redox balance to the right (oxidation) of baseline, by a brief exposure to H2O2, 
increases force production to a maximum (▼). However, further oxidation past the 
optimal redox state and further to the right of the figure (highly oxidised), due to 
prolonged exposure, decreases force production (▲). 
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Figure 1. Representative model of maximum isometric force production as a function 
of cellular redox balance in mouse hind-limb muscle (Figure redrawn from Andrade, 
et al., 1998). 
 
 
Xanthine oxidase is a form of the ROS producing enzyme xanthine oxidoreductase, 
present in human skeletal muscle (Hellsten et al., 1997), and one of its functions is 
thought to involve purine metabolism (Terada et al, 1990). It catalyses the oxidation 
of hypoxanthine to xanthine and can further catalyse the oxidation of xanthine to uric 
acid, and these reactions utilise molecular oxygen as an electron acceptor and form 
superoxide radicals (Volek et al., 2002). It has thus been shown to be involved in 
exercise-induced oxidative stress in COPD patients (Heunks, 1999). Giacomo et al. 
(1993) found evidence to suggest that acetyl-L-carnitine application in rat skeletal 
muscle, in vitro, reduced lipid peroxidation, and did so by inhibition of XO activity. 
Catalase is an enzyme that catalyses the decomposition of hydrogen peroxide to water 
and oxygen, and has a very high rate of turnover. It forms part of the endogenous 
antioxidant network opposing oxidative stress which also includes, among others, 
superoxide dismutase (SOD) and glutathione (GSH) peroxidase (Ramirez et al., 
2007). Together, these antioxidant enzymes protect cells from the deleterious effects 
of ROS. GSH is one of the most prevalently expressed and widely studied 
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antioxidants in this defensive network, and occupies many other cellular roles outside 
of its antioxidant duties. 
 
Pharmacotherapy for respiratory-related oxidative stress disorders is an attractive 
option, and antioxidant therapy may prove a viable and beneficial option. Skelly et al. 
(2012), found that Tempol, a superoxide scavenger, ameliorates pharyngeal dilator 
muscle dysfunction in a rodent model of CIH, important in the context of antioxidant 
therapy for respiratory disorders characterised by intermittent hypoxia such as sleep 
apnoea. Dutta et al. (2008) found that supplementation with L-carnitine, which plays a 
role in transport of fatty acids from the cytosol into the mitochondria during lipid 
peroxidation (stimulator of muscle bioenergetics), and is also an antioxidant, 
attenuated intermittent hypoxia induced oxidative stress and delayed muscle fatigue in 
rat limb muscle. L-carnitine has also been shown to favourably affect markers of 
muscle recovery from strenuous exercise by reducing oxidative stress (Volek et al., 
2002). 
 
N-acetylcysteine (NAC) is a highly effective free radical scavenger in its own right, 
but also functions as a major contributor to the maintenance of normal cellular GSH 
status in skeletal muscle cells (Kerksick and Willoughby, 2005). NAC has been 
credited with roles in improving skeletal muscle performance, including respiratory 
muscle, and preventing apoptosis following heavy exercise (Quadrilatero and 
Hoffman-Goetz, 2005, 2004; Reid et al., 1994; Shindoh et al., 1990; Supinski et al., 
1997), suggesting that NAC may be beneficial in cases of hypoxia-induced 
respiratory muscle weakness. NAC shall be discussed further in section 1.10 
Therapeutic Strategies below. 
 
 
1.9 Metabolism in Skeletal Muscle 
 
The patterns and strategies of lipid and carbohydrate metabolism in skeletal muscle 
change with muscle type and disease state (van Lunteren et al., 2010; van Lunteren 
and Moyer, 2013). The mitochondria are a prominent site within skeletal muscle 
fibres for ROS production (Muller et al., 2007; Murphy, 2009; Zorov et al., 2014). 
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Indeed, diaphragmatic mitochondrial ROS production is implicated in ventilation-
induced diaphragm weakness, and it has been demonstrated that targeting of 
mitochondrial ROS with specific mitochondrial targeted antioxidants prevents 
mechanical ventilation-induced increases in diaphragmatic mitochondrial ROS, and 
protects the diaphragm from mechanical ventilation-induced diaphragm weakness in 
animal models (Agten et al., 2011; Powers et al., 2011), suggesting that mitochondrial 
ROS may play a very central role in VIDD by weakening the diaphragm muscle. 
 
It has been suggested that mitochondrial membrane potential regulates the production 
of mitochondrial ROS. Therefore, uncoupling of oxidative phosphorylation from the 
electron transport chain in the mitochondrial membrane, dissipating the membrane 
potential as heat, may decrease mitochondrial superoxide production. Positive 
regulation of UCP-3 expression may therefore serve a protective role, by diminishing 
mitochondrial ROS generation in skeletal muscle. Indeed, ROS production is 
enhanced in UCP-3 knockout mice (Bodrova et al., 1998; Sastre et al., 2003). 
 
In sepsis, muscle dysfunction is observed and bioenergetics dysfunction and oxidative 
stress are implicated as underlying pathophysiological mechanisms. Increased UCP-3 
in sepsis is suggestive of increased proton leak, as described above, limiting ROS 
production at the cost of mitochondrial coupling and efficiency of ATP production. 
However, in mouse knockout model, UCP-3 did not appear to play a role in sepsis-
induced muscle dysfunction (Zolfaghari et al., 2015b), although mitochondrial 
bioenergetics were deranged. UCP-3 upregulation may also serve an antioxidant 
function in protecting muscle mitochondria from exercise-induced oxidative stress, at 
the compromise of oxidative phosphorylation efficiency in skeletal muscle during 
exercise (Jiang et al., 2009). It would appear that oxidative stress and ROS, 
particularly mitochondrial ROS production is an area warranting investigation in 
situations where muscle weakness occurs and oxygen homeostasis is altered. 
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1.10 Therapeutic Strategies 
 
1.10.1 Antioxidants and NAC 
The use of antioxidants has been suggested as a therapy in the treatment of many 
respiratory-related disorders such as ALI, sepsis, COPD, lung fibrosis and cystic 
fibrosis where oxidative stress or imbalance may feature (Campos et al., 2012; 
Cazzola et al., 2015; Conrad et al., 2015; Day, 2008; Skov et al., 2015; Suter et al., 
1994; Víctor et al., 2009). NAC, a thiol containing compound, is one such antioxidant 
with widespread clinical use and which has been used to treat a variety of respiratory 
and lung diseases as well as other pharmacological uses, such as the treatment of 
paracetamol overdose. NAC has been in clinical use for almost 50 years, primarily as 
a mucolytic but also in conditions characterised by oxidative stress or decreased GSH. 
It is the acetylated variant of the amino acid L-cysteine, is an excellent source of 
sulfhydryl groups, and is metabolised in the body into products capable of stimulating 
the synthesis of GSH, the important endogenous antioxidant, as well as acting directly 
as a free radical scavenger itself (Kelly, 1998). 
 
NAC has been shown to alleviate mechanical ventilation-induced collagen 
accumulation in the rat and may be a potential candidate in preventing ventilation-
induced lung fibrosis (Chen et al., 2015). Intravenous NAC administration during a 72 
hour period has been shown to improve systemic oxygenation and reduce the 
requirement for ventilator support in patients presenting with mild to moderate ALI 
subsequent to various underlying conditions. However, in that study, the incidence of 
ARDS development and mortality were not reduced significantly by this intervention 
(Suter et al., 1994). In a recent study by Azuelos et al. (2015), using a mouse model of 
VIDD, they found that treatment with an I.P. injection of NAC immediately after the 
initiation of 6 hours of mechanical ventilation completely prevented the development 
of mechanical ventilation-induced diaphragmatic weakness. However, it did not 
suppress autophagy but rather it augmented autophagosome formation. They suggest 
that this may elucidate a novel mechanism whereby NAC exerts its beneficial effects 
on VIDD via stimulation of autophagy (excess ROS can inhibit autophagy), which 
may in fact be a beneficial adaptive response in the diaphragm, as discussed 
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previously in section 1.6.1.1.6 Autophagy, to the physiological stress of mechanical 
ventilation rather than representing a contributing factor to the development of VIDD. 
 
1.10.2 NAC and Muscle Function 
Intravenous NAC pretreatment appears to be beneficial in offsetting the rate of 
development of muscle fatigue in the rabbit diaphragm in situ (Shindoh et al., 1990). 
Superoxide scavengers have been shown to increase upper airway/pharyngeal dilator 
muscle (sternohyoid) force under both hyperoxic and hypoxic conditions ex vivo and 
ameliorate sternohyoid muscle dysfunction in a rodent model of CIH, and may be of 
potential therapeutic value in OSA and central sleep apnoea patients (Skelly et al., 
2012b, 2010). Recently, it was found that NAC improved soleus, but not EDL, 
muscle fatigue resistance in a mouse model of peripheral arterial insufficiency 
(Roseguini et al., 2015), suggesting that the beneficial effects of NAC may be muscle 
specific under certain conditions. Finally, chronic antioxidant supplementation has 
been shown to prevent chronic hypoxia induced sternohyoid and diaphragm muscle 
weakness, and alter the activation of some of the chronic hypoxia induced signalling 
mechanisms in these muscles when given concomitantly (Lewis et al., 2015b, 2015c). 
Taken together these data suggest that NAC may hold great potential in alleviating 
muscle dysfunction in conditions of oxidative stress, hypoxia or muscle weakness. 
 
 
Currently, little to no research exists regarding how acute hypoxia exposure may 
affect the diaphragm. This is surprising given the clinical prominence and relevance 
of acute hypoxia, alongside the fact that it often presents in conditions concomitant 
with diaphragm weakness/dysfunction .Weakness, particularly diaphragm muscle 
weakness, potentially caused/exacerbated by acute hypoxia could accelerate critical 
diaphragm failure and thus respiratory failure, extend the timeframe in which an 
acute-respiratory patient may require mechanical ventilation, contribute significantly 
to an inability to wean patients from mechanical ventilation, and could thus lead to 
poor prognosis in ICU patients. Investigation of the potential role that hypoxia, as a 
feature of acute respiratory disorders, may play in the development and/or 
exacerbation of diaphragmatic dysfunction in acute respiratory-related disorders and 
mechanically ventilated patients is therefore pertinent and clinically relevant. 
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1.11 Thesis Aims 
 
The aim of this thesis is to determine if acute hypoxia is sufficient to cause diaphragm 
muscle dysfunction, to uncover some of the mechanisms by which this process may 
be occurring, and assess the efficacy of NAC in precluding any acute hypoxia-
induced diaphragmatic effects. The sternohyoid muscle is also of interest due to its 
clinical relevance discussed earlier. 
 
In order to study this, a mouse model was utilised whereby mice were exposed to 
different durations of acute hypoxia, with and without NAC pretreatment. Mouse 
diaphragm and sternohyoid muscle contractile function, and rat diaphragm contractile 
function, are reported in chapter 3. In vivo metabolic and respiratory responses to 
hypoxia of the mouse, as well as diaphragm proteasome activity and gene expression 
relating to metabolism, atrophy and SR calcium handling in diaphragm, sternohyoid, 
EDL and soleus (as comparators) muscles are described in chapter 4. Chapter 5 
describes the effects of NAC pretreatment on diaphragm muscle contractile function, 
alongside diaphragm and sternohyoid signalling pathway responses to hypoxia 
relating to hypertrophy/atrophy and HIF signalling, as well as the effects of NAC 
pretreatment on these signalling processes in the diaphragm. 
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Chapter 2: Materials and Methods 
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2.1 Ethical Approval and Animal Licence 
 
All protocols involving animals described in this study were approved by local ethics 
committee and were performed under licence from the Irish Government Department 
of Health and Children in accordance with EU legislation. 
 
 
2.2 Animal Model 
 
Mouse models of acute hypoxia were generated using adult male C57BL6/J mice 
(Envigo, formerly known as Harlan, UK). Mice (approximately 14 weeks of age) 
were placed in environmental plethysmography chambers (BUXCO Ltd, St. Paul, 
Minneapolis, USA), at room temperature,  in which ambient oxygen levels were 
measured and adjusted to desired levels (Gas Analyzer, ML206, AD Instruments, Fig. 
9), (Fig. 1(A)). Mice were exposed to 1, 4 or 8 hours of hypoxia (Fraction of inspired 
oxygen, FiO₂ = 0.10) or normoxia (FiO₂ = 0.21) (n = 8 per group, 4 groups). 
Reducing the fractional volume of oxygen within the environmental chamber results 
in a reduction of the fractional volume of oxygen in the inspired air in the mouse 
airway, alveoli and thus blood, resulting in hypoxaemia for the animals. Exposures to 
normoxia and hypoxia were performed in parallel, staggered, using a two-chamber 
set-up. In all instances, mice were in environmental chambers for approximately nine 
hours, between 0900h and 2100h (daytime) (Fig. 1(B)). For the first thirty minutes the 
mice were allowed to settle, under room air conditions. The second thirty minute 
period was used to establish baseline breathing parameters (see methods section 2.8 
Whole-Body Plethysmography). Then the animal was exposed to 8 hours of normoxia 
for the control group, 7 hours of normoxia followed by 1 hour of hypoxia for the 1 
hour hypoxia group, 4 hours of normoxia followed by 4 hours of hypoxia for the 4 
hour hypoxia group, or 8 hours of hypoxia for the 8 hour hypoxia group. Designing 
the experiments in this way allowed us to reduce the number of animals needed as we 
did not need a control group matched to each exposure duration but rather one control 
group to compare with all groups, as animals in all groups spent the same amount of 
time in the environmental chambers. During gas exposure animals had access to 
water. 
 38 | P a g e  
 
 
(A) 
 
 
(B) 
 
Figure 1: Gas exposure experiments. (A) Parallel environmental chamber set up 
and (B) Gas exposure experiments timeline. 
 
 
2.2.1 Sample Size Calculation 
N numbers for each group were based on previously published work by our lab group 
(McMorrow et al., 2011): 
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Diaphragm fatigue index (a percentage of force generation, relative to initial force, 
following a fatigue protocol/repeated stimulation): ~72.5% ± 6% and ~50% ± 6% in 
hypoxia and control groups respectively (difference to detect = 22.5%), n = 6 per 
group. 
Standard deviation: ~14% 
Experimental power desired: 80% 
Confidence level: 95% 
Sample size required: ~7 (n = 8 was used in case of animal/sample loss during 
technical experimental procedures) 
 
Calculations 
 
Sample size equation: 
 
Sample size (n) = (2 x SD2) x (Za/2 + Zβ)2/(d2) 
 
SD = standard deviation = 14 
Za/2 = Z0.05/2 = 1.96 (Z tables) for 5% significance level 
Zβ = Z0.2 = 0.842 (Z tables) for 80% power 
d = effect size to detect = 22.5 
 
n = (2 x 142) x (1.96 + 0.842)2 / (22.52) = 6.1 
 
n = ~7 (n = 8 was used in case of animal/sample loss during technical experimental 
procedures) 
 
 
2.2.2 Exposure Groups 
Five independent hypoxia exposure trials were carried out over the course of this 
study. Four of these were conducted on mice while one was conducted on rats, to 
determine if the phenotype was conserved across species. 
 
 40 | P a g e  
 
 
2.2.2.1 Mice 
Group 1: Thirty-two mice (4 groups; n = 8 per group) were exposed to hypoxia for 1, 
4 and 8 hours while mice in the fourth control group were exposed to normoxia (mice 
in all groups spent the same amount of time in the environmental chambers). Mice in 
these groups were used to harvest tissue for RNA analysis. 
 
Group 2: Sixteen mice (2 groups; n = 8 per group) were exposed to 8 hours of either 
hypoxia or normoxia in environmental plethysmography chambers, thus allowing us 
to monitor breathing in real-time, breath by breath, during gas exposure. Following 
gas exposure and respiratory analysis, muscles from these animals were excised for 
functional analysis. 
 
Group 3: Thirty-two mice mice (4 groups; n = 8 per group) were exposed to either 
hypoxia (sixteen mice, two groups of eight) or normoxia (sixteen mice, two groups of 
eight) for 8 hours. One control group and one hypoxia group were utilised to monitor 
breathing, in vivo metabolism, post-mortem body temperature and muscle contractile 
function. Muscle samples from these animals were also preserved in cryoprotectant 
medium (OCT) for future studies to measure muscle fibre cross sectional area. Mice 
in the remaining hypoxia and normoxia groups were used to harvest tissue for protein 
analysis. Post-mortem body temperatures were also taken from these animals. 
 
Group 4: Eight mice (1 groups; n = 8) were administered a single intraperitoneal (I.P.) 
injection of NAC immediately prior to entering the environmental chambers and 
subsequently being exposed to 8 hours of hypoxia. Following gas exposure these mice 
were used to analyse muscle function, post-mortem body temperature, and muscle 
tissue was snap-frozen for protein analysis. 
 
 
2.2.2.2 Rats 
Group 1: Sixteen male Wistar rats, approximately 14 weeks of age (Envigo, UK) (2 
groups; n = 8 per group) were exposed to either hypoxia or normoxia for 8 hours in 
environmental plethysmography chambers. Breathing parameters, in vivo metabolism, 
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post-mortem body temperature and muscle contractile function were measured in 
these animals. 
 
 
2.2.3 I.P Injection of NAC 
To prepare the NAC solution for I.P injection, one phosphate buffer saline (PBS) 
tablet was dissolved to 200ml in deionised H2O the day before injection. The PBS 
solution was then sterilised by autoclave and refrigerated until the next morning. NAC 
was dissolved in the PBS solution, pH adjusted to 7.4 using NaOH and filter 
(vacuum) sterilised. Mice were then injected with 200mg/kg NAC (Azuelos et al., 
2015), at room temperature, via I.P. injection in the lower left quadrant using a sterile 
syringe. 
 
 
Following gas exposures, animals were immediately euthanised using a rising 
concentration of CO2 until narcosis, followed immediately by cervical dislocation to 
confirm euthanasia. Care was taken while performing this procedure in order to 
prevent causing damage to the sternohyoid muscles. Core post-mortem body 
temperature was determined immediately (within 10 seconds of euthanasia), via 
insertion of a rectal thermometer probe and body weights were recorded. Diaphragm, 
sternohyoid, EDL and soleus muscles were excised post-mortem and either 
immediately used for functional analysis or immediately preserved in OCT or snap-
frozen in liquid nitrogen and stored at -80°C until further processing. 
 
 
2.3 Gene Expression 
 
2.3.1 RNA Extraction and Preparation 
Total RNA was extracted, using Tripure Isolation Reagent (Roche Diagnostics Ltd., 
West Sussex, UK), from 20 – 70 mg of frozen muscle tissue using a General 
Laboratory Homogenizer (Omni-Inc., Kennesaw, Georgia, USA) as per the 
manufacturer’s instructions, with an additional chloroform wash step during phase 
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separation. Following isolation, RNA was treated with TURBO DNA-free Kit (Life 
Technologies, Bio-Sciences, Dun Laoghaire, Ireland) as per the manufacturer’s 
instructions. RNA quantity and purity was assessed by spectrophotometry with a 
Nanodrop 1000 (Thermo Scientific, Wilmington, Delaware, USA) (Fig. 2). RNA 
integrity was assessed using an agarose gel electrophoresis system (E-gel, Life 
Technologies) and visualisation of clear 18S and 28S ribosomal RNA bands (Fig. 3). 
 
 
Figure 2: RNA quantity & purity control. Screenshot of the absorbance curve 
generated during the testing of one of the RNA samples on the Nanodrop 1000 
showing the RNA concentration of the sample in the bottom right corner and above 
that the 260/280 and 260/230 ratios which, along with the single peak on the trace at 
260, show that the purity of the sample is good. 
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Figure 3: RNA integrity control. A picture of one of some of the RNA samples after 
being run on the E-gels system, clearly showing the separate 28S and 18S ribosomal 
RNA bands indicating the RNA integrity is preserved. 
 
2.3.2 Reverse Transcription 
RNA was reverse transcribed using Transcriptor First Strand cDNA Synthesis Kit 
(Roche Diagnostics Ltd.) as per the manufacturer’s instructions. 
 
2.3.3 qPCR 
cDNA was amplified using Realtime ready Catalog or Custom Assays (Roche 
Diagnostics Ltd.) (Table 1, below) and Fast Start Essential DNA Probe Master 
(Roche Diagnostics Ltd.) in 20 μl reactions (5 μl  cDNA and 15 μl master mix) as per 
the manufacturer’s instructions, using the LightCycler 96 (Roche Diagnostics Ltd.) on 
96-well plates (Fig. 4). All reactions were performed in duplicate and reverse 
transcriptase negatives, RNA negatives, cDNA negatives (no template) and plate 
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calibrator controls were used on every plate. Data were normalised to a reference 
gene, hprt1, to compensate for variations in input RNA/cDNA amounts and efficiency 
of reverse transcription. Several candidate reference genes were screened and hprt1 
was found to be most stable considering tissue type, time and gas exposures. Figure 5 
below shows the standard deviations of quantification cycles (Cq) of the best four 
candidate reference genes screened across muscle type and gas exposure time. A 
standard deviation of less than or equal to 0.5 was set as an acceptable level. Hprt1 
was revealed to be the most stable reference gene for this model, with a standard 
deviation of 0.39. Relative expression was calculated using the ΔΔCT method to 
normalise expression of the gene of interest to that of the reference gene with changes 
in expression displayed as a fold change over the control group. 
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Table 1: Realtime ready Catalog and Custom Assays used for cDNA 
amplification. 
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Figure 4: PCR. LightCycler 96 instument, 96-well plate and an example of a single 
amplification curve created from the reaction in one well on a 96-well plate following 
PCR. 
 
 
 
Figure 5: Standard deviation (SD) values of candidate reference genes. Each 
column represents the SD of that gene across 16 samples – a sample from each 
muscle (diaphragm, sternohyoid, EDL and soleus) in each treatment group (control, 1 
hour, 4 hours and 8 hours of hypoxia). 
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2.4 Protein Extraction and Quantification 
 
Frozen muscle samples were removed from storage at -80ºC, weighed and 
homogenised, on ice, in ice-cold 2.5% w/v modified radio-immunoprecipitation assay 
(RIPA) buffer (1X RIPA, deionised H2O, 200mM sodium fluoride, 100mM 
phenylmethylsulfonylfluoride (PMSF), 1X protease inhibitor cocktail, 2X 
phosphatase inhibitor cocktail) using a General Laboratory Homogenizer (Omni-Inc., 
Kennesaw, Georgia, USA). Following 20 minutes lyse time on ice, with vortexing 
every 4 minutes, samples were centrifuged in a U-320R centrifuge (Boeckel + Co, 
Hamburg, Germany) at 14,000 RPM and at 4ºC for 20 minutes to separate insoluble 
cellular fractions from the protein homogenates. The protein containing supernatant 
was separated from the insoluble pellet in each sample and these were stored at -80ºC. 
The pellets were discarded. 
 
The protein concentration of each sample was determined using a bicinchoninic acid 
(BCA) protein quantification assay (Pierce Biotechnology, (Fisher Scientific), 
Ireland) as per the manufacturer’s instructions, at a dilution of 1:3. 
 
 
2.5 Hypertrophy and Atrophy Signalling 
 
2.5.1 Akt Signalling Panel – phospho-Akt, phospho-p70S6K, phospho-S6RP and 
phospho-GSK-3β 
The Akt signalling panel measures the phosphorylated content of four key signalling 
proteins in the Akt signalling cascade, namely Akt (a.k.a. Protein kinase B), p70S6K, 
ribosomal protein S6 (S6RP) and glycogen synthesis kinase-3 (GSK-3β). The 
Mesoscale multiplex format assay (Mesoscale Discovery, Gaithersburg, USA) allows 
the measurement of all four of these phosphor-proteins in one well.  The assay is a 
sandwich immunoassay. Each well of a 96-well plate is pre-coated with an array of 
capture antibodies targeted against each different protein of interest adhered to 
spatially distinct electrodes, or spots, within that well. The assay was carried out in 
accordance with the manufacturer’s instructions. Briefly, samples were loaded onto 
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the 96-well plate and incubated to allow the proteins of interest to be captured by their 
specific capture antibodies. Each well was then washed and incubated in a detection 
antibody solution. The detection antibodies, specific for each protein of interest, are 
conjugated with an electrochemiluminescent compound, or tag. The detection 
antibodies bind to the captured proteins of interest, which are bound to their specific 
capture antibodies, on the distinct spots on the bottom surface of the well. This 
completes the antibody-protein-antibody sandwich (Fig. 6). The well was then 
washed again and read buffer was added, creating the correct chemical environment 
for electrochemiluminescence. The plate was loaded into the MSD SECTOR Imager 
(a specialised spectrophotometer from Mesoscale) where a voltage is rapidly applied 
to the distinct working electrodes on the plate spots resulting in the tags conjugated to 
the antibodies attached to those electrodes emitting light, which is read by the imager 
at 620nm. The intensity of this emitted light from each spot, separated both 
temporally and spatially, provided a quantitative measurement for each protein of 
interest in the sample. This assay was performed on diaphragm samples from control, 
8 hours hypoxia and 8 hours hypoxia + NAC groups, and on sternohyoid samples 
from control and 8 hours hypoxia groups. A series of dilutions of an EDL sample was 
also assayed to demonstrate increased luminescence with increased protein content 
added to the well. 
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Figure 6: The Mesoscale 96-well plate. Including depiction of how the capture 
antibodies are laid out in distinct spots in each well and how the antibody-protein-
antibody sandwich is formed. 
 
 
2.5.2 Phospho-/Total mTOR Assay 
The Phospho-/Total mTOR Assay allows the measurement of both phosphorylated 
mammalian Target of rapamycin (mTOR) and total mTOR content on spatially 
distinct spots as described above for the Akt signalling panel but with some variation 
to the incubation periods. This assay was performed on diaphragm samples from 
control, 8 hours hypoxia and 8 hours hypoxia + NAC groups, and on sternohyoid 
samples from control and 8 hours hypoxia groups. A series of dilutions of an EDL 
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sample was also assayed to demonstrate increased luminescence with increased 
protein content added to the well. 
 
 
2.5.3 Phospho-FOXO3a Assay 
The Phospho-FOXO3a Assay is a singleplex version of the assays described above, 
examining phosphorylated Forkhead box O3a (FOXO3a) only. This assay was 
performed on diaphragm samples from control, 8 hours hypoxia and 8 hours hypoxia 
+ NAC groups, and on sternohyoid samples from control and 8 hours hypoxia groups. 
A series of dilutions of an EDL sample was also assayed to demonstrate increased 
luminescence with increased protein content added to the well. 
 
 
2.5.4 MAP Kinase Phosphoprotein Assay – phospho-MAP, phospho-ERK1/2, 
and phospho-JNK 
The MAP Kinase Phosphoprotein Assay quantifies at the phosphoprotein content of 
the Mitogen-Activated Protein (MAP) kinases ERK1/2, p38 and JNK in a multiplex 
fashion as described above. This assay was performed on diaphragm samples from 
control, 8 hours hypoxia and 8 hours hypoxia + NAC groups, and on sternohyoid 
samples from control and 8 hours hypoxia groups. A series of dilutions of an EDL 
sample was also assayed to demonstrate increased luminescence with increased 
protein content added to the well. 
 
 
2.6 Hypoxia Signalling 
 
2.6.1 Total HIF-1α Assay 
The Total HIF-1α Assay examines the Hypoxia-Inducible Factor (HIF) 1α protein 
content in samples. This assay was performed on diaphragm samples from control, 8 
hours hypoxia and 8 hours hypoxia + NAC groups, and on sternohyoid samples from 
control and 8 hours hypoxia groups. A series of dilutions of an EDL sample was also 
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assayed to demonstrate increased luminescence with increased protein content added 
to the well. 
 
 
2.7 Proteasome Activity 
 
Chymotrypsin-like 20S proteasome activity was measured via fluorescence in a 
spectrophotometric assay as per the manufacturer’s instructions (Abcam) and using a 
Spectramax M3 (Molecular Devices, CA, USA) spectrophotometer (Fig. 7). The 
assay employs a peptide substrate tagged to AMC. In the presence of proteasome 
activity the AMC tag is released and fluoresces. The kit includes a positive control in 
the form of Jurkat cell lysate with high proteasome activity and a specific proteasome 
inhibitor MG-132 which suppresses all proteolytic activity attributed to proteasomes, 
thus allowing the differentiation of proteasome activity from other protease activity in 
the sample. This assay was performed on diaphragm samples from control and 8 
hours hypoxia groups on a white 96-well plate and all samples and positive controls 
were assayed with and without the proteasome inhibitor. The samples, positive 
controls and standards were added to the 96-well plate. Inhibitor was added to their 
assigned wells (an equal volume of assay buffer was added to the uninhibited wells) 
and proteasome substrate was added to all wells except the standards. The plate was 
then incubated at 37°C in the spectrophotometer (protected from light) for one hour 
while fluorometric readings were made kinetically over that time at Ex/Em = 350/440 
nm. There is a slight nonlinearity to the reaction kinetics at the beginning due to the 
lag time it takes for the reaction to mix and warm to 37°C. Readings were made from 
the linear range of the reaction. Non-proteasome activity was then subtracted from 
total proteasome activity to give proteasome activity. One unit of proteasome activity 
is defined as the amount of proteasome which generates 1nmol of AMC per minute at 
37°C. 
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Figure 7: Spectromax M3 spectrophotometer. 
 
 
2.8 Whole-Body Plethysmography 
 
Respiratory recordings were made throughout the period of gas exposure in 
unrestrained, freely-behaving mice using whole-body plethysmography (Buxco Ltd). 
This allowed the measurement of breathing parameters on a breath-by-breath basis in 
real-time (Fig. 8). The technique is based on the measurement of pressure changes 
within the environmental chamber by a sensitive pressure transducer. These pressure 
changes are influenced by the animal’s breathing. The system allows for the 
continuous flow of gas, in this instance air or 10% O2 in N2, from an external source, 
through the chamber set-up. The chambers were fitted with screen 
pneumotachographs which allowed air to pass out of the chamber, so that small 
changes in pressure within the chamber were directly proportional to flow. The 
system was calibrated each morning, prior to beginning the experiment, by slowly and 
steadily injecting a known volume of air (1 ml) into the chamber, such that the 
volume of gas injected is within defined parameters of deflection along the x axis 
(time) and y axis (flow), allowing the system to accurately calibrate for determining 
respiratory parameters in the mouse. The Buxco FinePointe software derives 
ventilatory parameters from these small flow signals. Mice were introduced to the 
chamber and allowed to settle and acclimatise to their surroundings while breathing 
room air (normoxia) for approximately 30 minutes. Next, 30 minutes of baseline 
recording was then made under room air conditions. Then, respiratory recordings 
were made over 8 hours under either normoxic or hypoxic conditions depending on 
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which group the mouse was assigned to. Respiratory rate (frequency) and tidal 
volume were measured and from these values minute ventilation (the product of 
respiratory rate and tidal volume) was determined. These values were normalised to 
animal weight. 
 
 
(A) 
 
 
(B) 
 
Figure 8: Plethysmography set-up. (A) Two chamber set-up, run in parallel, one 
containing a mouse under hypoxic conditions and one containing a mouse under 
normoxic conditions. (B) FinePointe software respiratory trace showing respiration in 
real time breath-by-breath. 
 
 
2.9 In-Vivo Metabolism Measurement 
 
The O2 consumption and CO2 production of mice were both monitored over the 
course of the gas exposure, as an index of in-vivo metabolism. This was performed 
using a Gas Analyzer (ML206, AD Instruments, Fig. 9). The gas analyser allows the 
measurement of respiratory gas concentrations from mice in the chambers. It uses an 
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infrared CO2 transducer, calibrated to output voltages from 0 – 1 V proportional to the 
CO2 concentration between 0 – 10% of the sampled gas. The O2 transducer uses 
absorption spectroscopy in the visible spectrum whereby narrow band light is 
supplied by a laser diode, thermally tuned to an emission line in the oxygen spectrum, 
and is directed through a chamber through which the gas to be sampled flows. The 
detector on the other side of this sampling chamber then detects any change in the 
light intensity at the wavelength of interest. The more oxygen in the sample, the less 
light that the detector receives. Using a damped, micro-vacuum sampling pump, the 
analyser is used to sample gas from both the chamber input and the chamber output 
gases for percentage O2 and CO2. The analyser was calibrated using calibration gas 
mixtures. Room air was used to obtain one of the calibration points for each of O2 
(20.95%) and CO2 (0.039%) and 10% O2 in nitrogen was used to obtain a second O2 
calibration point (10%) while carbogen (5%CO2/95%O2) was used to obtain the 
second CO2 calibration point (5%). From these values, incorporating the flow of gas 
through the chamber and the body weight of the animal (taken post-mortem), we are 
able to calculate the oxygen consumption (VO2) and carbon dioxide production 
(VCO2), which are indices of basal metabolic rate in the animal. These data also 
allowed us to examine the respiratory exchange ratio and the ventilatory equivalent. 
As described at the end of section 2.2, post-mortem body temperature was also taken 
as another, albeit less precise, index of metabolic rate. 
 
VO2 = (flowin × O2concin) - (flowout × O2concout) 
 
VCO2 = (flowout × CO2concout) - (flowin × CO2concin) 
 
Ventilatory equivalent for CO2 = VE/VCO2   
 
Ventilatory equivalent for O2 = VE/VO2 
 
RER = VCO2/VO2 
 
 
 
 
 55 | P a g e  
 
(A) 
 
 
(B) 
 
Figure 9: In-vivo metabolism measurement. (A) AD Instruments Gas Analyzer (on 
bottom) running through an AD Instruments PowerLab (on top) before going to a PC. 
(B) Example of O2 (red) and CO2 (green) traces under normoxia and hypoxia. 
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2.10 Muscle Function – Experimental Protocol 
 
2.10.1 Muscle Dissection and Preparation 
Following euthanasia, as described above at the end of section 2.2, diaphragm and 
sternohyoid muscles were excised immediately for functional analysis. During the 
dissection a ventral incision was made along the midline of the torso from below the 
ribcage up to the top of the neck. The paired sternohyoid muscles and diaphragm, 
with central tendon and lower rib attached and intact, were excised and immediately 
placed in a storage bath containing continuously gassed hyperoxic (95% O2/5% CO2) 
Krebs solution (NaCl 120mM, KCl 5mM, Ca2+ gluconate 2.5 mM, MgSO4 1.2 mM, 
NaH2PO4 1.2 mM, NaHCO3 25 mM, glucose 11.5 mM and d-tubocurarine 25 μM (a 
neuromuscular blocking agent)) at room temperature. The sternohyoid muscles were 
separated and a thin strip (approximately 1mm in diameter) was cut longitudinally 
from one muscle and returned to the storage bath to recover from the dissection 
before function was assessed. A strip of diaphragm muscle was taken from the right 
hemidiaphragm running from the rib, parallel to the long axis of the muscle fibres, to 
the central tendon (approximately 2mm in diameter at the rib end and slightly 
narrower at the central tendon end) and the small sections of the rib and central 
tendon which were attached to the muscle were dissected out with it. The diaphragm 
strip was then returned to the storage bath to recover from the dissection. 
 
2.10.2 Isolated Muscle Preparation In-Vitro 
Sternohyoid muscle function was assessed first as the diaphragm is stable in the 
storage bath for a longer period of time. A single strip of sternohyoid muscle was 
suspended vertically in a water-jacketed organ bath. The bath was filled with Krebs 
solution which was bubbled with hyperoxic carbogen (95% O2/5% CO2) and the set-
up was maintained at 35°C. The strip of sternohyoid muscle was mounted, using non-
elastic string, between a stationary hook at the bottom and a dual-mode force 
transducer (Aurora Scientific, Canada) at the top (Fig. 10), and was flanked by a pair 
of platinum plate electrodes. For the diaphragm strip, the rib end was mounted on the 
stationary hook and the central tendon was attached to the transducer.  The dual-mode 
force transducer allowed the measurement of both isometric and isotonic contractions, 
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be measuring contractile force and shortening distance and velocity respectively, 
when the muscle was stimulated. The position of the force transducer could be 
adjusted, using a micro-positioner, to alter the length of the muscle strip. Once 
mounted in the bath, the muscle strip was left to equilibrate for 10 minutes before 
initiating the experimental protocol. 
 
 
 
Figure 10: The muscle bath set-up. 
 
 
2.10.3 Protocol 
 
2.10.3.1 Isometric Protocol 
For measurements of isometric contractions, the force transducer was set to maximum 
rigidity (~500nM; >100% load). 
 
2.10.3.1.1 Optimum Length 
The optimum length (Lo – the length at which peak isometric tetanic force is 
generated in response to a supra-maximal stimulation) of the muscle strip was 
determined by intermittently stimulating the muscle and adjusting the micro-
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positioner, and thus muscle length, between those stimulations. Once Lo was 
determined, this length was measured and recorded (in mm) and the muscle strip was 
kept at this length for the entire isometric protocol. The measurement was taken from 
the knot in the string at the hook end to the knot in the string at the transducer end so 
as to only include muscle fibres actively contracting between the hook and the force 
transducer. 
 
2.10.3.1.2 Peak Isometric Twitch and Tetanic Force and Twitch Contractile 
Kinetics 
The peak isometric twitch force was generated by stimulating the muscle strip with a 
single pulse. Twitch contractile kinetics – time to peak (TTP) and half relaxation time 
(T50) – were measured from the peak twitch contraction recorded. Peak isometric 
tetanic force was assessed by stimulating the muscle with a supra-maximal 
stimulation voltage (previously determined voltage, above which an increase in 
stimulation voltage will not result in an increase in contractile force, 80 V) at 100 
hertz (Hz) for 300ms. Figure 11 below is an example of a diaphragm tetanic 
contraction. Peak specific force (Fmax) was calculated in N/cm
2 of muscle cross 
sectional area (CSA). CSA was calculated by dividing muscle weight (weighted 
following blotting and air drying for 10 minutes) by the product of Lo and the specific 
density – assumed to be 1.056g/cm3. 
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Figure 11: An example of a diaphragm tetanic contraction. 
 
 
2.10.3.1.3 Force – Frequency Relationship 
Next, the relationship between stimulation frequency and force generation was 
assessed by stimulating the muscle strip at increasing stimulation frequencies from 10 
Hz to 160 Hz and recording the force generated at each frequency. Forces recorded as 
each frequency were then normalised to the muscle strip and expressed as specific 
forces in N/cm2 (described above). 
 
2.10.3.2 Isotonic Protocol 
For measurements of isotonic contractions, the force transducer was set to varying 
rigidity (0% to 100% load). 
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2.10.3.2.1 Step Test 
 
2.10.3.2.1.1 Shortening Length and Velocity 
The force transducer was initially set to a minimum rigidity, approximately 0%, and 
the muscle was stimulated to contract against “0% Load”, a load on the muscle that 
equals approximately 0% of the peak isometric tetanic force of that muscle strip, at 
Lo. This rigidity, or load on the muscle, was then increased in incremental steps from 
0% to 100% of peak isometric tetanic force while eliciting a muscle contraction at 
each step. Shortening length was defined as the maximum distance of shortening over 
the duration of the contraction.  Shortening velocity was derived from the distance of 
shortening during the first 30 ms of the shortening phase of the contraction as this is 
when contraction velocity is greatest. Peak shortening length and velocity were 
achieved at “0% load”. Peak specific shortening (Smax) was defined as the length of 
shortening per optimal length (L/Lo). Peak specific shortening velocity (Vmax) was 
defined as Lo/s. 
 
2.10.3.2.1.2 Work and Power 
From the protocol described above, work and power could be calculated at each step 
of the % load protocol as the product of force x shortening length and force x 
shortening velocity, respectively. From the work-load and power-load relationships 
achieved through this protocol, peak work and peak power were extrapolated. Peak 
specific mechanical work (Wmax) was calculated as Joules/cm
2 and peak specific 
mechanical power (Pmax) as Watts/cm
2. 
 
2.10.3.2.1.3 Fatigue 
After a 5 minute rest period following the step test, muscle endurance, or resistance to 
fatigue, was assessed by repeatedly stimulating the muscle strip at 100 Hz for 300 ms 
trains occurring every 2 seconds for a 5 minute period under isotonic conditions with 
a 33% load on the force transducer lever. 33% load is approximately the load at which 
peak power is achieved. Shortening length, shortening velocity, work and power were 
all extrapolated from each measurement, every 2 seconds, over the 300 second period, 
with the muscle strip at Lo. 
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2.11 Data Analysis 
 
GraphPad Prism (GraphPad Software Inc., CA, USA) was used to perform statistical 
analysis. Tests for normality and equal variance were performed (KS normality test, F 
test and Bartlett’s test where appropriate), Student’s t-test was performed for 
comparisons between two groups, and one-way or two-way ANOVA was utilised for 
comparisons between multiple groups larger than two and/or those with two different 
independent variables and appropriate post-hoc tests were used for multiple 
comparisons –Tukey’s test and Bonferroni’s test. Statistical significance was taken at 
the level of P < 0.05. All data is expressed as mean ± SEM. 
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Chapter 3: Acute Hypoxia Induces Respiratory 
Muscle Dysfunction in Mice and Rats 
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3.1 Introduction 
 
In this chapter, respiratory muscle contractile performance is assessed following 8 
hours of normoxia (Control) or 8 hours of hypoxia (Hypoxia). Muscle contractile 
function is tested ex vivo in this study in order to elucidate functional changes 
intrinsic to the muscle itself, and not attributed to other influential factors such as: 
conscious effort, anatomical shape of the diaphragm, neuronal drive – which are 
eliminated by this method (discussed in chapter 2) of isolating viable muscle strips in 
the muscle bath set-up and utilising d-tubocurarine as a neuromuscular blocking agent 
(Lewis et al., 2015a, 2015c, Skelly et al., 2012b, 2012c, 2011, 2010; Williams et al., 
2015). 
 
The diaphragm muscle, as discussed in chapter 1, is a highly malleable muscle which 
has been shown to functionally adapt, or maladapt, to hypoxia in animal models of 
chronic hypoxia (1 – 6 weeks) (Carberry et al., 2014a; Gamboa and Andrade, 2012, 
2010, Lewis et al., 2015a, 2015c; McMorrow et al., 2011). However, as of yet, there 
is a lack of information concerning how acute hypoxia influences diaphragm and 
sternohyoid muscle contractile performance. 
 
Acute hypoxia, as discussed in chapter 1, is a prominent feature of acute respiratory 
conditions such as acute respiratory distress syndrome (ARDS) and ventilator-
induced/associated lung injury (VILI/VALI). These conditions can go on to induce 
ICUAW, including respiratory muscle weakness, a sequela which is a robust predictor 
of poor outcome in patients (Batt et al., 2013; Sieck and Mantilla, 2013; Supinski and 
Callahan, 2013). Indeed, patients receiving chronic mechanical ventilation are weak 
and deconditioned, which can be due to one, or likely a combination, of inactivity, 
disease processes, infection and sepsis, and they respond to aggressive whole-body 
and respiratory muscle training with improved strength, weaning outcome and 
functional status (Martin et al., 2005). Whether or not hypoxia has a role in this 
weakness is unknown. However it is noteworthy that models of high altitude hypoxia 
also affects respiratory muscle contractile function (El-Khoury et al., 2012, 2003). 
Thus, insight into the adaptations of the respiratory muscle to acute hypoxic exposure 
may have wide-ranging relevance, from the clinic to altitude physiology. 
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Isometric muscle contractions, contractions of the muscle at a fixed and maintained 
length (i.e. no muscle shortening), allow the measurement of peak force generating 
capacity of the muscle at a particular stimulation frequency. This is a useful measure 
and/or index of muscle strength and performance overall. However, during normal 
diaphragm contraction during breathing in vivo, the expansion of the chest cavity and 
thus the generation of thoracic pressure changes necessary for breathing requires 
diaphragm muscle shortening, i.e. isotonic contractions (Goldman et al., 1978; 
Gorman et al., 2002; Pengelly et al., 1971). Isotonic muscle contraction are 
contractions of the muscle whereby the muscle length shortens at various speeds 
against various fixed loads on the muscle between 0 and 100 % load (100% load = 
Fmax of the muscle). Due to the variety of diaphragm functional activity necessary to 
maintain life, from the rhythmic activity of breathing to airway clearance manoeuvres, 
it is essential to review the broader scope of diaphragm contractile performance when 
examining how acute hypoxia potentially affects diaphragm function. 
 
The sternohyoid muscle, unlike the mixed muscle fibre type of the diaphragm, is 
composed of fast twitch muscle fibres and functions to maintain upper airway calibre 
during inspiration. Similarly to the diaphragm, while work has been carried out 
examining how chronic hypoxia affects the sternohyoid muscle (Lewis et al., 2015c), 
nothing is known about how (8 hours) acute hypoxia affects sternohyoid muscle 
performance. Clinically, the effects of acute hypoxia on the sternohyoid may have 
relevance to patients with acute respiratory diseases who also present with upper 
airway dysfunction and/or OSA – which is most prevalent among obese individuals. 
Indeed, obesity or body mass index is associated with ARDS development (Gong et 
al., 2010; Karnatovskaia et al., 2014). Moreover, persistent upper airway muscle 
weakness increases the risk of obstructive airway events during sleep, such that acute 
hypoxia could conceivably increase risk of subsequent sleep apnoea, which gives rise 
to further exposure to hypoxia and the establishment of a perpetual vicious cycle 
(O’Halloran, 2016; O’Halloran et al., 2016). 
 
Animal models are useful in that they afford the examination of the effects of acute 
hypoxia on respiratory muscle without the influence of other confounding factors 
which may be present in disease states. The reason for repeating the assessment of 
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diaphragm muscle contractile function in the rat following acute hypoxia is that the 
mouse and rat adopt slightly different metabolic strategies under hypoxic conditions 
(Haouzi et al., 2009). Therefore it was important to confirm that the muscle weakness 
observed in the mouse was also seen in the rat, and therefore more likely related to 
hypoxic stress per-se, rather than being solely due to the metabolic strategy adopted 
by the mouse (discussed further in chapter 4). 
 
Given the effects of chronic hypoxia on diaphragm and sternohyoid muscle 
contractile function (Lewis et al., 2016, 2015d; Lewis and O’Halloran, 2016), in this 
chapter we assessed whether an acute bout of sustained hypoxia would be sufficient to 
cause respiratory muscle dysfunction. Given that chronic hypoxia has been shown to 
weaken respiratory muscle, it would be interesting to determine whether an acute bout 
of hypoxia would be sufficient to cause respiratory muscle dysfunction, 
notwithstanding that the mechanisms at play may be quite different between 
respiratory muscle responses to acute and chronic hypoxia. 
 
Diaphragm muscle performance in the mouse is reported first, in section 3.2.1, 
followed by mouse sternohyoid muscle performance in section 3.2.2 and finally 
diaphragm isometric characteristics in the rat are reported in section 3.2.3. 
Assessment of EDL muscle function was attempted following respiratory muscle 
assessment, but a stable, repeatable preparation was not attained, possibly due to 
deterioration of the preparation while it was being kept in the storage bath during 
assessment of respiratory muscle performance. This period of time, between 
dissection and testing, was evidently too long. 
 
 
Chapter Aims 
The primary aims of this chapter are: 1) to assess the effects of an acute bout of 
sustained hypoxia on respiratory muscle function, primarily the diaphragm, in the 
mouse and 2) to determine if this effect is conserved in another mammalian species, 
the rat. 
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Methods Summary 
 
Respiratory muscle contractile function was examined ex vivo in a muscle bath set-up 
as described in more detail in Chapter 2 Materials and Methods, Section 2.10. 
 
Briefly, a strip of sternohyoid or diaphragm muscle from the mouse, or diaphragm 
muscle from the rat, was fixed between a stationary hook and a dual mode force 
transducer in an organ bath, filled with hyperoxic Krebs solution maintained at 30°C, 
allowing contractile performance to be assessed when the muscle strip was stimulated 
to contract. 
 
When assessing muscle isometric contractile performance, the length of the muscle 
strip was fixed to the length at which the muscle produced the highest force – 
optimum length (Lo). Under isometric conditions, peak force generating capacity, 
isometric twitch kinetics and the relationship between force generation and 
stimulation frequency of the muscle strip were measured. 
 
When assessing muscle isotonic contractile performance, the muscle strip was 
allowed to shorten when contracting against a fixed load (% Load) on the muscle 
strip, expressed as a percentage of the maximum force generating capacity of the 
muscle (Fmax). This allowed the measurement of shortening distance, velocity, work 
and power at various loads on the muscle. 
 
Finally, when measuring muscle fatigue, the muscle strip was repeatedly stimulated to 
contract every 2 seconds for a 5 minute period under isotonic conditions at a 33% 
load on the force transducer lever, allowing the measurement of shortening distance, 
velocity, work and power over repeated stimulation. 
 
These data were normalised to muscle cross sectional area. 
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3.2 Chapter Results 
 
3.2.1 Mouse Diaphragm 
Diaphragm isometric peak tetanic force, peak twitch force and twitch kinetics are 
shown in Fig. 1. There was a statistically significant reduction in diaphragm peak 
tetanic force (Fig.1A) (29.5 ± 3.2 vs. 20.8 ± 2.0 mean ± SEM N/cm2; Control vs. 
Hypoxia; n = 8 per group; p = 0.0334; unpaired t-test) of ~30% following 8 hours of 
hypoxia compared with control. There was no statistically significant change in 
diaphragm peak twitch force (Fig.1B) (4.4 ± 0.5 vs. 3.3 ± 0.4 mean ± SEM N/cm2; 
Control vs. Hypoxia; n = 8 per group; p = 0.1160; unpaired t-test) after 8 hours of 
hypoxia. There was no statistically significant change in diaphragm TTP (Fig.1C) 
(14.2 ± 0.4 vs. 14.4 ± 0.4 mean ± SEM N/cm2; Control vs. Hypoxia; n = 8 per group; 
p = 0.6676; unpaired t-test) after 8 hours of hypoxia. There was no statistically 
significant change in diaphragm T50 (Fig.1D) (14.3 ± 0.5 vs. 14.4 ± 0.6 mean ± SEM 
N/cm2; Control vs. Hypoxia; n = 8 per group; p = 0.8737; unpaired t-test) after 8 
hours of hypoxia. Although 8 hours of hypoxia did not affect diaphragm twitch 
kinetics, it did reduce the peak force-generating capacity of the diaphragm muscle by 
~30%. 
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Figure 1: Diaphragm isometric peak tetanic force, peak twitch force and twitch 
kinetic parameters. (A) Diaphragm peak tetanic force (mean ± SEM) expressed as 
force per unit CSA (N/cm2); n = 8 per group. (B) Diaphragm peak twitch force (mean 
± SEM) expressed as force per unit CSA (N/cm2); n = 8 per group. (C) Diaphragm 
time to peak twitch tension (TTP) (mean ± SEM) expressed as time (msecs); n = 8 per 
group. (D) Diaphragm twitch half relaxation time (T50) (mean ± SEM) expressed as 
time (msecs); n = 8 per group. *p < 0.05, unpaired t-test. 
 
 
The mouse diaphragm force–frequency relationship in a separate cohort of animals is 
displayed in Fig. 2. As one would expect, the specific force-generating capacity of the 
diaphragm muscle increased as the stimulation frequency is increased, from 10 to 160 
Hz, and this effect of stimulation frequency on muscle contractile force was 
statistically significant (p< 0.0001, two-way ANOVA). More importantly however, 
hypoxia caused a significant reduction in force generation over the range of 
stimulation frequencies tested (p = 0.0112, two-way ANOVA) compared with 
normoxia. The weakness was most prominent at higher frequencies. The hypoxia 
group was 37% weaker than the control group at maximum stimulation frequencies. 
There was no interaction (gas x stimulation; p = 0.8634). Bonferroni’s multiple 
comparisons test did not reveal any statistically significant differences at individual 
stimulation frequencies. 
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 Figure 2: Diaphragm muscle force–frequency relationship in the mouse. 
Diaphragm specific force (mean ± SEM) expressed as force per unit CSA (N/cm2) as 
a function of stimulation frequencies ranging between 10 and 160 Hz.  
 
 
Diaphragm muscle peak power, peak work, maximum shortening velocity and 
maximum shortening are displayed in Fig. 3. There were no statistically significant 
changes to (A) peak power (15.0 ± 2.1 vs. 12.1 ± 1.5 mean ± SEM Watts/cm2; 
Control vs. Hypoxia; n = 8 per group; p = 0.2780; unpaired t-test), (B) work (2.1 ± 0.3 
vs. 1.9 ± 0.2 mean ± SEM Joules/cm2; Control vs. Hypoxia; n = 8 per group; p = 0.6; 
unpaired t-test), (C) velocity (4.0 ± 0.2 vs. 4.1 ± 0.3 mean ± SEM Lo/s; Control vs. 
Hypoxia; n = 8 per group; p = 0.6932; unpaired t-test)  or (D) shortening (0.4 ± 0.02 
vs. 0.4 ± 0.02 mean ± SEM L/Lo; Control vs. Hypoxia; n = 8 per group; p = 0.1464; 
unpaired t-test)  between control and hypoxia groups. 
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Figure 3: Diaphragm muscle peak power, peak work, maximum shortening 
velocity and maximum shortening. (A) Diaphragm peak power (mean ± SEM) 
expressed as power/CSA (Watts/cm2); n = 8 per group. (B) Diaphragm peak work 
(mean ± SEM) expressed as work/CSA (Joules/cm2); n = 8 per group. (C) Diaphragm 
peak shortening velocity (mean ± SEM) expressed as optimal lengths/time (Lo/s); n = 
8 per group. (D) Diaphragm peak shortening distance (mean ± SEM) expressed as 
length/optimal length (L/Lo); n = 8 per group. 
 
 
Diaphragm muscle power–load relationship is shown in Fig. 4. This is specific power 
generated by the muscle at incremental loads on the muscle from 0-100% of the peak 
force generation capacity of the muscle strip. Two-way ANOVA revealed significant 
effects of both % load (p < 0.0001) and hypoxia (p = 0.0011) on power generation 
over the full range of loads tested; there was no interaction (p = 0.6829). The load on 
the muscle when it contracts, as one would expect, affects the power output of the 
muscle in a classic bell-shaped fashion, peaking at a load of around 40% of the 
maximum force generation capacity of the muscle. Hypoxia diminished the power–
load curve, reducing diaphragm power output over the range of loads as a whole, 
although not at every individual % load. 
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Figure 4: Diaphragm muscle power–load relationship. Diaphragm power (mean ± 
SEM) expressed as power per unit CSA (Watts/cm2) as a function of the load on the 
muscle expressed as a percentage of peak force (force/peak force*100); n = 8 per 
group. 
 
 
The diaphragm muscle work–load relationship is shown in Fig. 5. This is work 
generated by the muscle at incremental loads on the muscle from 0-100% of the peak 
force generation capacity of the muscle strip. Two-way ANOVA revealed a 
significant effect of % load (p < 0.0001), but not hypoxia (p = 0.0820) on work over 
the full range of loads tested; there was no interaction (p = 0.8096). Although hypoxia 
did not significantly reduce the mechanical work over the range of loads, a slight 
rightward shift is observed in the hypoxia curve. 
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Figure 5: Diaphragm muscle work–load relationship. Diaphragm work (mean ± 
SEM) expressed as work per unit CSA (Joules/cm2) as a function of the load on the 
muscle expressed as a percentage of peak force (force/peak force*100); n = 8 per 
group. 
 
 
The diaphragm muscle shortening velocity–load relationship is shown in Fig. 6. This 
is shortening velocity of the muscle at incremental loads on the muscle from 0-100% 
of the peak force generation capacity of the muscle strip. Two-way ANOVA revealed 
a significant effect of % load (p < 0.0001) and hypoxia (p = 0.003) on velocity over 
the full range of loads tested; there was no interaction (p = 0.9996). Shortening 
velocity was reduced in both groups as % load increased, and the hypoxia group 
produced a slightly elevated velocity over the range of loads in comparison with the 
control group. 
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Figure 6: Diaphragm muscle velocity–load relationship. Diaphragm shortening 
velocity (mean ± SEM) expressed as optimal lengths per unit time (Lo/s) as a function 
of the load on the muscle expressed as a percentage of peak force (force/peak 
force*100); n = 8 per group. 
 
 
The diaphragm muscle shortening–load relationship is shown in Fig. 7. This is 
specific shortening of the muscle at incremental loads on the muscle from 0-100% of 
the peak force generating capacity of the muscle strip. Two-way ANOVA revealed a 
significant effect of % load (p < 0.0001) and hypoxia (p < 0.0001) on shortening over 
the full range of loads tested; there was no interaction (p = 0.4155). Shortening 
distance was reduced in both groups as % load increased, and the hypoxia group 
shortened by a greater distance over the range of loads on the muscle compared with 
the control group. 
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Figure 7: Diaphragm muscle shortening–load relationship. Diaphragm shortening 
(mean ± SEM) expressed as length per unit optimal length (L/Lo) as a function of the 
load on the muscle expressed as a percentage of peak force (force/peak force*100); n 
= 8 per group. 
 
 
 
Fatigue 
Diaphragm muscle fatigue parameters are displayed below. Fig. 8 shows diaphragm 
fatigue in terms of power output over time during repeated fatiguing stimulation every 
2 seconds for a 300 second period (the power–time fatigue relationship). Data is 
displayed in (A) absolute power values and (B) the fall off in power over time relative 
to initial power production at the beginning of the fatigue protocol. For both 
approaches, two-way ANOVA revealed a significant effect of time (p < 0.0001) and 
hypoxia ((A) p < 0.0001 & (B) p < 0.0001) on diaphragm specific power (fatigue); 
there was no interaction (p = 1.0). The data reveal that the diaphragm muscle was 
weaker (although not with statistical significance) at the beginning of the fatigue 
protocol in the hypoxia group compared with control, producing a lower power 
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output. However, as the protocol progresses, the power produced by the hypoxia 
diaphragm did not fall off to the same extent as the power output of the control 
diaphragm, such that both groups produced the same power output by the end of the 
protocol (i.e. an apparent fatigue tolerance). 
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 Figure 8: Diaphragm muscle fatigue (power–time relationship). Diaphragm 
muscle power (mean ± SEM) expressed as (A) power per unit CSA (Watts/cm2) as a 
function of time (secs) over a 300sec period of repeated stimulation every 2 seconds 
and as (B) the change (Δ) in power (Watts/cm2) relative to the initial power of that 
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muscle upon the first contraction of the fatigue protocol as a function of time over the 
300sec fatiguing period of repeated stimulation every 2 seconds; n = 7-8 per group. 
 
 
Fig. 9 shows diaphragm fatigue in terms of work over time during repeated 
stimulation (the work–time relationship). Two-way ANOVA revealed a significant 
effect of time (p < 0.0001) and hypoxia (p < 0.0001) on diaphragm work (fatigue) 
over time; there was no interaction (p = 1.0000). Again, similar to observations in the 
power fatigue data, the hypoxia group produced less work than the control group at 
the beginning of the protocol but did not fall off to the same extent, producing the 
same amount of work as the control group by the end of the protocol (i.e. an apparent 
fatigue tolerance). 
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Figure 9: Diaphragm muscle fatigue (work–time relationship). Diaphragm muscle 
work (mean ± SEM) expressed as work per unit CSA (Joules/cm2) as a function of 
time (secs) over a 300sec fatiguing period of repeated stimulation every 2 seconds; n 
= 7-8 per group. 
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Fig. 10 shows diaphragm muscle fatigue in terms of muscle shortening velocity over 
time during repeated stimulation (the velocity–time relationship). Two-way ANOVA 
revealed a significant effect of time (p < 0.0001) and hypoxia (p < 0.0001) on 
diaphragm muscle specific shortening velocity over time; there was no interaction (p 
= 1.0000). The hypoxia group produced a faster shortening velocity over the course of 
the fatigue protocol compared with the control group. 
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Figure 10: Diaphragm muscle fatigue (velocity–time relationship). Diaphragm 
muscle specific shortening velocity (mean ± SEM) expressed as optimal lengths per 
unit time (Lo/s) as a function of time (secs) over a 300sec fatiguing period of repeated 
stimulation every 2 seconds; n = 7-8 per group. 
 
 
Fig. 11 shows diaphragm muscle fatigue in terms of muscle shortening over time 
during repeated stimulation (the shortening–time relationship). Two-way ANOVA 
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revealed a significant effect of time (p < 0.0001) and hypoxia (p < 0.0001) on 
diaphragm muscle shortening over time; there was no interaction (p > 0.9999). The 
hypoxia group produced a greater shortening distance than the control group over the 
duration of the fatigue protocol. 
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Figure 11: Diaphragm muscle fatigue (shortening–time relationship). Diaphragm 
muscle shortening (mean ± SEM) expressed as length per unit optimal length (L/Lo) 
as a function of time (secs) over a 300sec fatiguing period of repeated stimulation 
every 2 seconds; n = 7-8 per group. 
 
 
3.2.2 Mouse Sternohyoid 
Sternohyoid isometric peak tetanic force, twitch force and twitch kinetics are shown 
in Fig. 12. There was no statistically significant change in sternohyoid peak specific 
tetanic force (Fig. 12A) (12.8 ± 1.2 vs. 9.7 ± 1.1 mean ± SEM N/cm2; Control vs. 
Hypoxia; n = 8 per group; p = 0.0683; unpaired t-test) after 8 hours of hypoxia, 
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although there was a non-statistically significant reduction in peak tetanic force 
generating capacity by ~25%. There was no statistically significant change in 
sternohyoid peak twitch force (Fig. 12B) (1.9 ± 0.2 vs. 1.5 ± 0.2 mean ± SEM N/cm2; 
Control vs. Hypoxia; n = 8 per group; p = 0.1658; unpaired t-test) after 8 hours of 
hypoxia. There was no statistically significant change in sternohyoid TTP (Fig. 12C) 
(10.6 ± 0.5 vs. 10.1 ± 0.2 mean ± SEM N/cm2; Control vs. Hypoxia; n = 8 per group; 
p = 0.3426; unpaired t-test) after 8 hours of hypoxia. There was no statistically 
significant change in sternohyoid T50 (Fig. 12D) (16.6 ± 1.5 vs. 13.1 ± 0.9 mean ± 
SEM N/cm2; Control vs. Hypoxia; n = 8 per group; p = 0.0636; unpaired t-test) after 8 
hours of hypoxia, although there was a non-statistically significant reduction in T50. 
Hypoxia appears to weaken the sternohyoid muscle in terms of peak force generating 
capacity, with modest alterations to the twitch kinetics – namely the T50 which was 
reduced to near statistical significance (p = 0.0636). 
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Figure 12: Sternohyoid isometric peak tetanic force, twitch force and twitch 
kinetic parameters. (A) Sternohyoid peak tetanic force (mean ± SEM) expressed as 
Force per unit CSA (N/cm2); n = 8 per group. (B) Sternohyoid peak twitch force 
(mean ± SEM) expressed as Force per unit CSA (N/cm2); n = 8 per group. (C) 
Sternohyoid time to peak twitch tension (TTP) (mean ± SEM) expressed as time 
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(msecs); n = 8 per group. (D) Sternohyoid twitch half relaxation time (T50) (mean ± 
SEM) expressed as time (msecs); n = 8 per group. 
 
 
Sternohyoid muscle peak power, peak work, maximum shortening velocity and 
maximum shortening are displayed in Fig. 13. There were no statistically significant 
changes to (A) peak power (5.8 ± 0.8 vs. 4.4 ± 0.6 mean ± SEM Watts/cm2; Control 
vs. Hypoxia; n = 8 per group; p = 0.1900; unpaired t-test), (B) work (0.6 ± 0.1 vs. 0.5 
± 0.1 mean ± SEM Joules/cm2; Control vs. Hypoxia; n = 8 per group; p = 0.1152; 
unpaired t-test), (C) velocity (3.1 ± 0.2 vs. 3.1 ± 0.3 mean ± SEM Lo/s; Control vs. 
Hypoxia; n = 8 per group; p = 0.9853; unpaired t-test)  or (D) shortening (0.2 ± 0.01 
vs. 0.2 ± 0.01 mean ± SEM L/Lo; Control vs. Hypoxia; n = 8 per group; p = 0.7647; 
unpaired t-test)  between control and hypoxia groups. 
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Figure 13: Sternohyoid muscle peak power, work, shortening velocity and 
shortening. (A) Sternohyoid peak power (mean ± SEM) expressed as power per unit 
CSA (Watts/cm2); n = 8 per group. (B) Sternohyoid peak work (mean ± SEM) 
expressed as work per unit CSA (Joules/cm2); n = 8 per group. (C) Sternohyoid peak 
shortening velocity (mean ± SEM) expressed as optimal lengths per unit time (Lo/s); n 
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= 8 per group. (D) Sternohyoid peak shortening distance (mean ± SEM) expressed as 
length per unit optimal length (L/Lo); n = 8 per group. 
 
 
The sternohyoid muscle power–load relationship is shown in Fig. 14. This is power 
generated by the muscle at incremental loads on the muscle from 0-100% of the peak 
force generation capacity of the muscle strip. Two-way ANOVA revealed significant 
effects of% load (p < 0.0001) and hypoxia (p = 0.0009) on power generation over the 
full range of % loads tested; there was no interaction (p = 0.9695). The load on the 
muscle when it contracts, as expected, affected the power output of the muscle in a 
classic bell-shaped fashion, peaking at a load of around 35% of the maximum force 
generation capacity of the muscle. Hypoxia diminished the sternohyoid power–load 
curve, reducing sternohyoid power output over the range of loads as a whole, 
although not at the lowest % load. 
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 Figure 14: Sternohyoid muscle power–load relationship. Sternohyoid power 
(mean ± SEM) expressed as power per unit CSA (Watts/cm2) as a function of the load 
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on the muscle expressed as a percentage of peak force (force/peak force*100); n = 8 
per group. 
 
 
The sternohyoid muscle work–load relationship is shown in Fig. 15. This is work 
generated by the muscle at incremental loads on the muscle from 0-100% of the peak 
force generation capacity of the muscle strip. Two-way ANOVA revealed a 
significant effect of % load (p < 0.0001) and hypoxia (p < 0.0001) on work over the 
full range of % loads tested; there was no interaction (p = 0.3788).  Bonferroni’s post-
hoc multiple comparisons test also revealed significant differences in work at 60% 
and 80% load between control and hypoxia groups (p < 0.05). The load on the muscle 
when it contracts affected the work output of the muscle in a manner similar to its 
effect on power above. Here, hypoxia diminished the sternohyoid work output over 
the range of loads as a whole, except at the lowest load (~0% load), with most 
significant reductions in work seen at 60% and 80% load. 
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 Figure 15: Sternohyoid muscle work–load relationship. Sternohyoid work (mean 
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± SEM) expressed as work per unit CSA (Joules/cm2) as a function of the load on the 
muscle expressed as a percentage of peak force (force/peak force*100); n = 8 per 
group; *p < 0.05. 
 
 
The sternohyoid muscle shortening velocity–load relationship is shown in Fig. 16. 
This is shortening velocity of the muscle at incremental loads on the muscle from 0-
100% of the peak force generating capacity of the muscle strip. Two-way ANOVA 
revealed a significant effect of % load (p < 0.0001), but not hypoxia (p = 0.6577) on 
velocity over the full range of % loads tested; there was no interaction (p = 0.9997). 
Shortening velocity was reduced as expected in both groups as % load increased. 
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Figure 16: Sternohyoid muscle velocity–load relationship. Sternohyoid shortening 
velocity (mean ± SEM) expressed as optimal lengths per unit time (Lo/s) as a function 
of the load on the muscle expressed as a percentage of peak force (force/peak 
force*100); n = 8 per group. 
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The sternohyoid muscle shortening–load relationship is shown in Fig.17. This is 
shortening of the muscle at incremental loads on the muscle from 0-100% of the peak 
force generating capacity of the muscle strip. Two-way ANOVA revealed a 
significant effect of % load (p < 0.0001), but not hypoxia (p = 0.7574) on shortening 
over the full range of % loads tested; there was no interaction (p = 0.9986). 
Shortening distance was reduced as expected in both groups as % load increased. 
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Figure 17: Sternohyoid muscle shortening–load relationship. Sternohyoid 
shortening (mean ± SEM) expressed as length per unit optimal length (L/Lo) as a 
function of the load on the muscle expressed as a percentage of peak force (force/peak 
force*100); n = 8 per group. 
 
 
Fatigue 
Sternohyoid muscle fatigue parameters are displayed below. Fig. 18 shows 
sternohyoid fatigue in terms of power output over time during repeated fatiguing 
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stimulation every 2 seconds for a 300 second period (the power–time relationship). 
Data is displayed in (A) absolute power values and (B) the fall off in power over time 
relative to initial power production at the beginning of the fatigue protocol. When 
data was analysed in terms of absolute power values (A), two-way ANOVA revealed 
a significant effect of time (p < 0.0001), but not hypoxia (p = 0.9868) on sternohyoid 
power (fatigue); there was no interaction (p = 0.9985). However, when analysing the 
fall off in power relative to the initial power (B), two-way ANOVA revealed a 
significant effect of both time (p < 0.0001) and hypoxia (p < 0.0001) on sternohyoid 
specific power (fatigue); there was no interaction (p = 1.0000). The data reveal that 
the sternohyoid muscle was weaker at the beginning of the fatigue protocol in the 
hypoxia group compared with control, producing a lower power output. However as 
the protocol progressed, the power produced by the sternohyoid from hypoxic animals 
does not fall off to the same extent as the power output of the sternohyoid from 
control animals, and both groups were producing the same power output by the end of 
the protocol (i.e. an apparent fatigue tolerance). 
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Figure 18: Sternohyoid muscle fatigue (power–time relationship). Sternohyoid 
muscle power (mean ± SEM) expressed as (A) power per unit CSA (Watts/cm2) as a 
function of time (secs) over a 300sec period of repeated stimulation every 2 seconds 
and as (B) the change (Δ) in power (Watts/cm2) relative to the initial power of that 
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muscle upon the first contraction of the fatigue protocol as a function of time over the 
300sec fatiguing period of repeated stimulation every 2 seconds; n = 7 per group. 
 
 
Fig. 19 shows sternohyoid fatigue in terms of work over time during repeated 
stimulation (the work–time relationship). Two-way ANOVA revealed a significant 
effect of time (p < 0.0001) and hypoxia (p = 0.0292) on sternohyoid work (fatigue); 
there was no interaction (p > 0.9999). Again, similar to observations in the power 
fatigue data, the hypoxia group produced less work than the control group at the 
beginning of the protocol, but work did not fall off to the same extent, producing the 
same amount of work as the control group by the end of the protocol (i.e. an apparent 
fatigue tolerance). 
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Figure 19: Sternohyoid muscle fatigue (work – time relationship). Sternohyoid 
muscle work (mean ± SEM) expressed as work per unit CSA (Joules/cm2) as a 
function of time (secs) over a 300sec fatiguing period of repeated stimulation every 2 
seconds; n = 7 per group. 
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Fig. 20 shows sternohyoid muscle fatigue in terms of muscle shortening velocity over 
time during repeated stimulation (the velocity–time relationship). Two-way ANOVA 
revealed a significant effect of time (p < 0.0001) and hypoxia (p < 0.0001) on 
sternohyoid muscle specific shortening velocity; there was no interaction (p = 
1.0000). The hypoxia group produced a faster shortening velocity over the course of 
the fatigue protocol than the control group. 
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Figure 20: Sternohyoid muscle fatigue (velocity – time relationship). Sternohyoid 
muscle shortening velocity (mean ± SEM) expressed as optimal lengths per unit time 
(Lo/s) as a function of time (secs) over a 300sec fatiguing period of repeated 
stimulation every 2 seconds; n = 7 per group. 
 
 
Fig. 21 shows sternohyoid muscle fatigue in terms of muscle shortening over time 
during repeated stimulation (the shortening–time relationship). Two-way ANOVA 
revealed a significant effect of time (p < 0.0001) and hypoxia (p < 0.0001) on 
sternohyoid muscle specific shortening; there was no interaction (p = 1.0000). The 
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hypoxia group produced a greater shortening distance than the control group over the 
duration of the fatigue protocol. 
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Figure 21: Sternohyoid muscle fatigue (shortening–time relationship). 
Sternohyoid muscle shortening (mean ± SEM) expressed as length/optimal length 
(L/Lo) as a function of time (secs) over a 300sec fatiguing period of repeated 
stimulation every 2 seconds; n = 7 per group. 
 
 
3.2.3 Rat Diaphragm 
The force–frequency relationship of the rat diaphragm muscle is shown in Fig. 22. As 
one would expect, the force-generating capacity of the diaphragm muscle increased as 
the stimulation frequency is increased, from 10 to 160 Hz, and this effect of 
stimulation frequency on muscle contractile force was statistically significant (p < 
0.0001, two-way ANOVA). Importantly, hypoxia caused a significant reduction in 
force generation over the range of stimulation frequencies (p < 0.0001, two-way 
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ANOVA) and Bonferroni’s multiple comparisons test revealed statistically significant 
comparisons between the force generating capacity of control and hypoxia groups at 
40, 60, 80, 120, 140, and 160 Hz. There was no interaction (p = 0.0791). Consistent 
with observations in mice, the rat diaphragm was significantly weakened by exposure 
to 8 hours of hypoxia. 
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Figure 22: Rat diaphragm force–frequency relationship. Diaphragm force (mean 
± SEM) expressed as force per unit CSA (N/cm2) as a function of stimulation 
frequencies ranging between 10 and 160 Hz (n = 8 per group).  
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3.3 Chapter Discussion 
 
The main findings of this chapter are: 
 
1. 8 hours of hypoxia weakens the diaphragm significantly in terms of peak force 
generating capacity, the force – frequency relationship and power generating 
capacity. 
 
2. 8 hours of hypoxia significantly improved diaphragm resistance to fatigue, 
although this may be a bottoming out effect due to the hypoxic diaphragm 
being weaker at the beginning of the fatigue protocol. 
 
3. 8 hours of hypoxia weakens the sternohyoid significantly in terms of power & 
work generating capacity. 
 
4. 8 hours of hypoxia significantly improved sternohyoid resistance to fatigue, 
although this may be a bottoming out effect due to the hypoxic sternohyoid 
being weaker at the beginning of the fatigue protocol. 
 
5. 8 hours of hypoxia also weakens the rat diaphragm significantly in terms the 
force – frequency relationship, demonstrating conservation of the phenotype 
across both species despite notable differences in metabolic strategies in the 
face of hypoxia. 
 
 
3.3.1 Mouse Diaphragm 
There were no changes in the peak contractile kinetics of the diaphragm muscle 
following 8 hours of hypoxia when compared with control. This is also the case in 
studies examining the contractile kinetics of the diaphragm muscle following 
exposure of both mice and rats to chronic hypoxia (El-Khoury et al., 2003; Lewis et 
al., 2015b; McMorrow et al., 2011). While no change in peak contractile kinetics 
would suggest that Ca2+ handling, i.e. release and reuptake, at the SR is unaffected – 
T50 may be determined by SERCA activity (McMorrow et al., 2011), although there 
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exists some controversy in this matter (Hill et al., 2001) –, certain gene expression 
patterns revolving around Ca2+ handing at the SR that are uncovered in chapter 4, 
potentially suggest otherwise. This will be discussed further in chapter 4. However, 
while peak contractile kinetics were unaffected, diaphragm shortening and shortening 
velocity over the range of loads on the muscle from 0 – 100% load were both slightly, 
yet significantly, increased following hypoxia. 
 
8 hours of hypoxia was sufficient to weaken the diaphragm by 30% compared with 
control. Interestingly, this degree of weakness is reminiscent of the weakness induced 
in diaphragm muscle following 6 weeks of chronic hypoxia (Lewis et al., 2015b). The  
mechanism at play during diaphragm muscle remodelling – ultimately leading to 
muscle weakness – in response to chronic hypoxia are likely quite distinct from those 
inducing muscle weakness in this acute hypoxia model. Indeed, 6 weeks of chronic 
hypoxia induces diaphragm muscle fibre atrophy, reducing muscle fibre CSA 
(McMorrow et al., 2011) with evidence of increased proteolysis (Lewis and 
O’Halloran, 2016), likely contributing to chronic hypoxia induced diaphragm 
weakness. Diaphragm atrophy is also a likely factor contributing to diaphragm muscle 
weakness in VILI/VALI patients, leading to VIDD, due to unloading and inactivity of 
the diaphragm while the mechanical ventilator performs the work of breathing 
(Bruells et al., 2013; Jaber et al., 2011a; Supinski and Callahan, 2013), although there 
exists some controversy in this area and it is debated as to whether inactivity per se 
induced diaphragm muscle atrophy (Sieck and Mantilla, 2013). However, this is an 
unlikely factor contributing to diaphragm muscle weakness in acute hypoxia (see 
chapter 4). Similarly, in the second exposure study on separate groups of mice, 
diaphragm weakness was again observed, demonstrating the repeatability and 
reproducibility of the finding, with evidence that force production was reduced over a 
range of stimulation frequencies. In particular, the weakness is most strongly evident 
at the higher stimulation frequencies, with the hypoxia group diaphragms being 37% 
weaker than the control group diaphragms at the highest frequency of 160Hz. 
 
Diaphragm work output was unaffected by hypoxia, although there was a slight 
rightward shift in the work–load relationship, indicating an altered load at which peak 
work generation was achieved. However, while peak power generating capacity of the 
diaphragm was not significantly reduced, diaphragm muscle power output over the 
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range of loads on the muscle from 0 – 100% load was significantly reduced by 
hypoxia. During normal, healthy breathing the diaphragm is contracting against a 
relatively low load. Therefore there is a large reserve of power generating capacity 
remaining in the diaphragm. This power reserve can become a critical factor if airway 
clearance is required or indeed if the airway becomes blocked or obstructed. As such, 
the hypoxia induced reduction in the power–load relationship could make hypoxic 
respiratory patients more susceptible to a negative outcome if these complications 
arise. 
 
Diaphragm endurance, or resistance to fatigue, was tested by repeated stimulation 
every 2 seconds for 300 seconds, contracting against 33% load. The initial power 
generating capacity of the control diaphragm was significantly higher than that of the 
hypoxic diaphragm. As the protocol progressed, however, the control diaphragm 
power output fell off to a greater extent than that of the hypoxic group, and by the end 
of the 300 second protocol the power output was identical in the two groups. When 
these data were expressed as fall off in power output relative to the initial power 
output of each group at the beginning of the protocol, it became evident how 
significant this difference in fatigue was. There are two potential explanations for this. 
Firstly, the hypoxic diaphragm is, in fact, more endurant than the control diaphragm 
and is thus more resistant to fatigue over repeated stimulation. Secondly, it was a 
bottoming out effect, whereby repeatedly stimulating the diaphragm at 33% load 
could only fatigue the diaphragm so far, and as the hypoxic diaphragm was weaker to 
begin with then it did not have as far to fall in terms of reduction in power output. 
Both groups appeared to have the same profile in terms of rate of fatigue during the 
protocol, with power output falling off at the greatest rate, and at a similar rate in both 
groups, during the first 70 seconds of the protocol. Then, from 70 seconds onward, 
the rate of reduction in power output slowed in both groups, although it remained 
slightly faster in the control group, leading to both groups producing the same power 
output by the end of the protocol. Indeed, it has previously been postulated that 
chronic hypoxia increases diaphragm endurance in the rat (McMorrow et al., 2011). A 
potential method of allowing the weakened diaphragm to recover is to rest the muscle 
using controlled mechanical ventilation. However this then introduces another 
problem, namely disuse atrophy which can weaken the muscle further 
(Vassilakopoulos et al., 2006). Difficulty weaning patients from ventilators can be 
 95 | P a g e  
 
attributed to three primary causes: hypoxaemia, psychological issues and respiratory 
muscle dysfunction (Tobin, Jubran, 1998; Tobin et al., 1998). This chapter 
demonstrates that hypoxia itself can be a factor causing respiratory muscle 
dysfunction, and places hypoxia as a potential candidate for being a major contributor 
to diaphragm weakness following acute respiratory failure induced by acute 
respiratory-related disorders. Although hypoxia has been shown here to weaken the 
diaphragm, it has also been shown to increase fatigue resistance of the diaphragm. 
However, due to the muscle being weaker to begin with, this perceived increase in 
endurance of the muscle still ultimately leads to lower power generation capacity 
sooner during repeated stimulation. The power output by both muscles at 300 seconds 
was at about 3 Watts/cm2, a significant drop from the initial power outputs generated 
by the diaphragm under control and hypoxic conditions – 18 and 15 Watts/cm2 
respectively. However, the control diaphragm did not reach 6 Watts/cm2 (arbitrary 
value, for example purposes) of power output until 134 seconds into the fatigue 
protocol, while the hypoxic diaphragm reached a power output of 6 Watts/cm2 by 88 
seconds into the fatigue protocol. Approximately 20% of all mechanically ventilated 
patients fail their first attempt to wean (Eskandar and Apostolakos, 2007) However, 
diaphragm fatigue is not a common cause of this failure. In a study aiming to 
determine if weaning failure is caused by low-frequency fatigue of the diaphragm, it 
was discovered that weaning failure was not accompanied by low-frequency 
diaphragmatic fatigue, but that many of the weaning failure patients displayed 
diaphragm muscle weakness (Laghi et al., 2003), therefore diaphragmatic strength 
rather than fatigue properties may be of greater importance when determining the 
functional integrity of this pump muscle in mechanically ventilated patients. It is 
important to note, however, that diaphragm strength is not a primary predictor of 
whether a patient will or will not wean from mechanical ventilation successfully, 
often the reason behind weaning failure can be due to upper airway collapse, 
respiratory loading, neuropsychological/neuromuscular complications, and metabolic 
disorders. 
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3.3.2 Mouse Sternohyoid 
Similar to the diaphragm, there were no changes in the peak contractile kinetics of the 
sternohyoid muscle following 8 hours of hypoxia when compared with control, with 
the exception of peak T50 which was reduced to near significance at p = 0.0636. This 
is also the case for contractile kinetics of the sternohyoid muscle following exposure 
of mice to chronic hypoxia (Lewis et al., 2015c). While no change in contractile 
kinetics would suggest that Ca2+ handling, i.e. release and reuptake, at the SR is 
unaffected, certain gene expression patterns revolving around Ca2+ handing at the SR 
that are elucidated in chapter 4 suggest otherwise, and this evidence for alterations in 
the regulation in SR Ca2+ handing is stronger for the sternohyoid than the diaphragm 
(chapter 4). Sternohyoid muscle shortening and shortening velocity over the range of 
loads on the muscle from 0 – 100% load were also unaffected by hypoxia. 
 
8 hours of hypoxia was sufficient to weaken the sternohyoid muscle. Peak tetanic 
force generating capacity of the sternohyoid muscle was reduced by hypoxia to near 
statistical significance (p = 0.0683), while both power & work outputs of the 
sternohyoid muscle was significantly reduced by hypoxia over the range of loads on 
the muscle from 0 – 100% load. 
 
In terms of sternohyoid fatigue resistance, similar to the diaphragm the initial power 
generating capacity of the control sternohyoid was significantly higher than that of the 
hypoxic sternohyoid. As the protocol progresses, however, the control sternohyoid 
power output fell off to a greater extent than that of the hypoxic group, and by the end 
of the 300 second protocol the power output was identical in the two groups. When 
these data were then expressed as fall off in power output relative to the initial power 
output of each group at the beginning of the protocol, it was evident how significant 
this difference in fatigue was, with a greater fall off in power production in the control 
sternohyoid. As with the diaphragm, there are two potential explanations for this, as 
discussed above – the sternohyoid muscle was either more endurant than the control 
sternohyoid or it was a bottoming out effect. The profiles of the two groups in terms 
of the rate of fatigue during the protocol were slightly different between the control 
and hypoxic group. In the control sternohyoid, although initially producing more 
power at the beginning of the protocol, the power output diminished quickly and at a 
faster rate than did the power output from the weaker hypoxic sternohyoid, and by 50 
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seconds into the protocol both control and hypoxic sternohyoid muscles were 
producing the same power output. For the remainder of the 300 second protocol the 
power output of both control and hypoxic sternohyoid muscles was the same at each 
stimulation, leading to both groups producing the same power output by the end of the 
protocol. 
 
In both the diaphragm and the sternohyoid, if this is evidence of a true fatigue 
resistance, as opposed to a bottoming out effect, one potential mechanism for this 
fatigue resistance would be an increased oxidative capacity of the muscles. The data 
is not included in this thesis, and is as of yet unpublished, but recent findings in our 
laboratory demonstrate that citrate synthase enzyme activity is increased by 8 hours of 
hypoxia in both diaphragm and sternohyoid, which is a marker for increased oxidative 
capacity in skeletal muscle. 
 
As discussed in the introduction to this chapter, OSA is most prevalent in obese 
individuals, and obesity increases the risk of the development of ARDS in surgical 
patients. While the type of hypoxia experienced by OSA patients is primarily 
intermittent hypoxia during sleep, due to intermittent occlusion of the upper airway, 
the effects of acute hypoxia discussed in this thesis may have relevance to patients 
with acute respiratory diseases who also present with upper airway dysfunction and/or 
OSA. The sternohyoid muscle is an important upper airway dilator muscle and one 
which is the focus of much research on the deleterious effects of intermittent hypoxia 
on upper airway muscle with relevance to OSA (Shortt et al., 2014; Skelly et al., 
2012b, 2012c; Williams et al., 2015). The acute hypoxia induced sternohyoid 
weakness and dysfunction presented in this chapter could exacerbate and perpetuate 
the pathophysiology of OSA, as dysfunction of the pharyngeal dilator muscles of the 
upper airway, including the sternohyoid muscles, increases the susceptibility of 
patients to collapse and occlusion of the upper airway. 
 
 
3.3.3 Rat Diaphragm 
8 hours of hypoxia also caused diaphragm muscle weakness in the rat when exposed 
to hypoxia under the same conditions. Force production was reduced over the range 
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of stimulation frequencies tested. In particular, the weakness was most strongly 
evident at the higher stimulation frequencies. The relevance of this diaphragm 
weakness to human conditions is discussed in section 3.3.1 above. The implication of 
this hypoxia induced weakness being present in the rat as well as the mouse, however, 
is that the mouse and rat adopt slightly different metabolic strategies under hypoxic 
conditions, with the rat closer to the human response i.e. hyperventilation. These data 
confirm that the muscle weakness observed in the mouse was also present in the rat 
suggesting, importantly, that the hypoxia induced diaphragm weakness was most 
likely related to hypoxic stress per se, rather than being solely due to the metabolic 
strategy adopted by the mouse, or indeed the rat. These metabolic strategies will be 
discussed further in chapter 4. 
 
 
3.4 Chapter Conclusions 
 
Acute hypoxia (8 hours) is sufficient to cause diaphragm muscle weakness, in both 
mice and rats. Acute hypoxia primarily weakens and limits diaphragm force 
generating capacity, which in turn leads to reduced power generating capability of the 
diaphragm muscle. Acute hypoxia also reduces mouse sternohyoid power and work 
production, which is likely due to acute hypoxia effects on sternohyoid force 
generating capacity. 
 
Acute hypoxia appears to lead to dysfunction of both the diaphragm and sternohyoid 
muscles, and in both cases this dysfunction appears to stem from acute hypoxia 
induced muscle weakness. In the case of the diaphragm, this weakness has clinical 
relevance to a range of acute respiratory-related disorders in which hypoxia features, 
such as ARDS ALI, VILI/VALI/VIDD, acute respiratory failure and mechanical 
ventilation in patients, including attempts to wean patients from mechanical 
ventilatory support. In the case of the sternohyoid, the acute hypoxia induced muscle 
weakness has clinical relevance to patients with acute respiratory diseases who also 
present with risk of upper airway dysfunction and/or OSA. Respiratory muscle 
weakness could prove particularly problematic when the diaphragm is required to 
perform tasks other than quiet breathing, such as airway clearance manoeuvres and/or 
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ventilation through a narrowed airway, increasing the load on the muscle and in the 
context of upper airway muscle weakness may present problems for recovery of a 
collapsed upper airway during sleep. 
 
Diaphragm weakness can exacerbate and perpetuate respiratory morbidity in 
respiratory patients, prolonging the process of weaning a patient from mechanical 
ventilation and ultimately predisposing a patient to a poorer clinical outcome 
(Supinski and Callahan, 2013). Elucidating the mechanisms of acute hypoxia induced 
respiratory muscle dysfunction will pave the way for the development of suitable 
therapeutic strategies, that may be used as adjunct therapies, in a clinical setting, for 
respiratory patients, in which acute hypoxia features, in order to enhance respiratory 
muscle performance and increase the likelihood of positive outcomes for patients. 
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Chapter 4: Metabolic, Respiratory and Atrophic 
Mechanisms That May Underpin Acute 
Hypoxia Induced Respiratory Muscle 
Dysfunction in Mice 
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4.1 Introduction 
 
In this chapter, respiratory and limb muscle gene expression relating to metabolism 
and mitochondrial function, hypoxic signalling and inflammation, sarcoplasmic 
reticulum calcium handling, release and re-uptake, and atrophy and autophagy, is 
assessed following normoxia (control), 1 hour of hypoxia, 4 hours of hypoxia and 8 
hours of hypoxia. Given the potential contribution of muscle fibre atrophy to 
diaphragm weakness in models of chronic hypoxia and in VIDD (discussed in chapter 
1 and chapter 3), proteasome activity is assessed in this chapter following 8 hours of 
hypoxia compared with control. Respiration is assessed in vivo to determine if 
ventilatory activity is altered in hypoxia and in vivo metabolism is examined to give 
further insight into the metabolic strategy adopted by the mouse in an acute hypoxic 
environment. 
 
As previously stated, in chapter 1 and elsewhere, the effects of acute hypoxia on 
respiratory muscle are relatively unknown. Therefore, in attempting to uncover the 
mechanisms leading to diaphragm and sternohyoid muscle weakness highlighted in 
chapter 3, in the absence of previous literature in this area, previous work on chronic 
hypoxia and hypoxic (mal-)adaptation provided guidance and direction. In nature, a 
state of hypoxic tolerance is achieved through the integration of 1) a reduction in 
metabolic state; 2) protection against hypoxic cell death/injury; and 3) the 
maintenance of functional integrity (Ramirez et al., 2007). Mitochondrial effects of, 
and metabolic adaptations to, chronic hypoxia in diaphragm and sternohyoid muscle 
have been reported previously (Lewis et al., 2016, 2015c) and attributed to redox 
modulation. Indeed, muscle function, hypoxia and metabolism are intrinsically linked 
via HIF signalling as well as other transcription factors regulating metabolism and 
mitochondrial function being hypoxia responsive (Cummins and Taylor, 2005; 
Gutsaeva et al., 2008; Kim et al., 2006; Nanduri et al., 2008; Semenza et al., 1994; 
Vogt et al., 2001). 
 
Calcium handling at the SR is a key factor in ECC, ultimately affecting muscle 
contraction (discussed in chapter 1) and contractile kinetics (mentioned in chapter 3). 
Therefore, in a situation whereby muscle function is perturbed, calcium handling at 
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the SR is one of many logical processes to examine in attempting to unveil the cause 
of contractile dysfunction. 
 
Diaphragm muscle fibre atrophy occurs during exposure to chronic hypoxia and is a 
likely contributing factor to diaphragm dysfunction following chronic hypoxia (Lewis 
et al., 2016; McMorrow et al., 2011). As discussed in chapter 1, the diaphragm is an 
extremely adaptable and malleable muscle and can atrophy within a matter of hours 
under certain conditions such as mechanical ventilation. Combining this information 
it is pertinent to examine atrophy signalling in a model of acute hypoxia where 
diaphragm weakness occurs, and further to this, examine proteasome enzyme activity 
and autophagy signalling, given that autophagy can be induced in the diaphragm by 
mechanical ventilation, where it may limit VIDD, as well as being an atrophy 
inducing factor in mouse diaphragm following intermittent hypoxia, which can be 
activated by oxidative stress (Azuelos et al., 2015; Giordano et al., 2015). 
 
 
Study Aims 
Given the acute hypoxia induced respiratory muscle weakness and dysfunction 
uncovered in chapter three, the primary aims of this chapter are: 1) to examine gene 
expression changes in diaphragm and sternohyoid muscle, in order to elucidate certain 
molecular mechanisms relating to metabolism and mitochondrial function, hypoxic 
signalling and inflammation, sarcoplasmic reticulum calcium handling, release and re-
uptake, and atrophy and autophagy, that may be underpinning this respiratory muscle 
dysfunction, and to compare some of these responses to limb muscles (EDL & 
Soleus) in order to determine if certain acute hypoxia induced transcriptional changes 
are respiratory muscle specific; 2) to determine if proteasome activity is increased by 
acute hypoxia in the diaphragm, which could contribute to muscle weakness; and 3) 
to determine the in-vivo respiratory and metabolic remodelling strategy adopted by 
the mouse during acute hypoxic exposure, to see how these interact with each other, 
to further understand molecular changes. Furthermore, examining in vivo respiration 
informs whether diaphragm muscle activity is altered under acute hypoxia, as an 
increase in ventilation would mean an increase in respiratory muscle activity, which is 
a potential confounding factor with regards to muscle function in a hypoxic 
environment. 
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Methods Summary 
 
Gene expression in respiratory and limb muscle, diaphragm proteasome activity, in 
vivo respiration and in vivo metabolism were measured in mice, as described in more 
detail in Chapter 2 Materials and Methods, Sections 2.3, 2.7, 2.8 and 2.9. 
 
Briefly, gene expression data was obtained via qRT-PCR experiments, expressing 
changes in gene expression as a fold change over the control group. Genes were 
examined based on their involvement in the following cellular processes: metabolism 
and metabolic regulation, SR calcium handling, atrophy, autophagy and hypoxia 
signalling. 
 
Proteasome activity was measured via a fluorometric assay, whereby the presence of 
proteasome activity in a sample leads to the cleavage of a peptide substrate, releasing 
a fluorescent AMC tag. The level of fluorescence detected is relative to the 
proteasome activity in the sample. 
 
In vivo respiration was monitored using unrestrained whole body plethysmography in 
mice during gas exposure. This allowed the measurement of respiratory frequency, 
tidal volume and, from these values, minute ventilation. 
 
In vivo metabolism was measured by monitoring O2 consumption and CO2 production 
in the mice during gas exposure. Post-mortem core body temperature was also 
recorded immediately (within 10 seconds) following euthanasia of the mouse via 
insertion of a rectal thermometer probe, as a crude index of metabolism in rodents. 
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4.2 Chapter Results 
 
4.2.1 Gene Expression and Proteasome Activity 
 
4.2.1.2 Diaphragm 
The gene expression data for the mouse diaphragm is displayed below. These data are 
expressed as fold changes in mRNA levels, relative to the control (normoxia) group, 
following 1, 4 and 8 hours of sustained hypoxia. The expression of genes related to 
energy metabolism and mitochondrial function and biogenesis in the diaphragm are 
displayed in Fig. 1. PGC-1α mRNA expression was significantly increased (p<0.05, 
one-way ANOVA & Tukey’s post hoc test) at 1 hour of hypoxia compared with 
control, however expression returned to control levels by 8 hours (Fig. 1(A)). PGC-1β 
mRNA expression was not significantly affected compared with the control group, 
although there was a significant difference between the 8 hour and 4 hour hypoxia 
groups (p<0.05, one-way ANOVA & Tukey’s post hoc test) (Fig. 1(B)). NRF1 
mRNA expression was not significantly different between groups, although there was 
a trend toward decreased expression at 4 and 8 hours of hypoxia compared with 
control (Fig. 1(C)). Neither NRF2 nor PPARα displayed any significant changes in 
expression across groups (one-way ANOVA & Tukey’s post hoc test) (Fig. 1(D) & 
(E)). UCP-3 mRNA expression increased progressively with increased hypoxic 
exposure time compared with control; following 8 hours of hypoxic exposure, UCP-3 
mRNA levels were significantly increased compared with the control group (p<0.01, 
one-way ANOVA & Tukey’s post hoc test), and the 1 hour of hypoxia group (p<0.05) 
(Fig. 1(F)). 
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Figure 1: Diaphragm muscle gene expression related to metabolism and 
mitochondrial function. Fold changes in mRNA expression (relative to the control 
group) for (A) PGC-1α; (B) PGC-1β; (C) NRF1; (D) NRF2; (E) PPARα; and (F) 
UCP-3 (mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. control, **p  < 0.01 vs. 
control, #p < 0.05 vs. 1 hour, ψp < 0.05 vs. 8 hours, θp < 0.05 vs. 4 hours, one-way 
ANOVA and Tukey’s post hoc test) following 1, 4 and 8 hours of hypoxia or control 
(normoxia). 
 
 
Fig.2 shows the diaphragm expression data for genes related to hypoxic signalling and 
inflammation. There was no significant change in HIF-1α mRNA expression (one-
way ANOVA & Tukey’s post hoc test) across groups (Fig. 2(A)). There was no 
significant change in HIF-2α mRNA expression (one-way ANOVA & Tukey’s post 
hoc test) across groups (Fig. 2(B)). NF-κB1 mRNA expression displayed a trend 
toward decreased expression at 4 and 8 hours of hypoxia compared with control, with 
expression in the 4 hours hypoxia group significantly lower than expression in the 
control and 1 hour hypoxia groups (p<0.05 in both cases, one-way ANOVA & 
Tukey’s post hoc test) (Fig. 2(C)). 
 
 
PGC-1
Control 1 4 8
0.0
0.5
1.0
1.5
2.0
*

Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
PGC-1
Control 1 4 8
0.0
0.5
1.0
1.5
2.0

Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
NRF1
Control 1 4 8
0.0
0.5
1.0
1.5
Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
NRF2
Control 1 4 8
0.0
0.5
1.0
1.5
2.0
Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
PPAR
Control 1 4 8
0.0
0.5
1.0
1.5
2.0
2.5
Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
UCP-3
Control 1 4 8
0
1
2
3
**
#
Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
(B) (C)(A)
(E) (F)(D)
 106 | P a g e  
 
Figure 2: Diaphragm muscle gene expression related to hypoxic signalling and 
inflammation. Fold changes in mRNA expression (relative to the control group) for 
(A) HIF1α; (B) HIF2α; and (C) NF-κB1 (mean ± SEM, n = 7-8 per group) (*p < 0.05 
vs. control, #p < 0.05 vs. 1 hour, one-way ANOVA and Tukey’s post hoc test) 
following 1, 4 and 8 hours of hypoxia or control (normoxia). 
 
 
Fig.3 shows the diaphragm expression data for genes related to sarcoplasmic 
reticulum calcium handling, release and re-uptake. There were no significant changes 
in SERCA 1, SERCA 2a, Junctophilin 1, Junctophilin 2, Calsequestrin 1, Triadin, 
Ryanodine Receptor 1, Ryanodine receptor 3, Dihydropyridine Receptor or Inositol 
Trisphosphate Receptor 1 mRNA expression (one-way ANOVA & Tukey’s post hoc 
test) across groups (Fig. 3A-H, J & K). Selenoprotein N1 mRNA expression 
displayed a trend toward decreased expression at 1, 4 and 8 hours of hypoxia 
compared with control, with expression in the 4 hours hypoxia group significantly 
lower than expression in the control group (p<0.05, one-way ANOVA & Tukey’s 
post hoc test) (Fig. 3(I)). 
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Figure 3: Diaphragm muscle gene expression related to sarcoplasmic reticulum 
calcium handling, release and re-uptake. Fold changes in mRNA expression 
(relative to the control group) for (A) SERCA 1; (B) SERCA 2a; (C) Junctophilin 1; 
(D) Junctophilin 2; (E) Calsequestrin 1; (F) Triadin; (G) Ryanodine Receptor 1; (H) 
Ryanodine Receptor 3; (I) Selenoprotein N1; (J) Dihydropyridine Receptor; and (K) 
Inositol Triphosphate Receptor 1 (mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. 
control, one-way ANOVA and Tukey’s post hoc test) following 1, 4 and 8 hours of 
hypoxia or control (normoxia). 
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Fig.4 shows diaphragm expression data for genes related to atrophy and autophagy. 
There were no significant changes in Foxo-1, Atrogin-1, LC3B, BNIP3, or 
GABARAPL3 mRNA expression (one-way ANOVA & Tukey’s post hoc test) across 
groups (Fig. 4(A), (C), (E), (F), and (G) respectively). Foxo-1, Atrogin-1, and BNIP3 
displayed non-significant trends toward increased expression levels following 
increasing durations of hypoxic exposure. Both Foxo-3 and MuRF-1 mRNA 
expression was significantly increased following 8 hours of hypoxic exposure 
compared with control (p<0.05, one-way ANOVA & Tukey’s post hoc test) (Fig. 4B) 
and (D) respectively). 
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Figure 4: Diaphragm muscle gene expression related to atrophy and autophagy. 
Fold changes in mRNA expression (relative to the control group) for (A) Foxo-1; (B) 
Foxo-3; (C) Atrogin-1; (D) MuRF-1; (E) LC3B; (F) BNIP3; and (G) GABARAPL3 
(mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. control, one-way ANOVA and 
Tukey’s post hoc test) following 1, 4 and 8 hours of hypoxia or control (normoxia). 
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Fig. 5 is a heat map depicting the diaphragm expression data for all of the genes 
examined, as discussed above. 
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Figure 5: Diaphragm muscle gene expression data expressed in a heat map. Heat 
map depicting the fold changes in mRNA expression (relative to the control group) 
for genes related to metabolism and mitochondrial function, hypoxic signalling and 
inflammation, sarcoplasmic reticulum calcium handling, release and re-uptake, and 
atrophy and autophagy (mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. control, **p < 
0.01 vs. control, one-way ANOVA and Tukey’s post hoc test) following 1, 4 and 8 
hours of hypoxia or control (normoxia). Red represents an increase in expression; 
green represents a decrease in expression. 
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Fig. 6 shows diaphragm muscle chymotrypsin-like proteasome activity in control 
(normoxia) and hypoxia (8 hours) groups. There was no significant difference in 
chymotrypsin-like proteasome activity between the two groups (0.36 ± 0.03 vs. 0.35 ± 
0.01 mean ± SEM pmol/min/mg protein; Control vs. Hypoxia; n = 8 per group; p = 
0.9084; unpaired t-test). 
 
 
 
Figure 6: Diaphragm muscle chymotrypsin-like proteasome activity. 
Chimotrypsin-like proteasome activity in diaphragm muscle from control (normoxia) 
and (8 hours) hypoxia groups (mean ± SEM, n = 8 per group, unpaired t-test) 
expressed as rate of AMC tag release from peptide substrate (pmol/min/mg of 
protein). 
 
 
4.2.1.3 Sternohyoid 
The expression of genes related to energy metabolism and mitochondrial function and 
biogenesis in the sternohyoid muscle are displayed in Fig. 7. PGC-1α mRNA 
expression was unaffected by hypoxia across all time points (one-way ANOVA & 
Tukey’s post hoc test) (Fig. 7(A)). PGC-1β mRNA expression was not significantly 
affected compared with the control group, although there was a slight trend towards 
decreased expression levels in hypoxia (one-way ANOVA & Tukey’s post hoc test) 
(Fig. 7(B)). NRF1 mRNA expression was significantly decreased at 4 hours compared 
with control and 1 hour groups (p < 0.05 and p < 0.01 respectively, one-way ANOVA 
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& Tukey’s post hoc test) and decreased at 8 hours of hypoxia, non-significantly 
compared to the control group, but significantly compared with the one hour group 
(p< 0.05, one-way ANOVA & Tukey’s post hoc test) (Fig. 7(C)). Neither NRF2 nor 
PPARα displayed any significant changes in expression across groups (one-way 
ANOVA & Tukey’s post hoc test) (Fig. 7(D) & (E)). UCP-3 mRNA expression 
increased progressively with increased duration of hypoxic exposure compared with 
control; following 8 hours of hypoxic exposure, UCP-3 mRNA levels were 
significantly increased compared with the control (normoxia) group (p<0.01, one-way 
ANOVA & Tukey’s post hoc test), and the 1 hour of hypoxia group (p<0.05) (Fig. 
7(F)). 
 
 
 
Figure 7: Sternohyoid muscle gene expression related to metabolism and 
mitochondrial function. Fold changes in mRNA expression (relative to the control 
group) for (A) PGC-1α; (B) PGC-1β; (C) NRF1; (D) NRF2; (E) PPARα; and (F) 
UCP-3 (mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. control, **p  < 0.01 vs. 
control, #p < 0.05 vs. 1 hour, ##p < 0.001 vs, 1 hour, one-way ANOVA and Tukey’s 
post hoc test) following 1, 4 and 8 hours of hypoxia or control (normoxia). 
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Fig. 8 shows sternohyoid muscle expression data for genes related to hypoxic 
signalling and inflammation. There was no significant change in HIF-1α mRNA 
expression in hypoxia at any time point (one-way ANOVA & Tukey’s post hoc test) 
compared with control, although there was a decreased expression after 4 hours of 
hypoxia compared with the 1 hour hypoxia group (Fig. 8(A)). There was no 
significant change in HIF-2α mRNA expression (one-way ANOVA & Tukey’s post 
hoc test) across groups (Fig. 8(B)). NF-κB1 mRNA expression showed significantly 
decreased expression at 4 and 8 hours of hypoxia compared with both control and 1 
hour groups (p<0.01 4 hours vs. control, p < 0.001 8 hours vs. control, p< 0.05 4 
hours vs. 1 hour, p <0.01 8 hours vs. 1 hour, one-way ANOVA & Tukey’s post hoc 
test) (Fig. 8(C)). 
 
 
 
Figure 8: Sternohyoid muscle gene expression related to hypoxic signalling and 
inflammation. Fold changes in mRNA expression (relative to the control group) for 
(A) HIF1α; (B) HIF2α; and (C) NF-κB1 (mean ± SEM, n = 7-8 per group) (*p < 0.05 
vs. control, **p < 0.01 vs. control, ***p < 0.001 vs. control,  #p < 0.05 vs. 1 hour, ##p 
< 0.01 vs. 1 hour, one-way ANOVA and Tukey’s post hoc test) following 1, 4 and 8 
hours of hypoxia or control (normoxia). 
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test) (Fig. 9(C)). Junctophilin 2 mRNA expression was significantly decreased at 4 
hours compared with control (p < 0.05, one-way ANOVA & Tukey’s post hoc test) 
(Fig. 9(D)). Calsequestrin 1 mRNA expression was significantly decreased at 4 hours 
compared with control and 1 hour groups (p < 0.01 and p < 0.05 respectively, one-
way ANOVA & Tukey’s post hoc test) (Fig. 9(E)). Ryanodine Receptor 1 mRNA 
expression was significantly decreased at 4 hours compared with the 1 hour groups (p 
< 0.05, one-way ANOVA & Tukey’s post hoc test), but not compared with the 
control group (Fig. 9(G)). Dihydropyridine Receptor mRNA expression was 
significantly decreased at 4 hours compared with control and 1 hour groups (p < 0.05 
in both cases, one-way ANOVA & Tukey’s post hoc test) (Fig. 9(J)). Selenoprotein 
N1 mRNA expression displayed a trend toward decreased expression at 1, 4 and 8 
hours of hypoxia compared with control, with expression in the 4 hours and 8 hours 
hypoxia groups significantly lower than expression in the control group (p<0.05 in 
both cases, one-way ANOVA & Tukey’s post hoc test) (Fig. 3(I)). 
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Figure 9: Sternohyoid muscle gene expression related to sarcoplasmic reticulum 
calcium handling, release and re-uptake. Fold changes in mRNA expression 
(relative to the control group) for (A) SERCA 1; (B) SERCA 2a; (C) Junctophilin 1; 
(D) Junctophilin 2; (E) Calsequestrin 1; (F) Triadin; (G) Ryanodine Receptor 1; (H) 
Ryanodine Receptor 3; (I) Selenoprotein N1; (J) Dihydropyridine Receptor; and (K) 
Inositol Triphosphate Receptor 1 (mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. 
control, **p < 0.01 vs. control, #p < 0.05 vs. 1 hour, ##p < 0.01 vs. 1 hour, one-way 
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ANOVA and Tukey’s post hoc test) following 1, 4 and 8 hours of hypoxia or control 
(normoxia). 
 
 
Fig. 10 shows sternohyoid muscle expression data for genes related to atrophy. There 
were no significant changes in Foxo-1, Atrogin-1, or MuRF-1 mRNA expression 
(one-way ANOVA & Tukey’s post hoc test) across groups (Fig. 4 (A), (B) and (C) 
respectively). Foxo-1 and Atrogin-1 displayed non-significant trends toward increased 
expression levels following increasing durations of hypoxic exposure. 
 
 
 
Figure 10: Sternohyoid muscle gene expression related to atrophy. Fold changes 
in mRNA expression (relative to the control group) for (A) Foxo-1; (B) Atrogin-1; 
and (C) MuRF-1 (mean ± SEM, n = 7-8 per group) (one-way ANOVA and Tukey’s 
post hoc test) following 1, 4 and 8 hours of hypoxia or control (normoxia). 
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Fig.11 is a heat map depicting the sternohyoid muscle expression data for all of the 
genes examined, as discussed above. 
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Figure 11: Sternohyoid muscle gene expression data expressed in a heat map. 
Heat map depicting the fold changes in mRNA expression (relative to the control 
group) for genes related to metabolism and mitochondrial function, hypoxic signalling 
and inflammation, sarcoplasmic reticulum calcium handling, release and re-uptake, 
and atrophy and autophagy (mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. control, 
**p < 0.01 vs. control, ***p < 0.001 vs. control, one-way ANOVA and Tukey’s post 
hoc test) following 1, 4 and 8 hours of hypoxia or control (normoxia). Red represents 
an increase in expression; green represents a decrease in expression. 
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4.2.1.4 Limb Muscles 
 
4.2.1.4.1 EDL 
The expression of genes related to energy metabolism and mitochondrial function and 
hypoxia signalling in the EDL muscle are displayed in Fig. 12. PGC-1α mRNA 
expression was unaffected by hypoxia across all time points (one-way ANOVA & 
Tukey’s post hoc test) (Fig. 12(A)). NRF1 mRNA expression was also unaffected by 
hypoxia across all time points (one-way ANOVA & Tukey’s post hoc test) (Fig. 
12(B)), as was the expression of NFκB1, HIF1α, and HIF2α (one-way ANOVA & 
Tukey’s post hoc test) (Fig. 12 (C), (D) and (E)). UCP-3 mRNA expression increased 
with increased duration of hypoxic exposure compared with control. Following 4 
hours of hypoxic exposure, UCP-3 mRNA levels were significantly increased 
compared with the control (normoxia) group (p<0.01, one-way ANOVA & Tukey’s 
post hoc test), and the 1 hour of hypoxia group (p<0.05) (Fig. 12(F)); following 8 
hours of hypoxic exposure UCP-3 mRNA levels were increased significantly 
compared with the control group (p<0.05, one-way ANOVA & Tukey’s post hoc 
test). 
 
 
 
Figure 12: EDL muscle gene expression related to metabolism and mitochondrial 
function, and hypoxia signalling. Fold changes in mRNA expression (relative to the 
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control group) for (A) PGC-1α; (B) NRF1; (C) NFκB1; (D) HIF1α; (E) HIF2α; and 
(F) UCP-3 (mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. control, **p  < 0.01 vs. 
control, #p < 0.05 vs. 1 hour, one-way ANOVA and Tukey’s post hoc test) following 
1, 4 and 8 hours of hypoxia or control (normoxia). 
 
 
Fig. 13 shows EDL muscle expression data for genes related to sarcoplasmic 
reticulum calcium handling, release and re-uptake. There were no significant changes 
in SERCA 1, SERCA 2a, Calsequestrin 1, Junctophilin 1, Junctophilin 2, Triadin, 
Ryanodine Receptor 1, Ryanodine receptor 3, Selenoprotein N1, Dihydropyridine 
Receptor or Inositol Trisphosphate Receptor mRNA expression (one-way ANOVA & 
Tukey’s post hoc test) across groups (Fig. 13A-K).  
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Figure 13: EDL muscle gene expression related to sarcoplasmic reticulum 
calcium handling, release and re-uptake. Fold changes in mRNA expression 
(relative to the control group) for (A) SERCA 1; (B) SERCA 2; (C) Calsequestrin 1; 
(D) Junctophilin 1; (E) Junctophilin 2; (F) Triadin; (G) Ryanodine Receptor 1; (H) 
Ryanodine Receptor 3; (I) Selenoprotein N1; (J) Dihydropyridine Receptor; and (K) 
Inositol Triphosphate Receptor 1 (mean ± SEM, n = 7-8 per group) (one-way 
ANOVA and Tukey’s post hoc test) following 1, 4 and 8 hours of hypoxia or control 
(normoxia). 
 
 
Fig. 14 shows EDL muscle expression data for genes related to atrophy. MuRF-1 
gene expression in the EDL was significantly increased following 4 and 8 hours of 
hypoxic exposure compared with the control group (p < 0.05 in both cases, one-way 
ANOVA & Tukey’s post hoc test) (Fig. 14 (A)). FOXO-1 gene expression in the EDL 
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was significantly increased following 4 hours of hypoxic exposure compared with the 
control and 1 hour hypoxia groups (p < 0.01 in both cases, one-way ANOVA & 
Tukey’s post hoc test) and expression was also elevated in the 8 hours hypoxia group 
although not to statistical significance (Fig. 14 (B)). Atrogin-1 mRNA expression in 
the EDL was significantly increased following 4 hours of hypoxic exposure compared 
with the control group and the 1 hour group (p < 0.01 and p < 0.05 respectively, one-
way ANOVA & Tukey’s post hoc test) and expression was also increased 
significantly in the 8 hours group compared with the control group (p < 0.05, one-way 
ANOVA & Tukey’s post hoc test) (Fig. 14 (C)). 
 
 
 
Figure 14: EDL muscle gene expression related to atrophy. Fold changes in 
mRNA expression (relative to the control group) for (A) MuRF-1; (B) FOXO-1; and 
(C) Atrogin-1 (mean ± SEM, n = 7-8 per group) (one-way ANOVA and Tukey’s post 
hoc test) following 1, 4 and 8 hours of hypoxia or control (normoxia). 
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Fig.15 is a heat map depicting the EDL muscle expression data for all of the genes 
examined, as discussed above. 
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Figure 15: EDL muscle gene expression data expressed in a heat map. Heat map 
depicting the fold changes in mRNA expression (relative to the control group) for 
genes related to metabolism and mitochondrial function, hypoxic signalling and 
inflammation, sarcoplasmic reticulum calcium handling, release and re-uptake, and 
atrophy and autophagy (mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. control, **p < 
0.01 vs. control, one-way ANOVA and Tukey’s post hoc test) following 1, 4 and 8 
hours of hypoxia or control (normoxia). Red represents an increase in expression; 
green represents a decrease in expression. 
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4.2.1.4.2 Soleus 
The expression of genes related to energy metabolism and mitochondrial function and 
hypoxia signalling in the soleus muscle are displayed in Fig. 16. PGC-1α mRNA 
expression was unaffected by hypoxia across all time points (one-way ANOVA & 
Tukey’s post hoc test) (Fig. 16(A)). NRF1 mRNA expression was also unaffected by 
hypoxia across all time points (one-way ANOVA & Tukey’s post hoc test) (Fig. 
16(B)), as was the expression of NFκB1, HIF1α, and HIF2α (one-way ANOVA & 
Tukey’s post hoc test) (Fig. 16 (C), (D) and (E)). UCP-3 mRNA expression increased 
with increased hypoxic exposure compared with control. Following 8 hours of 
hypoxic exposure, UCP-3 mRNA levels were significantly increased compared with 
the control (normoxia) group (p<0.05, one-way ANOVA & Tukey’s post hoc test), 
and the 1 hour of hypoxia group (p<0.05) (Fig. 15(F)). 
 
 
 
Figure 16: Soleus muscle gene expression related to metabolism and 
mitochondrial function, and hypoxia signalling. Fold changes in mRNA expression 
(relative to the control group) for (A) PGC-1α; (B) NRF1; (C) NFκB1; (D) HIF1α; 
(E) HIF2α; and (F) UCP-3 (mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. control, 
#p < 0.05 vs. 1 hour, one-way ANOVA and Tukey’s post hoc test) following 1, 4 and 
8 hours of hypoxia or control (normoxia). 
 
PGC1
Control 1 4 8
0.0
0.5
1.0
1.5
Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
NRF1
Control 1 4 8
0.0
0.5
1.0
1.5
2.0
Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
NFB1
Control 1 4 8
0.0
0.5
1.0
1.5
Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
HIF1
Control 1 4 8
0.0
0.5
1.0
1.5
Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
HIF2
Control 1 4 8
0.0
0.5
1.0
1.5
Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
UCP-3
Control 1 4 8
0
1
2
3
4
*
#
Time (hours)
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l)
(B) (C)(A)
(E) (F)(D)
 123 | P a g e  
 
 
Fig. 17 shows soleus muscle expression data for genes related to sarcoplasmic 
reticulum calcium handling, release and re-uptake. There were no significant changes 
in SERCA 1, SERCA 2a, Calsequestrin 1, Junctophilin 1, Junctophilin 2, Triadin, 
Ryanodine Receptor 1, Ryanodine receptor 3, Selenoprotein N1, Dihydropyridine 
Receptor or Inositol Trisphosphate Receptor mRNA expression (one-way ANOVA & 
Tukey’s post hoc test) across groups (Fig. 17 A-K).  
 
 
 
 
Figure 17: Soleus muscle gene expression related to sarcoplasmic reticulum 
calcium handling, release and re-uptake. Fold changes in mRNA expression 
(relative to the control group) for (A) SERCA 1; (B) SERCA 2a; (C) Calsequestrin 1; 
(D) Junctophilin 1; (E) Junctophilin 2; (F) Triadin; (G) Ryanodine Receptor 1; (H) 
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Ryanodine Receptor 3; (I) Selenoprotein N1; (J) Dihydropyridine Receptor; and (K) 
Inositol Triphosphate Receptor 1 (mean ± SEM, n = 7-8 per group) (one-way 
ANOVA and Tukey’s post hoc test) following 1, 4 and 8 hours of hypoxia or control 
(normoxia). 
 
 
Fig. 18 shows soleus muscle expression data for genes related to atrophy. FOXO-1 
gene expression in the soleus muscle was significantly increased following 4 hours of 
hypoxic exposure compared to the control group (p < 0.05, one-way ANOVA & 
Tukey’s post hoc test) (Fig. 18 (A)). FOXO-1 expression was also increased in the 8 
hours of hypoxia group, although not to statistical significance. Atrogin-1 gene 
expression was not significantly affected by hypoxia in any group compared with 
control, although there was a trend towards increased atrogin-1 mRNA expression as 
the duration of hypoxic exposure increased (Fig. 18 (B)). MuRF-1 mRNA expression 
in the soleus muscle was significantly increased following 8 hours of hypoxic 
exposure compared with the control group and the 1 hour group (p < 0.05 in both 
cases, one-way ANOVA & Tukey’s post hoc test) (Fig. 18 (C)). 
 
 
 
Figure 18: Soleus muscle gene expression related to atrophy. Fold changes in 
mRNA expression (relative to the control group) for (A) FOXO-1; (B) Atrogin-1; and 
(C) MuRF-1 (mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. control, #p < 0.05 vs. 1 
hour, one-way ANOVA and Tukey’s post hoc test) following 1, 4 and 8 hours of 
hypoxia or control (normoxia). 
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Fig.19 is a heat map depicting the Soleus muscle expression data for all of the genes 
examined, as discussed above. 
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Figure 19: Soleus muscle gene expression data expressed in a heat map. Heat map 
depicting the fold changes in mRNA expression (relative to the control group) for 
genes related to metabolism and mitochondrial function, hypoxic signalling and 
inflammation, sarcoplasmic reticulum calcium handling, release and re-uptake, and 
atrophy and autophagy (mean ± SEM, n = 7-8 per group) (*p < 0.05 vs. control, one-
way ANOVA and Tukey’s post hoc test) following 1, 4 and 8 hours of hypoxia or 
control (normoxia). Red represents an increase in expression; green represents a 
decrease in expression. 
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4.2.2 Breathing and Metabolism 
 
 
4.2.2.2 Breathing 
Fig. 20 shows mouse respiratory rate over 8 hours of normoxia (control) and hypoxia 
exposure. Respiratory frequency was increased (p<0.01, two-way ANOVA & 
Bonferroni post hoc test) after 10 mins of hypoxia compared with normoxia, but 
returned to levels equivalent to normoxia by 20mins, and then dropped significantly 
below normoxic levels at 2 hours (p<0.05, two-way ANOVA & Bonferroni post hoc 
test), before returning to levels equivalent to normoxic levels, and remaining similar 
to normoxia for the remainder of the 8 hour hypoxia exposure. 
 
 
 
Figure 20: Mouse respiratory frequency during 8 hour exposure to either a 
normoxic (Control) or hypoxic (Hypoxia) environment. Mouse respiratory 
frequency (mean ± SEM) expressed as breaths per minute (bpm) over the 480 minute 
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(8 hour) period of exposure to gases (n = 6-7 per group) (*p < 0.05, **p < 0.01, two-
way ANOVA and Bonferroni’s multiple comparisons test). 
 
 
Fig. 21 shows mouse tidal volume over 8 hours of normoxia (control) and hypoxia. 
Tidal volume was increased significantly (p<0.001, two-way ANOVA & Bonferroni 
post hoc test) after 10 mins of hypoxia compared with normoxia, but returned to 
levels equivalent to normoxia by 20mins and remained at levels similar to normoxia 
for the remainder of the 8 hour hypoxia exposure. 
 
 
Figure 21: Mouse tidal volume during 8 hour exposure to either a normoxic 
(Control) or hypoxic (Hypoxia) environment. Mouse tidal volume (mean ± SEM) 
expressed as ml per gram of body weight (ml/g) over the 480 minute (8 hour) period 
of exposure to gases (n = 6-7 per group) (***p < 0.001, two-way ANOVA and 
Bonferroni’s multiple comparisons test). 
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Fig. 22 shows mouse minute ventilation, a product of respiratory frequency and tidal 
volume, over 8 hours of normoxia (control) and hypoxia. Minute ventilation was 
increased significantly (p<0.001, two-way ANOVA & Bonferroni post hoc test) after 
10 mins of hypoxia compared with normoxia, but returned to levels equivalent to 
normoxia by 20mins and remained at levels similar to normoxia for the remainder of 
the 8 hour hypoxia exposure. 
 
 
 
Figure 22: Mouse minute ventilation during 8 hour exposure to either a 
normoxic (Control) or hypoxic (Hypoxia) environment. Mouse minute ventilation 
(mean ± SEM) expressed as ml per minute per gram of body weight (ml/min/g) over 
the 480 minute (8 hour) period of exposure to gases (n = 6-7 per group) (***p < 
0.001, two-way ANOVA and Bonferroni’s multiple comparisons test). 
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4.2.2.3 Metabolism 
Fig. 23 displays mouse post-mortem body temperature following 8 hours of exposure 
to hypoxia or normoxia. Fig. 23(A) shows data for mice that were housed individually 
during gas exposure for the purpose of measuring breathing and metabolic parameters 
during gas exposure, whereas Fig. 23(B) shows data for mice that were housed in 
groups of 4 during gas exposure and subsequently used for tissue harvest for 
molecular analysis. In both instances, mice exposed to hypoxia had consistently lower 
body temperatures by ~ 2°C following hypoxia in comparison to mice in the control 
group that were exposed to normoxia (**p = 0.0021 for individually exposed mice; 
****p < 0.0001 for grouped mice, unpaired t-test). 
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Figure 23: Mouse post-mortem body temperature. Post-mortem rectal 
temperatures (mean ± SEM) of mice exposed to hypoxia or normoxia, either (A) 
individually or (B) in groups following 8 hours of exposure to hypoxia or normoxia (n 
= 6-8 per group) (**p = 0.0021, ****p < 0.0001, unpaired t-test). 
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Fig. 24 displays mouse post-mortem body temperature following 8 hours of hypoxia 
and normoxia. Fig. 24(A) shows data comparing control mice that were individually 
exposed to normoxic gas to control mice that were grouped during normoxic gas 
exposure, whereas fig. 24(B) shows data from hypoxic mice that were individually 
exposed to hypoxic gas compared with hypoxic mice that were grouped during 
hypoxic exposure. In both instances, there are no differences for temperature values 
between mice exposed to either gas individually or in groups (unpaired t-test). 
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Figure 24: Mouse post-mortem body temperature. Post-mortem rectal 
temperatures (mean ± SEM) of mice exposed to hypoxia or normoxia displayed as 
(A) Control (normoxia) mice exposed individually vs. those exposed in groups and 
(B) Hypoxia mice exposed individually vs. those exposed in groups, following 8 
hours of hypoxia or normoxia (n = 6-8 per group) (unpaired t-test). 
 
 
Fig. 25 shows mouse oxygen consumption over 8 hours of exposure to either a 
normoxic (Control) or hypoxic (Hypoxia) environment. Oxygen consumption showed 
an initial spike in the first 5–10 minutes of hypoxia and then dropped below the 
oxygen consumption level of the control group, over the course of the 8 hours of 
exposure. Hypoxia thus significantly affected oxygen consumption (***p = 0.0008, 
two-way ANOVA and Bonferroni’s multiple comparisons test), predominantly 
decreasing it over the 8 hours of gas exposure. 
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Figure 25: Mouse oxygen consumption during 8 hour exposure to either a 
normoxic (Control) or hypoxic (Hypoxia) environment. Oxygen consumption 
(mean ± SEM) in the mouse expressed as ml per minute per gram of body weight 
(ml/min/g) over the 480 minutes (8 hour) period of exposure to either hypoxia or 
normoxia (n = 6-7 per group) (two-way ANOVA and Bonferroni’s multiple 
comparisons test). 
 
 
Fig. 26 shows mouse carbon dioxide production over 8 hours of exposure to either a 
normoxic (Control) or hypoxic (Hypoxia) environment. Carbon dioxide production 
began to drop upon hypoxic exposure and dropped below the carbon dioxide 
production level of the control group, over the course of the 8 hours of gas exposure. 
Carbon dioxide production was significantly lower in the hypoxia group at 15, 20 and 
60 minutes of gas exposure (p < 0.01, p < 0.05, and p < 0.01 respectively, two-way 
ANOVA and Bonferroni’s multiple comparisons test), and hypoxia significantly 
reduced carbon dioxide production (****p < 0.0001, two-way ANOVA and 
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Bonferroni’s multiple comparisons test) over the duration of the 8 hours of gas 
exposure. 
 
 
CO2 Production
0 60 120 180 240 300 360 420 480
0.00
0.01
0.02
0.03
0.04
0.05 Control
Hypoxia
Time (mins) p = ns
Hypoxia p < 0.0001****
Interaction p = ns
*
*
*
*
*
Time (mins)
C
O
2
 P
ro
d
u
c
ti
o
n
 (
m
l/
m
in
/g
)
 
Figure 26: Mouse carbon dioxide production over 8 hours of breathing in either 
a normoxic (Control) or hypoxic (Hypoxia) environment. Carbon dioxide 
production (mean ± SEM) in the mouse expressed as ml per minute per gram of body 
weight (ml/min/g) over the 480 minutes (8 hour) period of exposure to either hypoxia 
or normoxia (n = 6-7 per group) (two-way ANOVA and Bonferroni’s multiple 
comparisons test). 
 
 
Fig. 27 shows the mouse carbon dioxide ventilatory equivalent ratio (ventilation/CO2 
production) over 8 hours of exposure to either a normoxic (Control) or hypoxic 
(Hypoxia) environment. The carbon dioxide ventilatory equivalent ratio was 
significantly increased in the hypoxic group upon gas exposure compared with the 
control group with significance reached at 10 and 20 minutes (p < 0.001 and p < 0.01 
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respectively, two-way ANOVA and Bonferroni’s multiple comparisons test), and 
remained elevated over the course of the 8 hours of gas exposure (****p < 0.0001, 
two-way ANOVA and Bonferroni’s multiple comparisons test). 
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Figure 27: Mouse ventilatory equivalent ratio over 8 hours of exposure to either 
a normoxic (Control) or hypoxic (Hypoxia) environment. Ventilatory equivalent 
ratio (mean ± SEM) in the mouse over the 480 minutes (8 hour) period of exposure to 
either hypoxia or normoxia (n = 6-7 per group) (two-way ANOVA and Bonferroni’s 
multiple comparisons test). 
 
 
Fig. 28 shows mouse ventilatory equivalent ratio over 8 hours of breathing in either a 
normoxic (Control) or hypoxic (Hypoxia) environment comparing ventilation to 
oxygen consumption. The oxygen ventilatory equivalent ratio was significantly 
increased in the hypoxic group upon gas exposure compared with the control group 
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and remained elevated over the course of the 8 hours of gas exposure (**p = 0.013, 
two-way ANOVA and Bonferroni’s multiple comparisons test). 
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Figure 28: Mouse oxygen ventilatory equivalent ratio over 8 hours of exposure to 
either a normoxic (Control) or hypoxic (Hypoxia) environment. Oxygen 
ventilatory equivalent ratio (mean ± SEM) in the mouse over the 480 minutes (8 hour) 
period of exposure to either hypoxia or normoxia (n = 6-7 per group) (two-way 
ANOVA and Bonferroni’s multiple comparisons test). 
 
 
Fig. 29 shows mouse respiratory exchange ratio (oxygen consumption/carbon dioxide 
consumption) over 8 hours of breathing in either a normoxic (Control) or hypoxic 
(Hypoxia) environment. There was no effect of hypoxia on the respiratory exchange 
ratio over the course of the 8 hours of gas exposure compared with control (two-way 
ANOVA and Bonferroni’s multiple comparisons test). 
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Figure 29: Mouse respiratory exchange ratio over 8 hours of exposure to either a 
normoxic (Control) or hypoxic (Hypoxia) environment. Respiratory exchange ratio 
(mean ± SEM) in the mouse over the 480 minutes (8 hour) period of exposure to 
either hypoxia or normoxia (n = 6-7 per group) (two-way ANOVA and Bonferroni’s 
multiple comparisons test). 
 
 
Fig. 30 shows the average mouse respiratory exchange ratio (oxygen 
consumption/carbon dioxide consumption) over 8 hours of breathing in either a 
normoxic (Control) or hypoxic (Hypoxia) environment. There was no effect of 
hypoxia on the respiratory exchange ratio over the course of the 8 hours of gas 
exposure compared with control (0.7 ± 0.1 vs. 0.7 ± 0.1 mean ± SEM RER; Control 
vs. Hypoxia; n = 6-7 per group; p = 0.5836; unpaired t-test). 
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Figure 30: Average mouse respiratory exchange ratio over 8 hours of exposure 
to either a normoxic (Control) or hypoxic (Hypoxia) environment. Respiratory 
exchange ratio (mean ± SEM) in the mouse over the 480 minutes (8 hour) period of 
exposure to either hypoxia or normoxia (n = 6-7 per group) (p = 0.5836, unpaired t-
test). 
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4.3 Chapter Discussion 
 
The main findings of this chapter are: 
 
1. 4-8 hours of hypoxia significantly increases mitochondrial UCP-3 mRNA 
expression across all 4 muscle types, suggestive of an increased reliance on 
fatty acid metabolism in skeletal muscle around the body, and potentially 
uncoupling of oxidative phosphorylation reducing ROS production. 
 
2. Differential and dynamic changes in mRNA expression of transcription factors 
involved in the regulation of mitochondrial biogenesis & energy metabolism 
are observed in respiratory, but not limb, muscle following 1, 4 & 8 hours of 
hypoxia. 
 
3. Pro-atrophy signalling mRNA expression is induced by hypoxia across all 4 
muscle types, although not with significance in sternohyoid muscle. There is 
no change in autophagy related gene expression, or proteasome enzymatic 
activity in the diaphragm. 
 
4. 4 hours of hypoxia caused a certain level of perturbation in SR calcium 
handling related gene expression in respiratory muscle, the sternohyoid in 
particular. 
 
5. Hypoxia did not cause any persistent change in ventilation (muscle activity), 
therefore muscle weakness and molecular changes are likely directly hypoxia-
dependent. 
 
6. Hypoxia decreased metabolism and body temperature, meaning that although 
ventilation is unaltered, there is in fact a relative hyperventilation when 
considering the corresponding metabolic rate. 
 
7. The Respiratory Exchange Ratio (RER) is unaffected by hypoxia, suggesting 
there is no detectable switch in metabolic energy source. An RER of 0.7 
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suggests that fatty acids are the primary substrate for oxidative metabolism 
and energy production, over glucose/carbohydrates in normoxia and hypoxia. 
 
 
4.3.1 Gene Expression and Proteasome Activity 
 
4.3.1.1 Mitochondrial Uncoupling 
UCP-3 encodes a protein that functions to uncouple oxidative phosphorylation from 
the electron transport chain (ETC), and dissipates the proton gradient generated by the 
ETC as heat, thus preventing ATPase from using that gradient to generate ATP (see 
fig. 31).  
 
 
 
Figure 31: Mitochondrial uncoupling protein 3 (UCP-3). UCP-3 dissipated the 
proton gradient set up by the ETC as heat, preventing ATPase from using that 
gradient to generate ATP. 
 
 
An increase in UCP-3 expression is suggested to be a marker for an increased reliance 
on fatty acid/lipid metabolism for energy production (Aguer et al., 2013; Giordano et 
al., 2015). An increased utilisation of fatty acids as metabolic substrate for energy 
production has been reported in the mouse diaphragm following exposure to 6 weeks 
of chronic hypoxia (Lewis et al., 2014). Here, UCP-3 mRNA levels are significantly 
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increased following 8 hours of hypoxia in the diaphragm, sternohyoid and soleus 
muscles, and at 4 and 8 hours in the EDL muscle. The fact that UCP-3 expression is 
increased in hypoxia across all 4 muscles, suggests that the effect is not respiratory 
muscle specific and is a ‘global’ phenomenon across skeletal muscle in general. The 
way in which expression increases incrementally across 1, 4 and 8 hours of hypoxia 
also suggests that the increase in UCP-3 mRNA expression under hypoxic conditions 
is temporally dependent, and positively correlated with the duration of hypoxic 
exposure, at least over this acute timeframe. If this increase in gene expression 
translates into an increase in UCP-3 protein, then this would suggest a decrease in 
ATP production via oxidative phosphorylation, due to UCP-3 dissipating the ETC 
proton gradient, which could contribute to diaphragm muscle weakness. This is 
somewhat surprising, as one would think that it would be more beneficial to the 
muscle to tighten coupling of the ETC and ATP production by reducing UCP-3 
expression and thus increase the efficiency of ATP production from available oxygen 
(Gamboa and Andrade, 2012). It may also indicate a metabolic state whereby fatty 
acids are preferred over glucose or carbohydrates as a metabolic substrate for energy 
production. Mitochondrial membrane potential has been posited to regulate the 
production of mitochondrial ROS. Therefore, mitochondrial uncoupling may decrease 
superoxide production by dissipating the membrane potential as heat, and so an 
increase in UCP-3 expression may serve a protective role by diminishing 
mitochondrial ROS generation in skeletal muscle. Indeed, ROS production is 
enhanced in UCP-3 knockout mice (Bodrova et al., 1998; Sastre et al., 2003). Others 
have reported increased UCP-3 expression in limb skeletal muscle in response to 
acute hypoxic stress (Zhou et al., 2000). Contrary to these finding in acute hypoxia, 
chronic hypoxia has been shown to decrease UCP-3 expression in the diaphragm, an 
adaptive mechanism thought to increase the efficacy of ATP production from 
available oxygen by tightening coupling, while UCP-3 content did not change in limb 
muscle (Gamboa and Andrade, 2012). This is further suggestive that the adaptive 
mechanisms of respiratory muscle to sustained hypoxia differ between acute and 
chronic exposures and compared with responses in limb muscles. 
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4.3.1.2 Regulation of Metabolism and Mitochondrial Function 
PGC-1α is a transcriptional co-activator involved in the regulation of mitochondrial 
biogenesis and energy metabolism in skeletal muscle, and it can interact with, and 
regulate the activity of, NRF1 and FoxO1 (Finck and Kelly, 2006; Levett et al., 2012; 
Liang and Ward, 2006). Expression of  PGC-1α is known to be increased in 
endurance exercise (Safdar et al., 2011), and the increased expression of PGC-1α 
mRNA observed in the diaphragm following 1 hour of hypoxia in this chapter may 
have been induced as a result of the initial hypoxic ventilatory response (HVR) 
observed in mice during the first 10 minutes of hypoxic exposure. This HVR requires 
an increase in diaphragm muscle activity to increase respiratory rate, tidal volume and 
thus minute ventilation. Consistent with the timing of this increased diaphragm 
activity is the observation that elevated PGC-1α expression is short lived, already 
declining toward control levels after 4 and 8 hours of hypoxia. There were no changes 
in PGC-1α mRNA expression levels in sternohyoid, EDL or soleus muscles. PGC-1β 
is another transcriptional co-activator, believed to control mitochondrial oxidative 
energy metabolism and lead to the activation of NRF1 (Sonoda et al., 2007). 
However, its mRNA expression was unaffected by acute hypoxia in the diaphragm. 
PPARα is transcriptionally co-activated by PGC-1α, involved in mitochondrial 
plasticity in response to exercise and linked to increased fatty acid oxidation in 
endurance training (Hoppeler and Fluck, 2003; Horowitz et al., 2000). PPARα mRNA 
expression was unaffected by acute hypoxia in the diaphragm. 
 
NRF1 is a transcription factor that regulates the expression of certain genes involved 
in oxidative stress and metabolic genes regulating cell proliferation, and proteins of 
the ETC. NRF1 also targets genes encoding enzymes involved in glutathione 
biosynthesis, as well as other oxidative stress defense enzymes (Biswas and Chan, 
2010; Liang and Ward, 2006). NRF2 is also crucial in the activation of genes which 
are regulated by the antioxidant response element, including glutathione synthesis 
proteins and NAD(P)H; quinone oxidoreductase 1, which it activates under oxidative 
stress conditions. Both NRF1 and NRF2, as well as having independent roles, such as 
those involved in the activation of antioxidant response element-dependent genes 
(Ohtsuji et al., 2008), also interact. Indeed, NRF2 upregulated the mRNA and protein 
levels of NRF1 (Ohtsuji et al., 2008; Piantadosi et al., 2008; Vomhof-DeKrey and 
Picklo, 2012). There was no significant change in NRF1 expression in the diaphragm, 
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although there was a trend toward decreased expression following 4 and 8 hours of 
hypoxia. NRF1 expression was significantly reduced in the sternohyoid muscle 
following 4 hours, but not 8 hours, of hypoxia relative to control. There were no 
changes in NRF1 expression in limb muscle following hypoxia. NRF2 expression is 
unaffected by hypoxia in all 4 muscles. NRF1 and NRF2 therefore do not appear to 
play a major role in diaphragm muscle dysfunction under acute hypoxic stress. The 
short lived reduction in NRF1 expression at 4 hours, but not 8 hours, may indicate 
some transient alterations in the cellular redox state. 
 
4.3.1.3 Inflammation and Hypoxic Signalling 
NF-κB1 mRNA expression is reduced by 4, but not 8 hours of hypoxia in the 
diaphragm, and reduced in the sternohyoid muscle following 4 and 8 hours of 
hypoxia, while NF-κB1 mRNA levels are unaffected by hypoxia in the limb muscles. 
NF-κB1 is a transcription factor which is involved in regulating cell survival and 
inflammation signalling, and which is responsive to oxidative stress, and hypoxia via 
HIF-1α (Carbia-Nagashima et al., 2007; Rius et al., 2008). NF-κB1, although 
classically associated with inflammation, is also linked to induction of skeletal muscle 
atrophy when activated, and NF-κB1 can mediate the upregulation of MuRF-1 (Glass, 
2005; Hunter and Kandarian, 2004; Jackman and Kandarian, 2004; Mourkioti and 
Rosenthal, 2008). The hypoxia induced reduction in NF-κB1 mRNA expression in 
respiratory muscle reported in this chapter may indicate a reduction in NF-κB1-
mediated atrophy and/or inflammation signalling in respiratory muscle following 
acute hypoxia. 
 
HIF2α but not HIF1α mRNA expression is increased by PGC-1α in exercise, while 
PGC-1α is linked to HIF1α dependent gene expression by increasing mitochondrial 
oxygen consumption in skeletal muscle (O’Hagan et al., 2009; Rasbach et al., 2010). 
HIF1α and HIF2α and their physiological roles are discussed in more depth in chapter 
1 and HIF1α is discussed further in chapter 5. Neither HIF1α nor HIF2α mRNA 
expression are affected by acute hypoxia in the diaphragm, sternohyoid, EDL or 
soleus muscles compared with respective controls. However, as HIF is post-
translationally modified (as discussed in chapter 1), HIF1α protein levels are assessed 
in diaphragm and sternohyoid in chapter 5. 
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4.3.1.4 SR Calcium Handling, Release and Re-uptake 
The roles of the proteins encoded by the various genes examined which are related to 
calcium handling at the SR are discussed in detail in chapter 1. Selenoprotein N1 
(SEPN1) was decreased after 4 hours of hypoxia in diaphragm, and 4 and 8 hours of 
hypoxia in the sternohyoid. SEPN1 was the only SR calcium handling related gene to 
show significant changes in expression in the diaphragm, while there were trends 
toward decreased mRNA expression of genes encoding proteins involved in SR 
calcium handling/release: Junctophilin 1, Junctophilin 2, Ryanodine receptor 3, 
Dihydropyridine receptor, and Calsequestrin 1 after 4 hours of hypoxia. Meanwhile 
Junctophilin 1, Junctophilin 2, Calsequestrin 1, Ryanodine Receptor 1 and 
Dihydropyridine receptor were all significantly reduced in the sternohyoid following 
4 hours of hypoxia, but not 8 hours. No SR calcium handling related gene expression 
changes were observed in the limb muscles. SEPN1 is essential for ryanodine receptor 
activity (possibly through controlling its redox state), and thus calcium release from 
the SR, which is fundamental to normal contractile function and calcium homeostasis 
in human muscle (Jurynec et al., 2008; Shchedrina et al., 2010). Indeed, SEPN1-
related myopathy, a human disorder whose symptoms include muscle weakness 
leading to respiratory insufficiency, is associated with defects in the SEPN1 gene 
(Kasaikina et al., 2012). The hypoxia induced reduction of SEPN1 mRNA expression 
in respiratory but not limb muscle, if translated to a reduction in SEPN1 protein, 
could alter calcium release from the SR during contraction in respiratory muscle, 
likely affecting muscle contractile performance. Although, it is pertinent to note that 
in the diaphragm this hypoxia induced reduction in expression is not maintained 
following 8 hours of hypoxia. These data suggest that SR calcium handling may be 
altered following acute hypoxic stress. Of note, however, diaphragm peak contractile 
kinetics (chapter 3) were unaffected by 8 hours of sustained hypoxia compared with 
control, although diaphragm shortening velocity was increased over the range of loads 
tested, which could be affected by altered calcium release or altered sensitivity to 
calcium. However sternohyoid contractile kinetics (chapter 3) were unaffected by 8 
hours of sustained hypoxia compared with control, and although T50 was reduced to 
near significance, this would be influenced by calcium uptake not release, and neither 
SERCA 1 nor SERCA 2a mRNA expression was significantly affected by hypoxia in 
sternohyoid, or diaphragm. It is plausible that perhaps some of the gene expression 
changes related to SR calcium handling discussed here are compensatory responses in 
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the muscle fibres to re-establish a state of functional homeostasis in the face of 
hypoxia, rather than being detrimental effects of hypoxia acting to perturb muscle 
contractile function. 
 
4.3.1.5 Atrophy 
Muscle fibre atrophy, and decreased fibre cross sectional area, is a factor contributing 
to muscle weakness in chronic hypoxia (Deldicque and Francaux, 2013; Favier et al., 
2010; Lewis et al., 2015d; McMorrow et al., 2011). Diaphragm muscle atrophy and 
dysfunction occurs within a matter of hours in mechanically ventilated hypoxaemic 
respiratory patients in the ICU (Powers et al., 2009; Bruells et al., 2013), and there is 
evidence to suggest that the ubiquitin-proteasome pathway, as well as mitochondrial 
abnormalities, may be involved (Hooijman et al., 2015; Picard et al., 2015), while the 
supposedly dominant role of diaphragm inactivity in VIDD is debated (Jaber et al., 
2011a, 2011b; Petrof et al., 2010; Petrof and Hussain, 2016; Sieck and Mantilla, 
2013; Supinski and Callahan, 2013). 
 
Muscle atrophy requires the transcription and activation of atrogenes (Cohen et al., 
2014; Lecker et al., 2004; Sanchez et al., 2014; Sandri et al., 2004). Here, Foxo-1, 
Foxo-3, Atrogin-1 and MuRF-1 atrogene expression is reported following control, 1, 
4 and 8 hours of hypoxia in the diaphragm. There were trends toward increased 
expression of Foxo-1 and Atrogin-1 mRNA expression in hypoxia, while there were 
significant increases in the expression of Foxo-3 and MuRF-1 following 8 hours of 
hypoxia. Some of these atrogenes were also examined in the sternohyoid, EDL and 
soleus muscles. There are no significant changes in the sternohyoid, but Foxo-1 and 
Atrogin-1 display non-significant trends toward increased expression levels following 
increasing durations of hypoxic exposure. While in the limb muscles, EDL MuRF-1 
expression was increased following 4 and 8 hours of hypoxia, Foxo-1 expression was 
increased following 4 hours of hypoxia, and non-significantly after 8 hours, and 
Atrogin-1 expression was increased following 4 and 8 hours, and in the soleus Foxo-1 
expression is increased following 4 hours of hypoxia, and non-significantly after 8 
hours, Atrogin-1 displays trends toward increased expression with increased hypoxia 
exposure, and MuRF-1 expression is increased following 8 hours of hypoxia. These 
data suggest that atrophy signalling via atrogene activation was induced in the 
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diaphragm, as well as skeletal muscle in general, in this model of acute hypoxia. The 
lack of significant increases in the sternohyoid, although there were trends toward 
increased expression, do not appear to be type 2b muscle fibre type specific as the 
EDL muscle, also predominantly type 2b (Soukup et al., 2002), showed significant 
increases in atrogene expression following acute hypoxia. This increase in atrophy 
signalling, if it leads to fibre atrophy would give us a plausible cause for diaphragm 
muscle weakness following acute hypoxia. However, although atrophy signalling is 
induced, we cannot definitively conclude from this that atrophy is occurring. 
 
In mammals, and indeed eukaryotes in general, most protein degradation occurs via 
the ubiquitin-proteasome system or the autophagy-lysosome system (Milan et al., 
2015b). We thus determined diaphragm muscle chymotrypsin-like proteasome 
activity following 8 hours of hypoxia and control. There was no acute hypoxia 
induced change in proteasome activity. This would suggest that although atrophy 
signalling is indeed increased, protein degradation and actual fibre atrophy was not 
occurring, at least not via the ubiquitin-proteasome system. 
 
4.3.1.6 Autophagy 
The expression of key genes relating to autophagy signalling - LC3B, BNIP3 and 
GABARAPL3 - was also examined in the diaphragm of control mice and those 
exposed to 1, 4 and 8 hours of hypoxia. There were no changes in the expression 
profiles of any of these genes, other than a slight, non-significant, trend toward 
increased expression of BNIP3 following 8 hours of hypoxia. It is therefore unlikely 
that muscle fibre atrophy was occurring within 8 hours of hypoxia via the autophagy-
lysosome system. 
 
4.3.2 Breathing 
The diaphragm is the primary pump muscle of inspiration. Therefore, a change in 
ventilation requires, and is mediated via, a change in diaphragm muscle activity. An 
increase in diaphragm muscle activity due to hyperventilation under hypoxic 
conditions would be a confounding factor which could affect diaphragm muscle 
contractile ability and influence the cellular milieu. It would therefore be misleading 
to attribute altered diaphragm characteristics to hypoxic stress per se if the activity of 
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the muscle is also altered during hypoxic exposure. However, in this mouse model 
ventilation is unchanged for the majority of the 8 hours of hypoxic exposure. 
Respiratory rate, or frequency, (the number of breaths an animal breathes per minute) 
and tidal volume (the volume of gas that passes in an out of the lung with each breath) 
were both measured over the course of the 8 hours of hypoxia. The initial increase in 
respiratory frequency, which manifests during the first 10 minutes of hypoxic 
exposure, is a reflex hyperventilation, due to the HVR of the animal (Palmer et al., 
2013; Powell et al., 1998), and is short lived, with frequency returning to levels 
equivalent to normoxia within 20 minutes of hypoxic exposure. Respiratory frequency 
then actually drops slightly below normoxic levels for a short time before returning to 
levels equivalent to normoxia for the remainder of the 8 hours. Tidal volume follows 
a similar profile, increasing in the first 10 minutes and then returning to levels 
equivalent to normoxia for the remainder of the 8 hours. The product of respiratory 
frequency and tidal volume is minute ventilation (the volume of gas passing in and 
out of the lungs per minute), an index of overall ventilation. Minute ventilation, 
staying true to its components, mirrors the profile described above with an initial 
increase during the initial 10 minutes of hypoxia and then returning to levels 
equivalent to normoxia by 20 minutes into hypoxia, remaining equivalent to normoxia 
for the remainder of the 8 hours of hypoxia. The implication of this observation is that 
the activity of the diaphragm is therefore likely unchanged in hypoxia compared with 
normoxia over the 8 hours, as the work of ventilation is not different between the two 
groups. Therefore, although the influence of the initial increase in ventilation during 
hypoxic exposure cannot be discounted, it is likely that increased muscle activity due 
to hyperventilation is not likely a confounding factor in this model and thus the 
muscle weakness and molecular changes reported herein are likely due to direct 
effects of hypoxic stress per se. 
 
The decline of minute ventilation from the peak HVR returning toward normoxic 
levels is likely partly due to hypocapnia, resulting from hyperventilation in a non-
isocapnic hypoxic environment. Hypocapnia (and the resultant effects on acid-base 
balance) can affect the diaphragm (Shee and Cameron, 1990) and there is evidence 
that molecular CO2, independent of pH, can cause alterations in gene expression 
(Cummins et al., 2010). Although ventilation is equivalent in normoxia and hypoxia, 
there is a relevant hyperventilation in mice exposed to hypoxia compared with 
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normoxia, owing to the elaboration of a hypometabolic state in the mouse in response 
to hypoxia. 
 
4.3.3 Metabolism 
Hypometabolism is an adaptive mechanism in hypoxia-tolerant animals (Gamboa and 
Andrade, 2012; Ramirez et al., 2007; St-Pierre et al., 2000). Hypoxic hypometabolism 
is a general characteristic of the mammalian response to hypoxia, and one whose 
magnitude is inversely proportional to the resting or basal VO2 of the species, making 
it more prominent in smaller mammals (with higher VO2) and less prominent in larger 
mammals (with lower VO2) (Frappell et al., 1992). Here, 8 hours of hypoxia 
decreased metabolic measurements and post-mortem body temperature by approx. 
2°C compared with control. Hypoxia may decrease metabolic rate by decreasing 
thermogenesis (Frappell et al., 1992) and body temperature can be considered a crude 
index of in vivo metabolism. Importantly, there was no difference in post-mortem 
body temperature between the mice that were exposed to hypoxia individually (for 
muscle function studies) and those mice that were exposed to hypoxia in groups of 4 
(for tissue harvest), suggesting that isolating mice had no effect on their metabolic 
strategy to hypoxic exposure compared with the grouped response. 
 
It is clear from the significant effect of hypoxia to reduce O2 consumption (VO2) and 
CO2 production (VCO2) that the hypoxic group adopted a hypoxic hypometabolic 
state. Interestingly, the time-scale of the drop off in VCO2 matches closely with the 
cessation of the HVR in the minute ventilation, further bolstering the notion that this 
return of breathing to normoxic levels is prompted by a hypometabolic state rather 
than hypocapnic alkalosis. 
 
The ventilatory equivalents for both CO2 and O2 (VE/VCO2 & VE/VO2, respectively) 
are increased in hypoxia, due to minute ventilation remaining at normoxic levels 
while VCO2 and VO2 are reduced, leading to a relative hyperventilation for the 
prevailing level of metabolism, in comparison with the control group. Although 
VE/VCO2 is increased in hypoxia, following the large increase during the first 20-30 
minutes of hypoxia (due to the HVR and the drop in VCO2) the increased VE/VCO2 
in hypoxia is only modestly higher than the VE/VCO2 in control for the remainder of 
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the 8 hours. It is worth noting, however, that this slightly elevated VE/VCO2 could 
lead to hypocapnia (respiratory alkalosis), due to normal CO2 blow off via respiration 
while CO2 production is reduced. 
 
Finally, the respiratory exchange ratio is unaffected by hypoxia, suggesting that there 
is no global change in metabolic substrate for energy production. An RER of 0.7 in 
both groups suggests that fatty acids are the primary substrate for oxidative 
metabolism and energy production, over glucose/carbohydrates (Marvyn et al., 2016). 
The increase in UCP-3 mRNA expression in skeletal muscle discussed earlier is 
suggested as a marker for an increased reliance on fatty acids as a metabolic energy 
source. Here the RER of the control group suggests that these mice are already in a 
metabolic state whereby they are utilising fatty acids as their primary substrate for 
energy production. 
 
 
4.4 Chapter Conclusions 
In conclusion, hypoxia did not cause any persistent change in ventilation (muscle 
activity) and therefore muscle weakness and molecular changes are likely directly 
related to hypoxia per se. Hypoxia induces a hypometabolic state in the mouse, and 
although ventilation is unaltered, there is in fact a relative hyperventilation when 
metabolism is accounted for. This hypometabolic state could potentially impact 
diaphragm performance. Therefore, in chapter 5, when examining how NAC pre-
treatment may affect acute hypoxia-induced diaphragm dysfunction, we will also 
examine how NAC pre-treatment impacts post-mortem body temperature as an index 
of metabolism. The UCP-3 findings suggest that skeletal muscle signals, at least at an 
mRNA level, drive toward an increased reliance on fatty acid metabolism in skeletal 
muscle around the body. Given that the RER is unaffected by hypoxia, suggesting 
there is no switch in metabolic energy source, perhaps the effects of this mRNA 
signal do not manifest within 8 hours. Or perhaps the effect is not observed because 
the RER in both groups is 0.7, suggestive that fatty acids are already the primary 
substrate for oxidative metabolism and energy production, over 
glucose/carbohydrates, in normoxia in these mice. The increase in UCP-3 may, 
however, be a compensatory mechanism to reduce oxidative stress and ROS 
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production in the muscle. The differential and dynamic changes in mRNA expression 
of transcription factors regulating mitochondrial biogenesis & energy metabolism in 
respiratory, but not limb, muscle are complex and somewhat inconclusive. However 
there are obviously certain metabolic shifts occurring in the mitochondria, evident 
from the UCP-3 data and the hypoxic hypometabolic state observed. Acute hypoxia 
perturbs SR calcium handling related gene expression in respiratory muscle, the 
sternohyoid in particular, which may be a contributing factor to muscle dysfunction, 
or may be a compensatory mechanism acting to bring about a homeostatic state. It is 
interesting to note, however, that SEPN1 is redox sensitive and so alterations in its 
expression may relate to redox changes in the muscle (Jurynec et al., 2008; 
Shchedrina et al., 2010). Finally, pro-atrophy signalling is induced by hypoxia across 
all 4 muscle types, although not with significance in sternohyoid muscle. However, 
there is no change in autophagy related gene expression, or proteasome enzymatic 
activity in the diaphragm, suggesting that protein catabolism is not occurring, at least 
not within 8 hours of hypoxia, which suggests that muscle weakness in hypoxia is not 
likely related to muscle atrophy. 
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Chapter 5: N-acetylcysteine Ameliorates Acute 
Hypoxia-Induced Diaphragm Dysfunction 
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5.1 Introduction 
 
In this chapter, diaphragm muscle contractile performance is assessed following 8 
hours of normoxia (Control), 8 hours of hypoxia (Hypoxia) or 8 hours of hypoxia 
with N-acetylcysteine (NAC) pre-treatment (NAC + Hypoxia). Signalling pathways 
associated with hypertrophy-atrophy balance and hypoxia signalling are also 
examined, to determine how hypoxia influences these mechanisms and if NAC 
treatment prior to hypoxia alters the response of these mechanisms to hypoxia. 
Signalling pathways associated with hypertrophy-atrophy balance and hypoxia 
signalling are also examined in the sternohyoid following 8 hours of normoxia 
(Control) and 8 hours of hypoxia (Hypoxia). 
 
Diaphragm muscle weakness can be an important determinant of poor outcome in 
patients, particularly those respiratory patients requiring mechanical ventilation 
(Supinski and Callahan, 2013). If it is possible to prevent, dampen or delay the onset 
of diaphragm muscle weakness in hypoxaemic respiratory patients, this could have 
substantially positive effects on the outcome of patients with acute respiratory 
diseases. The potential role of acute hypoxia in the development of diaphragm muscle 
weakness has been overlooked, despite hypoxaemia being a hallmark of ARDS and 
other acute respiratory conditions, with evidence of severe hypoxaemia in up to 30% 
of ARDS patients, and evidence that hypoxia alters skeletal muscle physiology, 
including mitochondrial derangement, in humans (Murray 2009). As highlighted in 
this thesis, chapter 3, for the first time acute hypoxia is sufficient to weaken the 
mouse diaphragm by 30%. Given that acute hypoxia features in many acute 
respiratory conditions (discussed in chapter 1), if this acute hypoxia induced 
diaphragm weakness translates to humans, avoiding the potential onset and 
progression of acute hypoxia induced diaphragm dysfunction could substantially 
improve patient outcome, removing an as of yet overlooked factor which may be 
contributing to diaphragm weakness in patients. 
 
NAC, as discussed in chapter 1, is an antioxidant, both in its own right as a free 
radical scavenger as well as by way of boosting synthesis of the endogenous 
antioxidant GSH and other antioxidant systems. NAC already has a widespread 
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clinical use, going back almost 50 years, as a treatment for a variety of conditions 
(chapter 1). Chronic antioxidant supplementation has been shown to prevent chronic 
hypoxia induced sternohyoid and diaphragm muscle weakness in animal models 
(Lewis et al., 2015b, 2015c). Indeed, patients with ARDS are in a dysfunctional 
oxidant to antioxidant ratio and this balance can be improved by NAC 
supplementation, via increasing GSH, thiol molecules and antioxidant defences 
(Soltan-Sharifi et al., 2007). Redox balance is known to affect muscle contractile 
function (Lewis et al., 2015b, 2014; Magalhães et al., 2005; Smith and Reid, 2006). If 
a single I.P. injection of NAC could alleviate acute hypoxia induced diaphragm 
dysfunction, similarly to how chronic NAC treatment prevents chronic hypoxia 
induced diaphragm dysfunction in the mouse, either by a similar mechanism or 
otherwise, this could prove extremely valuable to hypoxaemic patients with acute 
respiratory diseases in the clinic. However, it is worth noting here that NAC was 
administered immediately prior to onset of the bout of acute hypoxia, and it is 
uncertain whether NAC would be beneficial were it administered after the onset of 
acute hypoxia, which is more closely aligned to a clinical situation where patients can 
present with already worsening O2 levels due to exacerbation of disease. 
 
HIF1α is a master regulator of hypoxia signalling, playing a central role in 
orchestrating the cellular response to hypoxia via the induction of transcriptional 
programmes comprising an array of hypoxia-inducible genes. Although HIF1α 
mRNA expression was unaltered by acute hypoxia in chapter 4, HIF1α is post-
translationally regulated by oxygen dependent degradation (discussed in chapter 1) 
and so it is pertinent to examine HIF1α protein content in the diaphragm and 
sternohyoid muscles from these animals to determine if HIF1α signalling is occurring 
in respiratory muscle following acute hypoxia. 
 
The balance between hypertrophy/cell survival and atrophy/cell death signalling is a 
fundamental aspect of cellular signalling when discussing muscle weakness. In 
chapter 4, we observe an increase in atrogene mRNA expression across skeletal 
muscle, including diaphragm and sternohyoid muscle. However, there is no change in 
proteasome activity following 8 hours of hypoxia. It may be that acute adaptations to 
hypoxia do not include protein breakdown, but that if hypoxia persists then the acute 
hypoxia induced increases in atrogene expression translate to muscle atrophy, as 
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atrophy and increased proteasome activity are observed the diaphragm following 
chronic hypoxia (Lewis et al., 2016, 2014; McMorrow et al., 2011). It may be that the 
diaphragm staves off atrophy for a time in an attempt to preserve functional 
performance, as the diaphragm muscle is perpetually active due to spontaneous 
breathing. However, as hypoxia persists, protein turnover and amino acid dependent 
ATP generation may be a favourable use of resources within the muscle for energy 
homeostasis at the expense of force generating capacity. Many of the signalling 
pathways that influence the hypertrophy/atrophy balance, such as Akt, mTOR, 
MAPK, FoxO ultimately influence, via hypertrophy and atrophy, the balance between 
cell survival/development/proliferation/growth and cell death/catabolism/anti-
anabolism/inflammation. These pathways are complex and interact with each other to 
achieve desirable cellular outcomes. Therefore, when a muscle like the diaphragm is 
stressed, by oxygen deprivation for example, the ultimate goal is not simply 
hypertrophy or atrophy, but rather muscle optimisation for the maintenance of 
functional integrity. 
 
 
Study Aims 
The primary aims of this chapter are: 1) to determine if pre-treatment with the 
antioxidant N-acetylcysteine (NAC) prior to hypoxic exposure can prevent acute 
hypoxia-induced diaphragm dysfunction; and 2) to further examine and elucidate 
signalling mechanisms and pathways associated with hypertrophy-atrophy balance 
and hypoxia signalling affected by acute hypoxia, in both diaphragm and sternohyoid 
muscle, and to determine how NAC pre-treatment prior to hypoxia affects these 
pathways in the diaphragm. 
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Methods Summary 
 
Diaphragm muscle ex vivo contractile function, post-mortem body temperature and 
signalling protein/phosphoprotein levels were examined in control, hypoxia and 
hypoxia + NAC groups as described in more detail in Chapter 2 Materials and 
Methods, Sections 2.10, 2.5, 2.6 and 2.2. Signalling protein/phosphoprotein levels 
were also examined in sternohyoid muscle from mice in both control and hypoxia 
groups. Mice in the hypoxia + NAC group were given a single I.P. injection of NAC 
immediately prior to hypoxia exposure. 
 
Briefly, a strip of mouse diaphragm muscle, was fixed between a stationary hook and 
a dual mode force transducer in an organ bath, filled with hyperoxic Krebs solution 
maintained at 30°C, allowing contractile performance to be assessed when the muscle 
strip was stimulated to contract. 
 
When assessing muscle isometric contractile performance, the length of the muscle 
strip was fixed to the length at which the muscle produced the highest force – 
optimum length (Lo). Under isometric conditions, force generation capacity was 
assessed over a range of stimulation frequency in the muscle strip. 
 
Core post-mortem body temperature was measured immediately (within 10 seconds) 
following euthanasia of the mouse via insertion of a rectal thermometer probe. 
 
Protein/Phosphoprotein levels were assessed using sandwich immunoassays targeted 
for signaling proteins involved in hypoxia signalling and hypertrophy/atrophy balance 
signalling. These signaling pathways were chosen for their relevance to skeletal 
muscle strength and responses to hypoxia. Atrophy is a likely factor contributing to 
chronic hypoxia induced diaphragm weakness, and it is therefore pertinent to examine 
hypertrophy/atrophy balance signalling following acute hypoxia, given how quickly 
the diaphragm can atrophy in certain conditions. These assays were performed in 
sternohyoid muscle from Control and Hypoxia groups, and diaphragm muscle from 
Control, Hypoxia and Hypoxia + NAC groups. 
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5.2 Chapter Results 
 
5.2.1 Diaphragm Function 
The mouse diaphragm force–frequency relationship following 8 hours of normoxia, 
hypoxia, and NAC + Hypoxia is displayed in Fig. 1. As one would expect, the 
specific force generating capacity of the diaphragm muscle increases as the 
stimulation frequency is increased, from 10 to 160 Hz, and this effect of stimulation 
frequency on muscle contractile force is statistically significant (p< 0.0001, two-way 
ANOVA). Force generation over the range of stimulation frequencies tested was 
lower in the hypoxia group compared with the control group, and this weakness was 
most prominent at higher frequencies (as discussed in chapter 3). A single I.P. 
injection of NAC prior to hypoxic exposure prevented this hypoxia induced 
diaphragm weakness from manifesting and the NAC + Hypoxia group actually 
developed the highest forces over the range of stimulation frequencies tested (p< 
0.0001, two-way ANOVA). Bonferroni’s multiple comparisons test revealed 
statistically significant differences between the Hypoxia and NAC + Hypoxia groups 
at 120, 140 and 160 Hz. There was no interaction (p = ns) between treatment and 
stimulation frequency. 
 
 
Figure 1: Diaphragm muscle force – frequency relationship in the mouse. 
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function of stimulation frequencies ranging between 10 and 160 Hz (n = 6-8 per 
group; *p < 0.05, **p<0.01, Bonferroni’s post-hoc multiple comparisons test NAC + 
Hypoxia vs. Hypoxia). 
 
 
Figure 2 displays diaphragm isometric peak tetanic force generation capacity 
following 8 hours of normoxia, hypoxia, or NAC + Hypoxia. There was a statistically 
significant reduction in diaphragm peak tetanic force (29.5 ± 3.2 vs. 20.8 ± 2.0 mean 
± SEM N/cm2; Control vs. Hypoxia; n = 8 per group; p = 0.0334; unpaired t-test) of 
~30% following 8 hours of hypoxia compared with control. This hypoxia-induced 
diaphragm weakness did not appear in the NAC + Hypoxia group and peak force 
generation capacity was even slightly elevated in this group, although not quite to 
statistical significance (34.5 ± 6.5 vs. 20.8 ± 2.0 mean ± SEM N/cm2; NAC + 
Hypoxia vs. Hypoxia; n = 8 per group; p = 0.0782; unpaired t-test with Welch’s 
correction). 
 
 
Diaphragm Peak Tetanic Force
0
5
10
15
20
25
30
35
40
45
NAC + Hypoxia
Control
Hypoxia
p=0.0782
*p=0.0334
S
p
e
c
if
ic
 F
o
rc
e
(N
/c
m
2
)
 
Figure 2: Diaphragm isometric peak tetanic force. Diaphragm peak tetanic force 
(mean ± SEM) expressed as force/CSA (N/cm2); n = 8 per group. *p = 0.0334, 
unpaired t-test, p = 0.0782, unpaired t-test with Welch’s correction. 
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5.2.2 Temperature 
Fig. 3 shows mouse post-mortem body temperature following 8 hours of normoxia 
(Control), 8 hours of hypoxia, and 8 hours of hypoxia with NAC pretreatment. Mice 
exposed to hypoxia, and hypoxia following NAC pretreatment had lower post-mortem 
body temperatures following gas exposure compared with mice in the control group 
that were exposed to normoxia (****p < 0.0001 for Hypoxia vs. Control, unpaired t-
test, and *p = 0.0105 for NAC + Hypoxia vs. Control, unpaired t-test with Welch’s 
correction). There was no difference in post-mortem body temperature between 
Hypoxia and NAC + Hypoxia. 
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Figure 3: Mouse post-mortem body temperature. Post-mortem body temperatures 
(mean ± SEM) of mice exposed to 8 hours of normoxia, 8 hours of hypoxia or 8 hours 
of hypoxia with NAC pretreatment (n = 4-8 per group) (****p < 0.0001, unpaired t-
test, *p = 0.0105, unpaired t-test with Welch’s correction). 
 
 
5.2.3 Diaphragm Signalling 
 
5.2.3.1 HIF Signalling 
Figure 4 shows HIF1α protein content in diaphragm muscle from mice exposed to 8 
hours of normoxia, hypoxia, or hypoxia with NAC pretreatment. Hypoxia 
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significantly increased HIF1α protein content compared with the control group (**p = 
0.0019; unpaired t-tests). Hypoxia with NAC pretreatment increased HIF1α protein 
content further still compared with the control group (****p < 0.0001; unpaired t-
tests) and significantly higher than the Hypoxia group (*p = 0.0332; unpaired t-tests). 
 
 
 
Figure 4: Diaphragm HIF1α protein content following 8 hours of normoxia, 
hypoxia, and hypoxia + NAC pre-treatment. Diaphragm HIF1α protein content 
(mean ± SEM) expressed as signal/μg of total protein (corrected for background 
signal); n = 6-8 per group. *p = 0.0332, **p = 0.0019, ****p < 0.0001; separate 
unpaired t-tests. 
 
 
5.2.3.2 Pro-Hypertrophy/Cell Survival Signalling 
 
5.2.3.2.1 Akt Pathway 
Figure 5 shows phospho-Akt protein content in diaphragm muscle from mice exposed 
to 8 hours of normoxia, hypoxia, or hypoxia with NAC pretreatment. Hypoxia 
significantly increased phospho-Akt protein content compared with the control group 
(*p = 0.0109; unpaired t-tests). Hypoxia with NAC pretreatment increased phospho-
Akt protein content further still compared with the control group (****p = 0.0001; 
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unpaired t-tests) and significantly higher than the Hypoxia group (***p = 0.0004; 
unpaired t-tests). 
 
 
 
Figure 5: Diaphragm phospho-Akt (S473) protein content following 8 hours of 
normoxia, hypoxia, and hypoxia + NAC pre-treatment. Diaphragm phospho-Akt 
(S473) protein content (mean ± SEM) expressed as signal/μg of total protein 
(corrected for background signal); n = 8 per group. *p = 0.0109, ****p = 0.0001, 
***p = 0.0004; separate unpaired t-tests. 
 
 
Figure 6 shows phospho-p70S6K protein content in diaphragm muscle from mice 
exposed to 8 hours of normoxia, hypoxia, or hypoxia with NAC pretreatment. 
Hypoxia has no significant effect on phospho-p70S6K protein content compared with 
the control group (unpaired t-tests). However, Hypoxia with NAC pretreatment 
increased phospho-p70S6K protein content compared with the control group (**p = 
0.0019; unpaired t-tests) and increases phospho-p70S6K protein content above the 
level of the Hypoxia group, but not quite to statistical significance (p = 0.0616; 
unpaired t-tests). 
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Figure 6: Diaphragm phospho-p70S6K (T389) protein content following 8 hours 
of normoxia, hypoxia, and hypoxia + NAC pre-treatment. Diaphragm phospho-
p70S6K (T389) protein content (mean ± SEM) expressed as signal/μg of total protein 
(corrected for background signal); n = 8 per group. **p = 0.0019; separate unpaired t-
tests. 
 
 
Figure 7 shows phospho-S6RP protein content in diaphragm muscle from mice 
exposed to 8 hours of normoxia, hypoxia, or hypoxia with NAC pretreatment. 
Hypoxia significantly increased phospho-S6RP protein content compared with the 
control group (*p = 0.0434; unpaired t-tests). The Hypoxia with NAC pretreatment 
group also increased phospho-S6RP protein content compared with the control group 
(**p = 0.0099; unpaired t-tests), but there is no difference between the Hypoxia and 
Hypoxia + NAC groups (unpaired t-tests). 
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Figure 7: Diaphragm phospho-S6RP (S235/236) protein content following 8 
hours of normoxia, hypoxia, and hypoxia + NAC pre-treatment. Diaphragm 
phospho-S6RP (S235/236) protein content (mean ± SEM) expressed as signal/μg of 
total protein (corrected for background signal); n = 8 per group. *p = 0.0434, **p = 
0.0099; separate unpaired t-tests. 
 
 
Figure 8 shows phospho-GSK-3β protein content in diaphragm muscle from mice 
exposed to 8 hours of normoxia, hypoxia, or hypoxia with NAC pretreatment. 
Hypoxia significantly increased phospho-GSK-3β protein content compared with the 
control group (***p = 0.0009; unpaired t-tests). Hypoxia with NAC pretreatment 
increased phospho-GSK-3β protein content further still compared with the control 
group (****p = 0.0006; unpaired t-tests), and there is no difference between the 
Hypoxia and Hypoxia + NAC groups (unpaired t-tests). 
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Figure 8: Diaphragm phospho-GSK-3β protein content following 8 hours of 
normoxia, hypoxia, and hypoxia + NAC pre-treatment. Diaphragm phospho-GSK-
3β protein content (mean ± SEM) expressed as signal/μg of total protein (corrected 
for background signal); n = 8 per group. ****p = 0.0006, ***p = 0.0009; separate 
unpaired t-tests. 
 
 
5.2.3.2.2 mTOR Pathway 
Figure 9 shows mTOR protein content in diaphragm muscle from mice exposed to 8 
hours of normoxia, hypoxia, or hypoxia with NAC pretreatment. Hypoxia 
significantly increased mTOR protein content compared with the control group (*p = 
0.0107; unpaired t-tests). Hypoxia with NAC pretreatment, however, did not increase 
mTOR protein content compared with the control group (unpaired t-tests) and mTOR 
protein content was significantly lower in the Hypoxia + NAC group than the 
Hypoxia group (**p = 0.0020; unpaired t-tests). 
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Figure 9: Diaphragm mTOR protein content following 8 hours of normoxia, 
hypoxia, and hypoxia + NAC pre-treatment. Diaphragm mTOR protein content 
(mean ± SEM) expressed as signal/μg of total protein (corrected for background 
signal); n = 7-8 per group. *p = 0.0107, **p = 0.0020; separate unpaired t-tests. 
 
 
Figure 10 shows phospho-mTOR protein content in diaphragm muscle from mice 
exposed to 8 hours of normoxia, hypoxia, or hypoxia with NAC pretreatment. 
Hypoxia significantly increased phospho-mTOR protein content compared with the 
Control group (*p = 0.0123; unpaired t-tests). Hypoxia with NAC pretreatment 
increased phospho-mTOR protein content further still compared with the control 
group (***p = 0.0001; unpaired t-tests) and significantly higher than the Hypoxia 
group (**p = 0.0067; unpaired t-tests). 
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Figure 10: Diaphragm phospho-mTOR protein content following 8 hours of 
normoxia, hypoxia, and hypoxia + NAC pre-treatment. Diaphragm phospho-
mTOR protein content (mean ± SEM) expressed as signal/μg of total protein 
(corrected for background signal); n = 7-8 per group. *p = 0.0123, **p = 0.0067, ***p 
= 0.0001; separate unpaired t-tests. 
 
 
5.2.3.2.3 MAPK Pathway 
Figure 11 shows phospho-ERK1/2 protein content in diaphragm muscle from mice 
exposed to 8 hours of normoxia, hypoxia, or hypoxia with NAC pretreatment. 
Hypoxia significantly increased phospho-ERK1/2 protein content compared with the 
Control group (*p = 0.0406; unpaired t-tests). Hypoxia with NAC pretreatment 
increased phospho-ERK1/2 protein content further still compared with the control 
group (***p = 0.0020; unpaired t-tests) and significantly higher than the Hypoxia 
group (**p = 0.0046; unpaired t-tests). 
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Figure 11: Diaphragm phospho-ERK1/2 protein content following 8 hours of 
normoxia, hypoxia, and hypoxia + NAC pre-treatment. Diaphragm phospho-
ERK1/2 protein content (mean ± SEM) expressed as signal/μg of total protein 
(corrected for background signal); n = 5-8 per group. *p = 0.0406, ***p = 0.0020, **p 
= 0.0046; separate unpaired t-tests. 
 
 
5.2.3.2.4 FoxO3a Pathway 
Figure 12 shows phospho-FOXO-3a protein content in diaphragm muscle from mice 
exposed to 8 hours of normoxia, hypoxia, or hypoxia with NAC pretreatment. 
Hypoxia significantly increased phospho-FOXO-3a protein content compared with 
the Control group (***p = 0.0002; unpaired t-tests). Hypoxia with NAC pretreatment 
increased phospho-FOXO-3a protein content further still compared with the control 
group (****p < 0.0001; unpaired t-tests) and significantly higher than the Hypoxia 
group (**p = 0.0024; unpaired t-tests). 
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Figure 12: Diaphragm phospho-FOXO-3a protein content following 8 hours of 
normoxia, hypoxia, and hypoxia + NAC pre-treatment. Diaphragm phospho-
FOXO-3a protein content (mean ± SEM) expressed as signal/μg of total protein 
(corrected for background signal); n = 7-8 per group. **p = 0.0024, ***p = 0.0002, 
****p < 0.0001; separate unpaired t-tests. 
 
 
5.2.3.3 Pro-Atrophy/Cell Death Signalling 
 
5.2.3.3.1 MAPK Pathway 
Figure 13 shows phospho-JNK protein content in diaphragm muscle from mice 
exposed to 8 hours of normoxia, hypoxia, or hypoxia with NAC pretreatment. 
Hypoxia significantly increased phospho-JNK protein content compared with the 
Control group (*p = 0.0120; unpaired t-tests). Hypoxia with NAC pretreatment 
increased phospho-JNK protein content further still compared with the control group 
(***p = 0.0058; unpaired t-tests) and significantly higher than the Hypoxia group 
(**p = 0.0108; unpaired t-tests). 
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Figure 13: Diaphragm phospho-JNK protein content following 8 hours of 
normoxia, hypoxia, and hypoxia + NAC pre-treatment. Diaphragm phospho-JNK 
protein content (mean ± SEM) expressed as signal/μg of total protein (corrected for 
background signal); n = 8 per group. *p = 0.0120, **p = 0.0108, ***p = 0.0058; 
separate unpaired t-tests. 
 
 
Figure 14 shows phospho-p38 protein content in diaphragm muscle from mice 
exposed to 8 hours of normoxia, hypoxia, or hypoxia with NAC pretreatment. 
Hypoxia increased phospho-p38 protein content compared with the Control group but 
not quite to statistical significance (p = 0.0515; unpaired t-tests). Hypoxia with NAC 
pretreatment increased phospho-p38 protein content further still compared with the 
control group (***p = 0.0030; unpaired t-tests) and significantly higher than the 
Hypoxia group (**p = 0.0092; unpaired t-tests). 
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Figure 14: Diaphragm phospho-p38 protein content following 8 hours of 
normoxia, hypoxia, and hypoxia + NAC pre-treatment. Diaphragm phospho-p38 
protein content (mean ± SEM) expressed as signal/μg of total protein (corrected for 
background signal); n = 6-8 per group. **p = 0.0092, ***p = 0.0030; separate 
unpaired t-tests. 
 
 
5.2.4 Sternohyoid Signalling 
 
5.2.4.1 HIF Signalling 
Figure 15 shows HIF1α protein content in sternohyoid muscle from mice exposed to 8 
hours of normoxia or hypoxia. Hypoxia significantly decreased HIF1α protein content 
compared with the Control group (*p = 0.0269; unpaired t-tests) in the sternohyoid 
muscle. 
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Figure 15: Sternohyoid HIF1α protein content following 8 hours of normoxia, 
and hypoxia. Sternohyoid HIF1α protein content (mean ± SEM) expressed as 
signal/μg of total protein (corrected for background signal); n = 7-8 per group. *p = 
0.0269; unpaired t-test. 
 
 
5.2.4.2 Pro-Hypertrophy/Cell Survival Signalling 
 
5.2.4.2.1 Akt Pathway 
Figure 16 shows phospho-Akt protein content in sternohyoid muscle from mice 
exposed to 8 hours of normoxia or hypoxia. Hypoxia significantly decreased 
phospho-Akt protein content compared with the Control group (**p = 0.0028; 
unpaired t-tests) in the sternohyoid muscle. 
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Figure 16: Sternohyoid phospho-Akt (S473) protein content following 8 hours of 
normoxia, and hypoxia. Sternohyoid phospho-Akt (S473) protein content (mean ± 
SEM) expressed as signal/μg of total protein (corrected for background signal); n = 8 
per group. **p = 0.0028; unpaired t-test. 
 
 
Figure 17 shows phospho-p70S6K protein content in sternohyoid muscle from mice 
exposed to 8 hours of normoxia or hypoxia. Hypoxia had no statistically significant 
effect on phospho-p70S6K protein content compared with the Control group, 
although there was a slight decrease in expression in the Hypoxia group (p = 0.0776; 
unpaired t-tests) in the sternohyoid muscle. 
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Figure 17: Sternohyoid phospho-p70S6K (T389) protein content following 8 
hours of normoxia, and hypoxia. Sternohyoid phospho-p70S6K (T389) protein 
content (mean ± SEM) expressed as signal/μg of total protein (corrected for 
background signal); n = 8 per group. Unpaired t-test. 
 
 
Figure 18 shows phospho-S6RP protein content in sternohyoid muscle from mice 
exposed to 8 hours of normoxia or hypoxia. Hypoxia significantly increased phospho-
S6RP protein content compared with the Control group (*p = 0.0232; unpaired t-tests) 
in the sternohyoid muscle. 
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Figure 18: Sternohyoid phospho-S6RP (S235/236) protein content following 8 
hours of normoxia, and hypoxia. Sternohyoid phospho- S6RP (S235/236) protein 
content (mean ± SEM) expressed as signal/μg of total protein (corrected for 
background signal); n = 8 per group. *p = 0.0232; unpaired t-test. 
 
 
Figure 19 shows phospho-GSK-3β protein content in sternohyoid muscle from mice 
exposed to 8 hours of normoxia or hypoxia. Hypoxia had no statistically significant 
effect on phospho-GSK-3β protein content compared with the Control group 
(unpaired t-tests) in the sternohyoid muscle. 
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Figure 19: Sternohyoid phospho-GSK-3β protein content following 8 hours of 
normoxia, and hypoxia. Sternohyoid phospho-GSK-3β protein content (mean ± 
SEM) expressed as signal/μg of total protein (corrected for background signal); n = 8 
per group. Unpaired t-test. 
 
 
5.2.4.2.2 mTOR Pathway 
Figure 20 shows mTOR protein content in sternohyoid muscle from mice exposed to 
8 hours of normoxia or hypoxia. Hypoxia had no statistically significant effect on 
mTOR protein content compared with the Control group (unpaired t-tests) in the 
sternohyoid muscle. 
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Figure 20: Sternohyoid mTOR protein content following 8 hours of normoxia, 
and hypoxia. Sternohyoid mTOR protein content (mean ± SEM) expressed as 
signal/μg of total protein (corrected for background signal); n = 8 per group. Unpaired 
t-test. 
 
 
Figure 21 shows phospho-mTOR protein content in sternohyoid muscle from mice 
exposed to 8 hours of normoxia or hypoxia. Hypoxia had no statistically significant 
effect on phospho-mTOR protein content compared with the Control group (unpaired 
t-tests) in the sternohyoid muscle. 
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Figure 21: Sternohyoid phospho-mTOR protein content following 8 hours of 
normoxia, and hypoxia. Sternohyoid phospho-mTOR protein content (mean ± 
SEM) expressed as signal/μg of total protein (corrected for background signal); n = 8 
per group. Unpaired t-test. 
  
 
5.2.4.2.3 MAPK Pathway 
 
There were not enough numbers available for phospho-ERK1/2 due to low signal in 
sternohyoid muscle samples. 
 
 
5.2.4.2.4 FoxO3a Pathway 
Figure 22 shows phospho-FOXO-3a protein content in sternohyoid muscle from mice 
exposed to 8 hours of normoxia or hypoxia. Hypoxia had no statistically significant 
effect on phospho-FOXO-3a protein content compared with the Control group 
(unpaired t-tests) in the sternohyoid muscle. 
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Figure 22: Sternohyoid phospho-FOXO-3a protein content following 8 hours of 
normoxia, and hypoxia. Sternohyoid phospho-FOXO-3a protein content (mean ± 
SEM) expressed as signal/μg of total protein (corrected for background signal); n = 8 
per group. Unpaired t-test. 
 
 
5.2.4.3 Pro-Atrophy/Cell Death Signalling 
 
5.2.4.3.1 MAPK Pathway 
Figure 23 shows phospho-JNK protein content in sternohyoid muscle from mice 
exposed to 8 hours of normoxia or hypoxia. Hypoxia had no statistically significant 
effect on phospho-JNK protein content compared with the Control group (unpaired t-
tests) in the sternohyoid muscle. 
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Figure 23: Sternohyoid phospho-JNK protein content following 8 hours of 
normoxia, and hypoxia. Sternohyoid phospho-JNK protein content (mean ± SEM) 
expressed as signal/μg of total protein (corrected for background signal); n = 8 per 
group. Unpaired t-test. 
 
 
 
 
Figure 24 shows phospho-p38 protein content in sternohyoid muscle from mice 
exposed to 8 hours of normoxia or hypoxia. Hypoxia had no statistically significant 
effect on phospho-p38 protein content compared with the Control group (unpaired t-
tests) in the sternohyoid muscle. 
 
 
Phospho-JNK
Control Hypoxia
0
5
10
15
20
25
S
ig
n
a
l/

g
 p
ro
te
in
 178 | P a g e  
 
 
Figure 24: Sternohyoid phospho-p38 protein content following 8 hours of 
normoxia, and hypoxia. Sternohyoid phospho-p38 protein content (mean ± SEM) 
expressed as signal/μg of total protein (corrected for background signal); n = 5-7 per 
group. Unpaired t-test. 
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5.3 Chapter Discussion 
 
The main findings of this chapter are: 
 
1. The antioxidant NAC ameliorates acute hypoxia induced diaphragm 
dysfunction. 
 
2. Acute hypoxia induces both pro-atrophic and pro-hypertrophic signalling 
pathways and HIF signalling in the diaphragm, while reducing HIF signalling 
in the sternohyoid. 
 
3. A single I.P. injection of NAC prior to hypoxic exposure appears to bolster 
many of these endogenous signalling responses to acute hypoxia in the 
diaphragm. 
 
 
5.3.1 Muscle Function 
NAC pre-treatment prior to hypoxic exposure rescues the diaphragm from acute 
hypoxia induced diaphragm weakness, both in terms of the peak tetanic force 
generating capacity of the muscle and the force frequency relationship. Not only does 
NAC prevent the hypoxia induced diaphragm dysfunction, but it actually appears to 
enhance muscle performance slightly following hypoxia, above control levels. 
Oxidative stress is a feature of many respiratory conditions and indeed animal models 
of chronic hypoxia, and as discussed in chapter 1 section 1.8, ROS levels within 
muscle cells can influence muscle contractile force. Given this positive influence of 
the antioxidant NAC, preventing acute hypoxia induced diaphragm 
dysfunction/weakness, it is plausible that oxidative stress due to increased levels of 
ROS could be a factor leading to this observed muscle weakness. Increased 
mitochondrial ROS production is a potential source for this increase in oxidative 
stress.  
 
In a recent study by Azuelos et al. (2015), using a mouse model of VIDD, they found 
that treatment with an I.P. injection of NAC immediately after the initiation of 6 hours 
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of mechanical ventilation completely prevented the development of mechanical 
ventilation-induced diaphragmatic weakness. However, it did not suppress autophagy 
but rather it augmented autophagosome formation. Autophagy is a lisosomally 
mediated catabolic and proteolytic process. They suggest that this may elucidate a 
novel mechanism whereby NAC exerts its beneficial effects on VIDD via stimulation 
of autophagy (excess ROS can inhibit autophagy), which may in fact be a beneficial 
adaptive response in the diaphragm to the physiological stress of mechanical 
ventilation rather than representing a contributing factor to the development of VIDD 
(Azuelos et al., 2015).  In the mouse model of acute hypoxia discussed in this thesis, 
NAC prevented the development of acute hypoxia induced diaphragm weakness, and 
although there were no significant hypoxia induced changes in the mRNA expression 
of the genes related to autophagy which were examined in this model, whether or not 
NAC, concomitant with hypoxia, influenced autophagy was not examined. This is one 
potential mechanism by which NAC could be exerting a beneficial effect on the 
hypoxic diaphragm, acting to streamline cellular processes and optimise performance. 
Indeed, under conditions of nutrient deprivation, autophagy augments cellular energy 
production, and functions to maintain cellular homeostasis via degradation of 
dysfunctional proteins and damaged mitochondria (mitophagy), so here autophagy 
may exert beneficial effects via bolstering amino acid dependent ATP generation and 
improving mitochondrial efficiency by removal of damaged mitochondria. 
 
As well as the potential benefits of using NAC as an adjunct therapy in patients with 
acute respiratory diseases to prevent acute hypoxia induced diaphragm dysfunction, 
elucidated in this chapter, NAC has also been shown to protect the diaphragm from 
the damaging effects of controlled mechanical ventilation such as diaphragmatic 
oxidative stress and proteolysis, as well as controlled mechanical ventilation induced 
contractile dysfunction (Agten et al., 2011). 
 
 
5.3.2 Metabolism 
Interestingly, the post-mortem body temperature was still reduced by hypoxia in the 
hypoxia + NAC group compared to control. This suggests that the beneficial effects 
of NAC on hypoxic diaphragm performance are unlikely to be influencing the 
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hypoxic hypometabolic/hypothermic state (and any associated alkalosis caused by the 
reduction in CO2 production, concomitant with maintained ventilation – relative 
hyperventilation) adopted by the mouse in hypoxia. Thus NAC is likely exerting its 
benefits on muscle performance via an independent mechanism, or set of 
mechanisms. This is encouraging, as humans do not adopt this pronounced 
hypometabolic state when hypoxic. 
 
 
5.3.3 Respiratory Muscle Hypoxia Signalling 
HIF1α protein content was increased in the diaphragm following 8 hours of hypoxia. 
This is not altogether surprising given that HIF1α protein accumulation is indirectly 
proportional to cytosolic oxygenation. ROS can induce HIF1α expression, but this 
effect can be dependent on exposure time, and ROS can exert the opposite effect over 
prolonged periods, thus creating some uncertainty regarding how swings in cellular 
redox balance affect HIF1α expression (Bonello et al., 2007; Jusman et al., 2010; 
Niecknig et al., 2012; Schieber and Chandel, 2014). One might expect that NAC, 
being an antioxidant, would prevent this hypoxia induced increase in HIF1α protein 
content. However, HIF1α is responsive to redox balance within the intracellular 
environment and reducing conditions can stabilise HIF1α, and NAC induced 
increases in cellular GSH could elevate HIF1α expression (Jin et al., 2011; Nikinmaa 
et al., 2004; Sceneay et al., 2013; Zhang et al., 2014). Here, pre-treatment with NAC 
prior to hypoxic exposure enhances HIF1α protein content in diaphragm muscle 
compared with hypoxia alone, enhancing the HIF1α signalling response in hypoxia + 
NAC. Indeed, it has been reported that HIF1 contributes to the neuroprotective effect 
of NAC in an ischaemic stroke model of transient cerebral ischaemia in rats (Zhang et 
al., 2014). In contrast to these findings regarding diaphragm HIF1α protein content in 
acute hypoxia and acute hypoxia following NAC pre-treatment in diaphragm, chronic 
hypoxia induced increases in HIF1α protein content in the diaphragm were attenuated, 
rather than being augmented, by chronic antioxidant treatment (administered orally) 
concomitant with chronic hypoxia (Lewis et al., 2015b). In the current study, HIF1α 
protein content accumulated further still in hypoxia + NAC due to being stimulated 
on two fronts; induction by hypoxia and induction by altered cellular redox state. 
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Interestingly, and rather unexpectedly, HIF1α protein content was significantly 
reduced in the sternohyoid following 8 hours of hypoxia. This may have been due to 
muscle fibre type differences or muscle activity difference. These differences could 
give rise to differential redox states in each of the two muscles following acute 
hypoxia, leading to differential HIF1α protein responses. Indeed, chronic hypoxia has 
also been shown to have differential effects on HIF1α protein content in sternohyoid 
and diaphragm (Lewis et al., 2015d). This data suggests that HIF1α signalling in the 
sternohyoid is unaffected by acute hypoxia. 
 
 
5.3.4 Respiratory Muscle Hypertrophy/Atrophy Signalling 
Finally, we examined the protein and/or phosphoprotein content of various key 
proteins (fig. 25) associated with signalling pathways involved in the balance between 
cell survival and death and protein balance, or hypertrophy/atrophy, in diaphragm and 
sternohyoid muscle. We also elucidated the influence of NAC pre-treatment prior to 
hypoxia on these proteins in the diaphragm. 
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Figure 25: Schematic depicting the various hypertrophy/atrophy signalling 
pathways examined in this chapter. Green arrows indicate activation, red lines 
indicate inhibition. 
 
 
5.3.4.1 Pro-Hypertrophy/Cell Survival Signalling 
 
5.3.4.1.1 Akt Pathway 
The Akt signalling pathway is discussed in chapter 1. Akt, particularly the Akt/mTOR 
pathway, is central to the control of the hypertrophic/atrophic state or balance in 
muscle, acting in a phosphorylation dependent manner as a key regulator of 
downstream effectors involved in modulating cell growth and survival. Activated 
(phosphorylated) Akt is predominantly pro-hypertrophic, via inhibition of atrophic 
signals and promotion of hypertrophic signals. Here, phosphorylated (active) Akt, or 
phospho-Akt, protein content is upregulated following acute hypoxia, and upregulated 
further still following hypoxia + NAC in the diaphragm. It has been previously 
demonstrated that, under certain conditions, hypoxia can activate Akt and it is 
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suggested that that hypoxia induced Akt activation may play a role in protection 
against apoptosis (Alvarez-Tejado et al., 2001; Beitner-Johnson et al., 2001; Dai et 
al., 2008; Stegeman et al., 2012). Similarly, in this model it would appear that acute 
hypoxia induced Akt activation is a beneficial compensatory mechanism by the 
muscle, rather than being a negative consequence of hypoxic damage, attempting to 
maintain muscle functional integrity. When NAC pre-treatment is administered prior 
to acute hypoxia, it appears to enhance this endogenous induction of Akt signalling, 
potentially bolstering the cellular defensive efforts against acute hypoxia. This may be 
(part of) the mechanism by which NAC rescues diaphragm force in hypoxia. It is also 
worth noting that Akt/mTOR signalling can regulate HIF1α and may play a role in 
hypoxia induced HIF1α expression (Kilic-Eren et al., 2013; Land and Tee, 2007; 
Yang et al., 2009). Akt also exerts pro-hypertrophic effects via inhibition of atrophic 
signalling, which shall be discussed later on. 
 
In the sternohyoid, hypoxia caused a reduction in phospho-Akt protein content, 
suggesting a lack of pro-hypertrophy signalling in the hypoxic sternohyoid. Indeed, 
Akt is activated by hypoxia, as mentioned above, and may play a role in hypoxia 
induced HIF1α expression. Perhaps a hypoxia induced increase in Akt activation is 
HIF1α dependent. Therefore, the reduction in HIF1α protein content in the acute 
hypoxic sternohyoid would lead to this reduced phospho-Akt protein content. Indeed, 
the relationship between hypoxia and Akt is believed to be HIF1α mediated (Bedogni 
et al., 2005). This is therefore a likely mechanism for this reduced Akt protein content 
in the hypoxic sternohyoid.  
 
Phospho-p70S6K, which is downstream of Akt, is slightly but not significantly 
elevated by acute hypoxia in the diaphragm. Its protein content was, however, 
significantly elevated by hypoxia + NAC in the diaphragm. p70S6k activation by Akt 
is mediated via the indirect activation of mTOR by Akt. p70S6K, when activated, 
promotes translation/protein synthesis and cell survival in muscle (Baar and Esser, 
1999; Gran et al., 2014; Zanchi and Lancha, 2008). The fact that the induction of 
elevated phospho-p70S6K is greater in hypoxia + NAC compared with hypoxia itself 
is likely due to the greater elevation of phospho-Akt, and phospho-mTOR and 
phospho-ERK1/2 (see below) in hypoxia + NAC, which both activate phospho-
p70S6K (Krolikowski et al., 2006). Again this is indicative of pro-hypertrophy 
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signalling being induced in hypoxia + NAC, a mechanism which could be beneficial 
to maintaining diaphragm muscle performance. Indeed, decreased phospho-p70S6K 
expression occurs in the diaphragm of mechanically ventilated rats prior to decreased 
protein synthesis (McClung et al., 2008). 
 
There is no difference in phospho-p70S6K protein content between the control and 
hypoxic sternohyoid muscle, although there is a slight non-significant reduction in 
phospho-p70S6K protein content, again suggesting a lack of pro-hypertrophy 
signalling in the acutely hypoxic sternohyoid muscle. The lack of any change in 
phospho-mTOR in hypoxic sternohyoid is a likely cause of this (see below). 
 
The phosphoprotein content of phospho-S6RP, which is downstream of both 
Akt/mTOR and p70S6K, is significantly increased by both hypoxia and hypoxia + 
NAC in the diaphragm. The phosphorylation of S6RP by phospho-p70S6K, driven by 
Akt/mTOR, drives translation/protein synthesis and growth. Phospho-S6RP protein 
content is also increased in the hypoxic sternohyoid muscle compared with control. 
This increase in phospho-S6RP in the sternohyoid must be through activation from 
another pathway as the phosphoprotein content of its upstream effectors, mTOR and 
p70S6K, are unaltered. Therefore protein synthesis signalling, via a mechanism other 
than Akt/mTOR, may be induced in the hypoxic sternohyoid. 
 
Hypoxia, as discussed above, can activate Akt, and this leads to GSK-3 
phosphorylation (Beitner-Johnson et al., 2001). Phosphorylation negatively regulates 
GSK-3β, inhibiting it, resulting in the activation of protein synthesis and a cessation 
of anti-anabolic signalling from GSK-3β. Here, phospho-GSK-3β protein content is 
increased significantly by hypoxia, and increased further still by hypoxia + NAC. 
Again, these data suggest a drive toward a pro-hypertrophic/pro-protein synthesis 
state in hypoxia that is further augmented by NAC pre-treatment. There is no 
difference in phospho-GSK-3β protein content between the control and hypoxic 
sternohyoid muscle, suggesting that the anti-anabolic effects of GSK-3β are unhalted 
in hypoxic sternohyoid. 
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5.3.4.1.2 mTOR Pathway 
mTOR, as discussed in chapter 1 and in the paragraphs above, is a protein kinase 
functioning in the regulation of growth, survival and protein synthesis in skeletal 
muscle. Both mTOR and phospho-mTOR were measured here. mTOR mediates its 
hypertrophic/cell survival signalling effects via its phosphorylated/activated state. 
Here, hypoxia significantly increased mTOR protein content while this was not the 
case in hypoxia + NAC. While both hypoxia and hypoxia + NAC increased phospho-
mTOR protein content, expression being augmented furthest in the hypoxia + NAC 
group. It would appear that hypoxia alone, in the absence of NAC, may induce an 
increase in mTOR protein expression, or indeed a reduction in mTOR degradation, 
while phosphorylation of mTOR was upregulated or induced by hypoxia and further 
still by hypoxia concomitant with NAC. Phospho-p70S6K and phospho-s6RP, 
discussed above, are also both downstream of, and activated by, mTOR, and so the 
increase in phospho-mTOR likely contributes to the increases in phospho-p70S6K 
and phospho-s6RP reported above. 
 
There was no difference in mTOR or phospho-mTOR protein content between the 
control and hypoxic sternohyoid muscle, likely contributing to the lack of difference 
in phospho-p70S6K between control and hypoxic sternohyoid. 
 
5.3.4.1.3 MAPK Pathway 
ERK1/2 is a member of the MAPK family which positively regulates p70S6K, 
negatively regulates GSK-3β and itself positively regulates cellular proliferation, 
survival and development. Through these mechanisms it is pro-cell 
survival/hypertrophy. Here, acute hypoxia increased diaphragm phospho-ERK1/2 
protein content, and NAC pretreatment augmented this acute hypoxia induced 
phospho-ERK1/2 protein content increase. This, combined with the Akt signalling 
data above, further supports the theory that NAC pre-treatment bolsters the 
endogenous cellular signalling mechanisms acting to promote protein synthesis and 
cell survival in the acutely hypoxic diaphragm. Meanwhile, the phospho-ERK1/2 
signal was too low in too many of the sternohyoid muscle samples to obtain any 
meaningful data on its expression profile in control and hypoxia. 
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5.3.4.1.4 FoxO3a Pathway 
The FoxO pathway is generally associated with atrophy and protein degradation in its 
dephosphorylated state. However, when phosphorylated, FoxO3a, as discussed in 
chapter 1, is inhibited from translocation into the nucleus and exerting its atrophic 
effects. One of the ways in which Akt exerts a hypertrophic effect is by the 
phosphorylation and thus inhibition of FoxO3a, preventing the atrophic action of 
MuRF1 and Atrogin-1, which would otherwise be transcriptionally upregulated by 
FoxO3a. In this chapter, acute hypoxia increased phospho(inhibited)-FoxO3a protein 
content in the diaphragm and NAC pre-treatment further augmented this acute 
hypoxia induced increase in protein content, thus enhancing and adding to the pro-
hypertrophic/anti-atrophic signalling cascades described above, via the down-
regulation of FoxO3a induced proteasomal and autophagy mediated protein 
degradation. This increase in phosphoprotein content was likely mediated via the 
increase in phospho-Akt in diaphragm. There was no difference in phospho-FoxO3a 
protein content between the control and hypoxic sternohyoid muscle. 
 
 
5.3.4.2 Pro-Atrophy/Cell Death Signalling 
 
5.3.4.1.1 MAPK Pathway 
While there appears to be a predominant drive toward protein synthesis in the acutely 
hypoxic diaphragm, augmented further by NAC, as discussed above, there was also 
an increase in a certain amount of atrophic signalling via the MAPK pathway. JNK 
promotes autophagy, apoptosis, inflammation and cell death, and is activated by 
phosphorylation (Berdichevsky et al., 2010). Here, acute hypoxia elevated levels of 
phospho-JNK protein, an effect which is further augmented by NAC. This is 
somewhat surprising given that Akt, which was also activated, negatively regulates 
the JNK pathway via a cross-talk mechanism (Levresse et al., 2000). JNK 
phosphorylation in this model is therefore likely induced by some other 
mechanism/stress affecting the MAPK pathway. There was no difference in phospho-
JNK protein content between the control and hypoxic sternohyoid muscle. 
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p38 can promote inflammation and apoptosis, while also negatively regulating GSK-
3β to promote survival (Thornton et al., 2008). Here, acute hypoxia increased 
phospho-p38 expression to near significant levels in the diaphragm, while NAC 
concomitant with acute hypoxia significantly augments this increase. This suggests a 
pro-atrophic effect of hypoxia + NAC in the diaphragm. There is no difference in 
phospho-p38 protein content between the control and hypoxic sternohyoid muscle. 
 
 
These signalling pathways are complex. They interact with each other and a host of 
other signalling mechanism, combining in synergy or antagonistically, to exert a 
variety of effects (Fey et al., 2012). In this chapter, when attempting to group these 
data together in order to form conclusions as to the overall direction in which these 
signalling pathways are converging, we report a general increase in cell survival and 
pro-hypertrophy/protein synthesis signalling in acute hypoxia, accompanied by a 
concurrent, albeit less robust, increases in cell death and pro-atrophy/protein 
degradation signalling in the diaphragm. Most interestingly, both of these signalling 
programmes are enhanced further still by NAC pre-treatment. Given that NAC 
improves functional outcome and performance in the diaphragm muscle, this suggests 
that these signalling initiatives are attempting to drive beneficial responses to acute 
hypoxia, and they become effective when augmented by NAC pre-treatment. Indeed, 
NAC appears to bolster, or amplify, these endogenous signalling endeavours in the 
diaphragm in response to acute hypoxia, rather than abate them, suggesting that NAC 
may exert its beneficial effects on diaphragm muscle performance, namely mitigating 
acute hypoxia induced diaphragm weakness, via enhancement of the endogenous 
signalling responses acting to maintain function and thwart the detrimental effects of 
acute hypoxia, rather than acting antagonistically against acute hypoxia induced 
signalling programmes that are inimical to muscle function. While hypoxia signalling 
through HIF1α was increased by hypoxia in the diaphragm, it was in fact reduced by 
hypoxia in the sternohyoid highlighting, as mentioned previously, the differential 
effects that hypoxia can exert on the two muscles, given the different fibre type 
composition of the two muscles. Another fibre type difference between the two 
muscles is that the diaphragm is more oxidative than the sternohyoid, and could 
therefore potential respond differently to changes in oxidative stress, and indeed 
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experience a different degree of oxidative stress, in response to the same hypoxic 
insult on the animal as a whole. 
 
 
5.4 Chapter Conclusions 
 
Acute hypoxia induced diaphragm weakness is ameliorated by NAC pre-treatment, 
via a mechanism which does not influence the hypometabolic state of the hypoxic 
mouse. Since this murine hypometabolic strategy is unaffected by NAC pre-
treatment, which prevents diaphragm weakness, hypometabolism is not likely a 
driving force for diaphragm weakness following hypoxic exposure. This is important 
as humans do not adopt this prominent hypometabolic state, and so in attempting to 
extrapolate these findings to the human condition it is encouraging that this murine 
strategy does not appear to play a role in the beneficial potential of NAC to prevent 
acute hypoxia induced diaphragm dysfunction. NAC pre-treatment bolsters 
endogenous acute hypoxia induced hypoxic, hypertrophic and atrophic signalling 
mechanisms. This drive to increase both hypertrophy and atrophy signalling could be 
a gear change to drive an increase in protein turnover and amino acid dependent ATP 
generation. Further downstream the atrophic drive may be driving the degradation of 
non-essential proteins for performance optimisation and amino acid fuel source while 
the hypertrophic response may be driving the generation of fundamental proteins to 
muscle performance and cellular optimisation. NAC appears to boost these signalling 
cascades to further drive this initiative and, potentially through this mechanism, lead 
to the preservation of diaphragm functionality. These findings further highlight the 
potentially critical role of hypoxia in the diaphragm muscle dysfunction observed in 
patients with acute respiratory diseases. NAC may be a beneficial adjunct therapy in 
these patients, alleviating acute hypoxia induced diaphragm dysfunction, and 
potentially improving patient outcome. 
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Chapter 6: Summary and Conclusions 
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6.1 Summary 
 
The link between hypoxia and respiratory disease is not a new concept. However, 
while much research in this area has focused on the role of hypoxia in chronic 
respiratory or cardiac conditions such as COPD or CHF, or indeed the role of 
intermittent hypoxia in SDB conditions such as OSA and central sleep apnoea, little is 
known regarding the potential role of acute hypoxia in diaphragm muscle dysfunction 
in acute respiratory-related conditions and mechanically ventilated patients. This is 
surprising given the clinical relevance. Indeed, diaphragm muscle weakness is a 
strong indicator of poor outcome in patients (Supinski and Callahan, 2013), and acute 
hypoxia can present during airway obstruction, blockage of the alveoli by oedema or 
infectious exudate, acute haemorrhage, and acute respiratory-related disorders such as 
VILI/VALI, ARDS and ALI. These conditions are associated with ICUAW, including 
diaphragm muscle weakness. Chronic and intermittent hypoxia are known to 
independently affect respiratory muscle performance. It is therefore pertinent to 
explore whether acute hypoxia alters respiratory muscle contractile performance. In 
this thesis we aimed to determine whether acute hypoxia would affect: 1) respiratory 
(diaphragm and sternohyoid) muscle contractile performance; 2) ventilation and 
metabolism; and 3) the hypertrophy/atrophy balance, mitochondrial function, hypoxic 
signalling and SR calcium handling in respiratory muscle (and compare some of these 
to non-respiratory skeletal muscle). Finally, 4) we sought to determine whether a 
single I.P. injection of NAC immediately prior to hypoxic exposure would alter how 
the diaphragm responded to acute hypoxia. 
 
A murine model exposed to 1, 4 or 8 hours of hypoxia (10% O2) or normoxia (21% 
O2) was utilised in this study for gene expression analysis in diaphragm sternohyoid, 
EDL and soleus muscles. Mice exposed to 8 hours of normoxia or hypoxia were used 
for in vivo measurements, ex vivo functional analysis, and protein assays. 
 
In chapter three, we demonstrate a 30% reduction in force-generating capacity of the 
diaphragm, with resultant depression in power output following acute hypoxia, and a 
similar acute hypoxia induced magnitude of weakness in the sternohyoid. This 
diaphragm weakness, observed in both mice and rats, could be thought of as 
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functionally significant, particularly in situations where a patient’s ventilation may 
already be compromised as is often the case in the ICU (assuming a similar response 
in human diaphragm). This weakness could prove particularly problematic when the 
diaphragm is required to carry out tasks other than quiet breathing, such as airway 
clearance manoeuvres and/or ventilation through a narrowed airway (increasing the 
load on the muscle). 
 
In chapter four, we aimed to uncover some of the molecular mechanisms that may be 
underpinning acute hypoxia induced respiratory muscle dysfunction, and examine 
ventilation and metabolism in vivo in order to ascertain if ventilation, and therefore 
diaphragm muscle activity, is increased in acute hypoxia in this mouse model. We 
also wished to characterise the acute hypoxia induced hypometabolic strategy adopted 
by the mouse in acute hypoxia so that this could be matched to ventilation in order to 
explain the ventilatory profile more completely, and to provide a more elaborate 
picture of oxygen supply and utilisation, providing information such as the RER. In 
terms of the gene expression data, we profiled gene expression in key areas relating to 
muscle function (those that may contribute to muscle weakness in an acute hypoxic 
environment), namely mitochondrial metabolism, atrophy signalling, SR calcium 
handling and hypoxia signalling. We measured expression of these genes following 1, 
4 and 8 hours of hypoxia in order to profile the temporal profile of the expression of 
these genes over the course of 8 hours of hypoxia. We examined proteasome activity 
to further assess the atrophy profile of the acutely hypoxic diaphragm. We found that 
4-8 hours of hypoxia significantly increases mitochondrial UCP-3 mRNA expression 
across all 4 muscle types, suggestive of an increased reliance on fatty acid metabolism 
in skeletal muscle around the body, and potentially reducing ROS production. 
Differential and dynamic changes in mRNA expression of transcription factors 
involved in the regulation of mitochondrial biogenesis & energy metabolism are 
observed in respiratory, but not limb, muscle following 1, 4 & 8 hours of hypoxia. 
Pro-atrophy signalling mRNA expression is induced by hypoxia across all 4 muscle 
types, although not with significance in sternohyoid muscle. There was no change in 
autophagy related gene expression, or proteasome enzymatic activity in the 
diaphragm. 4 hours of hypoxia caused a certain level of perturbation in SR calcium 
handling related gene expression in respiratory muscle, the sternohyoid in particular. 
Hypoxia did not cause any persistent change in ventilation (muscle activity), therefore 
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muscle weakness and molecular changes are likely hypoxia-dependent. Hypoxia 
decreased metabolism and body temperature, meaning that although ventilation is 
unaltered, there is in fact a relative hyperventilation when metabolic rate is 
considered. The Respiratory Exchange Ratio (RER) was unaffected by hypoxia, 
suggesting there is no switch in metabolic energy source. An RER of 0.7 suggests that 
fatty acids are the primary substrate for oxidative metabolism and energy production, 
over glucose/carbohydrates. 
 
In chapter 5, we tested whether the antioxidant NAC could prevent the acute hypoxia 
induced diaphragm dysfunction observed in chapter 1, to ascertain whether this NAC 
pre-treatment would alter the hypoxic hypometablism, and to examine hypoxic and 
hypertrophy/atrophy signalling pathways in control and 8 hours hypoxic diaphragm 
and sternohyoid muscle, and determine how NAC pretreatment would alter the way in 
which hypoxia affects these cascades in the diaphragm. We found that NAC 
ameliorates acute hypoxia induced diaphragm dysfunction. Acute hypoxia induced 
both pro-atrophic and pro-hypertrophic signalling pathways and HIF signalling in the 
diaphragm, and a single I.P. injection of NAC prior to hypoxic exposure appeared to 
bolster many of these endogenous signalling responses to acute hypoxia, which may 
be the mechanism by which NAC exerts its beneficial effects on diaphragm muscle 
function. Alternatively NAC may prevent hypoxia induced redox modulation of 
contractile function, as observed following chronic exposure to hypoxia (Lewis et al., 
2016). NAC may be a beneficial adjunct therapy in patients with acute respiratory 
diseases, alleviating acute hypoxia induced diaphragm dysfunction, and potentially 
improving patient outcome. 
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Figure 1: The effects of acute hypoxia on the diaphragm. A summary of the effects 
of acute hypoxia on diaphragm muscle in mice. NAC pre-treatment ameliorated acute 
hypoxia-induced diaphragm dysfunction. 
 
 
6.2 Limitations 
 
As is the case with any scientific study, there are limitations to this study which must 
be acknowledged. First and foremost, it must be noted that when conducting any 
research utilising animal models of human conditions one must concede that data or 
phenotypes observed in the animal, in this instance the mouse, do not always translate 
directly to the human condition. One primary concern along those lines in this study is 
the pronounced hypoxic hypometabolic state adopted by the mouse, which is not 
present in humans. However, it is encouraging that while NAC was effective in 
preventing acute hypoxia induced diaphragm weakness, it did not alter the hypoxia 
induced reduction in post mortem body temperature, and is therefore unlikely to be 
altering that hypometabolic state to improve diaphragm performance i.e. acute 
hypoxia-induced diaphragm dysfunction is unrelated to metabolic consequences of 
hypoxia. In humans, rather than a reduction in metabolism, as is observed in the 
mouse, exposure to hypoxia results in an increase in ventilation (diaphragm activity). 
Meanwhile the rat adopted a strategy of adaptation which lies somewhere in between 
the human and the mouse, whereby the rat maintains a slightly elevated ventilation 
while also reducing metabolism, although not to the extent of the mouse 
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hypometabolic response. Therefore, while the difference in hypoxic strategy between 
the mouse and the human is an important point of consideration when extrapolating 
these data to humans, it is encouraging that the same level of diaphragm weakness is 
observed in both the mouse and the rat, despite the difference in hypoxic 
ventilatory/metabolic strategy. 
 
The duration of time chosen to represent ‘acute hypoxia’ is another factor worth 
consideration. 8 hours or less was chosen because, from review of the literature, 
mechanical ventilation induced diaphragm maladaptation, weakness and atrophy can 
manifest within that timeframe in animals and humans (Azuelos et al., 2015; Bruells 
et al., 2013; Chen et al., 2015; Hooijman et al., 2015; Jaber et al., 2011a; Levine et al., 
2008; Picard et al., 2015), demonstrating how quickly these changes can occur in the 
diaphragm and how quickly the diaphragm can be altered. While disuse or unloading 
of the diaphragm is obviously a different stimulus to hypoxia alone, the fact that the 
diaphragm can adapt in this short space of time lead us to believe it was worth 
looking at hypoxia in this timeframe. Indeed, this fixed time point for measuring 
muscle function, and other parameters, only gives us a snap shot of how the 
diaphragm is affected at that time. As evident from the gene expression data at 1, 4 
and 8 hours, the expression changes of certain genes under hypoxic conditions is time 
dependent and differ temporally between those time points. It is also unclear from this 
study whether, if the mice were reintroduced into a normoxic environment, the 
diaphragm muscle would recover over time. 
 
Examining muscle contractile performance ex vivo has the benefit of allowing us to 
examine contractile changes intrinsic to the muscle itself. However, the muscle may 
function differently in vivo. There may also be compensatory mechanisms, neural, 
intercostal muscle assistance, or otherwise, present in vivo that allow the diaphragm to 
perform optimally even with this intrinsic weakness. Performing the functional 
analysis in hyperoxic conditions allowed for maximum muscle performance to be 
assessed and gave the best chance to maintain muscle viability, although it is worth 
noting that this is not physiological and may also have biased results insofar as 
hypoxic diaphragm may have performed better than control diaphragm under 
conditions of hypoxic exposure. In other words, the cellular strategy adopted by the 
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diaphragm in the face of hypoxic stress may be one which confers advantage to the 
diaphragm in hypoxia (Lewis et al., 2015a), which was not examined in our study. 
 
The method of euthanasia used is another point worth mentioning. Using a rising 
concentration of CO2 for euthanasia allowed us to euthanise the animals without re-
exposure to a normoxic environment before being euthanised. The concern with this 
method is that CO2 can alter gene expression, amongst many other things. However, 
in this time frame we do not feel that CO2 would have had any significant effect on 
our data. 
 
We must also acknowledge certain limitations in extrapolating conclusions from these 
data. In terms of the fatigue data, as mentioned in chapter 1, it must be noted that 
what could be perceived as an increased fatigue resistance following hypoxia may 
well be a bottoming out effect, whereby the hypoxic muscle is already weaker at the 
beginning of the fatigue protocol and power output at 33% load merely does not fall 
off to the same extent as does the more powerful normoxic muscle. While we 
observed some evidence of increased atrophic signalling, we did not see any change 
in proteasome activity between groups in the diaphragm. We thus cannot say whether 
or not muscle fibre CSA is being reduced due to muscle atrophy occurring in this 
model at this time point.  
 
 
6.3 Future Directions and Studies 
 
The putative contribution of atrophy, if it is occurring in the diaphragm following 8 
hours of hypoxia, is something that needs to be determined. We plan on employing 
immunohistochemical staining of muscle samples taken from diaphragm and 
sternohyoid muscles from control and hypoxic animals in order to measure fibre CSA 
in these muscles and determine if muscle fibre atrophy is occurring, which would be 
consistent with muscle weakness.  
 
The next step in determining how relevant the ex vivo diaphragm weakness observed 
in this study might be to a clinical setting is to determine whether or not this acute 
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hypoxia induced diaphragm dysfunction also presents in vivo. Our group has plans to 
study this measuring transdiaphragmatic pressure in the anaesthetised mouse and rat 
following 8 hours of hypoxia and normoxia. Transdiaphragmatic pressure during 
normal respiration and more importantly during airway obstruction and phrenic nerve 
stimulation, which elicit maximum transdiaphragmatic pressure changes in vivo 
would provide important information on the effects of acute hypoxia on diaphragm 
function in vivo. This could also be examined in hypoxic rodents pre-treated with 
NAC. 
 
It would be most interesting to examine ex vivo muscle function in EDL and soleus 
muscle in this model to determine whether muscle weakness induced by acute 
hypoxia is respiratory muscle specific or whether it elicits a global skeletal muscle 
phenomenon. 
 
It would also be of interest to determine if acute hypoxia induced diaphragm 
dysfunction would persist following re-exposure to normoxia following 8 hours of 
hypoxia. If acute hypoxia induced diaphragmatic dysfunction is perennial, it would 
have further still implications for patients with acute respiratory diseases. 
 
 
6.4 Conclusions and Clinical Implications 
 
Acute hypoxia causes diaphragm muscle weakness. Acute hypoxia-induced 
diaphragm dysfunction (acute HIDD), is prevented by antioxidant pre-treatment 
immediately prior to hypoxic exposure. As NAC is administered immediately prior to 
the beginning of the protocol, via a single I.P. injection, as opposed to being given for 
a number of days prior to hypoxic exposure, its effectiveness in preventing acute 
HIDD bodes well for an ICU or critical care setting, where a hypoxaemic acute 
respiratory patient could be given NAC immediately via I.V. infusion/injection upon 
admission to an ICU. It implies that it is not necessary to preempt hypoxia induced 
diaphragm dysfunction, widening its utility in the clinical context. NAC is already 
approved for clinical use for other conditions (discussed in chapter 1) and can be 
bought as a dietary supplement. It would therefore seem that it would be relatively 
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simple to implement as an adjunct therapy for hypoxaemic patients with acute 
respiratory diseases, in comparison to developing a new drug or therapeutic agent 
from bench to bedside that does not have any prior clinical use. It is, however, 
important to note that while NAC was beneficial in this model, hypoxaemic patients 
with acute respiratory diseases often have a whole host of added complications other 
than solely being hypoxaemic, which may culminate in NAC being less effective in 
rescuing diaphragm performance. These findings highlight a potentially critical role 
for hypoxia in the diaphragm muscle dysfunction observed in patients with acute 
respiratory diseases. NAC may be a beneficial adjunct therapy in these patients. 
 
 
 
Figure 2: Clinical Relevance. Schematic depicting how acute hypoxia induced 
diaphragm dysfunction (acute HIDD) may be clinically relevant in acute respiratory 
conditions, and how NAC may be useful, as an adjunct therapy, in alleviating acute 
HIDD in respiratory patients. 
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